Insights into Protein-Ligand Molecular Recognition: Thermodynamic, Kinetic and Structural Characterization of Inhibitor Binding to Aldose Reductase and Carbonic Anhydrase II by Rechlin, Chris & Klebe, Gerhard (Prof. Dr.)
  
Insights into Protein-Ligand Molecular Recognition: 
Thermodynamic, Kinetic and Structural Characterization of 
Inhibitor Binding to Aldose Reductase and  
Carbonic Anhydrase II 
 
 
Dissertation 
 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
(Dr. rer. nat.) 
 
dem 
Fachbereich Pharmazie der 
Philipps - Universität Marburg 
vorgelegt 
 
von 
Chris Rechlin 
aus 
Flensburg 


Marburg/Lahn 2015 
  







 
 
 
 
 
 
Erstgutachter: Prof. Dr. Gerhard Klebe 
 
Zweitgutachter:  Prof. Dr. Andreas Heine 
 
 
Eingereicht am 17.08.2015 
 
 
Tag der mündlichen Prüfung am 14.10.2015 
 
 
Hochschulkennziffer: 1180 
  
  
3 

Die Untersuchungen zur vorliegenden Arbeit wurden auf Anregung von Herrn Prof. Dr. Gerhard 
Klebe am Institut für Pharmazeutische Chemie der Philipps-Universität Marburg in der Zeit vom 
Juli 2011 bis August 2015 durchgeführt. 


 
  

  
4 

 

 
 

  
5 

 

  
6 


 

Abbrevations 
 
7 

Abbrevations 

2-h PG 2-h plasma glucose  
Å Ångström (1Å= 10-10 m) 
A1C  Glycated hemoglobin 
A600 Absorption at 600 nm 
ADME Absorption, distribution, metabolism and excretion 
AGE Advanced glycation end product 
AKR1A1 Aldo-keto reductase family 1, member A1 (aldehyde reductase) 
AKR1B1 Aldo-keto reductase family 1, member B1 (aldose reductase) 
AKR1B10 Aldo-keto reductase family 1, member B10 
Ala Alanine 
 ALR1 Human aldehyde reductase 
ALR2 Human aldose reductase 
APCI Atmospheric pressure chemical ionisation 
API Active pharmaceutical ingredient 
APS Ammoniumpersulfate 
Arg Arginine 
 ARI Aldose reductase inhibitor 
Asn Asparagine 
 Asp Aspartic acid 
BEI Binding efficiency index 
B-factor Debye-Waller factor 
CA Carbonic anhydrase 
 CAII Human carbonic anhydrase II 
 CARP Carbonic anhydrase related proteins  
 CV Collective Variable 
 Cys Cysteine 
 D Distribution ratio 
 Da Dalton 
 DMSO Dimethyl sulfoxide 
 DPP-4  Dipeptidyl peptidase-4 
 DTT Dithiothreitol 
 E. coli Escherichia coli 
 EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
 EDTA Ethylene diamine tetra acetate  
 Fc Calculated structure amplitudes 
 Fo Observed structure amplitudes 
 FPG Fasting plasma glucose  
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G0 Gibbs free energy 
 Gln Glutamine 
 GLP-1  Glucagon-like peptide-1 
 Glu Glutamic acid 
 Gly Glycine 
 GSH Reduced glutathione 
 GSSG Oxidized gluathione 
 GST Glutathione-S-transferase 
h Hour 
 H0 Enthalpy 
 H-bond Hydogen bond 
HEPES 4-(2-Hydroxyethyl)-1-piperazine ethan sulfonic acid 
His  Histidine 
 HP Hydrophobic patch 
IC50 Half maximal inhibitory concentration 
IDD Institute for diabetes discovery 
Ile Isoleucine 
 IPTG Isopropyl--D-thiogalactopyranosid  
ITC Isothermal microcalorimetry 
K Kelvin 
 k Kilo 
 KA Association constant 
KD Dissociation constant  
koff Rate of binary complex dissociation 
kon Rate of ligand association 
LE Ligand efficiency 
LELP Ligand efficiency-dependent lipophilicity 
Leu Leucin 
 LLE Lipophilic ligand efficiency  
Lys Lysine 
 M Molarity (mol/L) 
MD Molecular dynamics simulation 
MES 2-(N-morpholino)ethanesulfonic acid 
Met Methionine 
 min Minute 
 NAD+  Nicotinamide adenine dinucleotide 
NADP+ Nicotinamide adenine dinucleotide phosphate 
NADPH Nicotinamide adenine dinucleotide phosphate, reduced 
NHS N-hydroxysuccinimide  
Abbrevations 
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NMR Nuclear magnetic resonance 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PDB Protein Data Bank 
PEG 6000 Polyethylene glycole 6000 
pH  Potentialis hydrogenii 
Phe Phenylalanine 
pKa Logarithmic acid dissociation constant 
PKC Protein kinase C  
Pro Proline 
 R Ideal gas constant  
R-factor Reliability factor 
RMSD Root mean square determination 
rpm Revolution per minute 
S0 Entropy 
 SD Standard deviation 
SDS Sodium dodecyl sulfate 
Ser Serine 
 SFF Stopped-flow fluorescence 
SGLT Sodium-glucose transport proteins 
siRNA Small interfering RNA 
SPR Surface plasmon resonance  
T Absolute temperature 
tHP Lifetime of the intermediate state at the hydrophobic patch domain  
Thr Threonine 
 TRIS Tris(hydroxamethyl)aminomethane 
Trp Tryptophane 
 Tyr Tyrosine 
 Val Valine 
 w/v  Weight per volume 
X-ray Röntgen radiation 
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1 Introduction and Aims of this Work 
1.1 Drug Design 
At the beginning of the last century serendipity was often the base for the discovery of new 
drugs. The most famous example for such a finding is presumably the detection of the antibiotic 
penicillin by Alexander Flemming in 1928. Thanks to his attentive mind he noticed that 
Penicillum notatum leads to bacteria-free areas in a plate of a Staphylococcus culture. Such 
empiric observations helped to identify active ingredients. The mode of action and the target in 
the organism was often elucidated long after the discovery of a drug. Today the rational drug 
design takes the opposite approach. It starts with the identification of possibly disease-related 
targets in the human or animal body, a molecular structure which can interact specifically with 
drugs. The pharmacological modulation of the target is validated for its intended therapeutic use. 
X-ray crystallography is used to solve the three-dimensional structure of the target. Possible drug 
molecules are designed with the help of computational approaches. The most promising 
compounds are synthesized and tested in biological and biophysical assays. This step is further 
supported by protein crystallography to obtain complex structures of the ligand and its target with 
the aim to generate ideas for the next design cycle. Furthermore, at early stages the ADME 
(absorption, distribution, metabolism and excretion) parameters and possible side effects like 
affinity for the hERG channel are taken into account. After the in vitro testing identifies a 
promising drug candidate this molecule is tested in animal models. In the end, phase I-III trials in 
humans have to prove the safety and efficacy which paves the way to the approval as a drug. 
Altogether, the development of one new API (active pharmaceutical ingredient) costs up to 1.6 
billion US Dollars. Thus, there is a strong need for the most promising lead substances to be 
chosen very carefully in the early stages of the development process. A profound understanding 
of the process of molecular recognition between target protein and ligand is therefore essential.1-3 
  
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(Figure 1-1a). Several injections of a certain volume of the ligand are performed with a time lag 
in between. A feedback power holds both cells on the same temperature. An exothermic reaction 
decreases temporarily the feedback power, as shown in Figure 1-1b. During data evaluation each 
of the peaks of the thermogram is integrated. The resulting value is divided by the injected 
amount of ligand (in mole) and plotted against the molar ratio of ligand to protein. The enthalpy 
H0 is represented by the difference of the upper and lower plateau of the resulting fitted 
regression curve, the association constant Ka by its slope and the stoichiometry by the x-axis 
value of its inflection point (Figure 1-1b). G0, H0 and -TS0 can be calculated using 
equation 1-1: 
                                   G0= -RT ln Ka= H0-TS0                                          (1-1) 
with R= 8.314 J K-1 mol-1 and absolute temperature T.5 
The characterization of the full thermodynamic profile can provide valuable information. A 
favorable H0 indicates a net increase in the number and strength of non-covalent bonds during 
the formation of the protein-ligand complex. Thus, to choose the most promising compounds 
between several ligands with similar G0 the enthalpic term can be used as an indicator which of 
the compounds forms the strongest H-bonds. In following design cycles the entropic portion can 
be improved by simply increasing the size of the ligand. Water molecules will be displaced and 
released to the bulk which increases the degrees of freedom of this system. However, these 
principles have to be used reluctantly since the loss in degrees of freedom of rotatable bonds of 
the ligand might influence the entropic portion unfavorably. A similar unfavorable influence on 
G0 can be assumed if polar groups of the protein residues are shielded by hydrophobic parts of a 
ligand which is accompanied by a loss in the enthalpic portion.4, 6 Additionally, the capturing of 
water molecules is followed by a changed thermodynamic profile. The formed H-bonds between 
water molecule and ligand usually lead to a gain in enthalpy while the entropy develops 
unfavorably since the water molecules are fixed in a certain position.7, 8 
The association and dissociation constants can be measured by surface plasmon resonance (SPR). 
The structure of the biosensor of this instrument is shown in Figure 1-2. 
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A thin layer of gold is in tight contact to a glass prism on the one side and to a flow cell which is 
flushed by buffer on the other side. A beam of light is directed on the glass prism under the angle 
of total internal reflection. In the gold layer the light interacts with free oscillating electrons 
(plasmons). Due to this phenomenon a dip in the intensity of the reflected beam of light is 
detected under the SPR angle (right side of Figure 1-2). The SPR angle is dependent on the 
refractive index in the buffer close to the surface of the gold layer. Different procedures are 
available to attach protein molecules to the gold layer. In the amine coupling procedure a mixture 
of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-hydroxysuccinimide (NHS) are 
used to activate the carboxymethyl dextran surface which generates reactive succinimide esters. 
Afterwards a solution of the protein is injected over the surface of the protein. The amine groups 
of the lysine residues of the protein molecules react with the succinimide esters which attaches 
them covalently to the sensor chip. This changes the SPR angle (green dip in Figure 1-2b). 
Remaining succinimide esters are deactivated with ethanolamine. For the measurement of kinetic 
constants increasing concentrations of the inhibitors are injected over the sensor chip surface for 
a certain time. Afterwards buffer flows over the sensor chip so that the ligand can dissociate from 
the protein. The binding of the ligand is visible by the change of the SPR angle (blue dip in 
Figure 1-1c). This change is plotted (Response Units, on the y-axis) against the time (on the x-
axis), resulting in a SPR sensorgram. With an evaluation software a suitable binding model can 
be fitted onto the measured sensorgrams (Figure 1-2d) which gives the kinetic constants kon and 
koff. The KD value is obtained by the ratio of koff/kon.10, 11 
The half-life of a receptor-ligand complex is defined as 0.693/koff. This half-life is directly related 
to the residence time of the ligand complexed to the protein. Since inhibitors which exhibit a 
similar KD value can show different values for koff and kon the kinetic constant can be used to 
classify the screening hits. Dependent on the intended pharmacological use a short or a long 
residence time is desired. For example, for drugs which lower the blood pressure a slow 
dissociation (long residence time) is advantageous. On the contrary, drugs which could have 
toxic side effects should have a short residence time.10, 12 
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1.3 Human Aldose Reductase: a Target for Drug Design to Treat Diabetic 
Complications and a Model System for Structural, Thermodynamic and 
Kinetic studies 
1.3.1 Introductory remarks about diabetes mellitus 
The World Health Organization defines diabetes mellitus as a hyperglycemic condition with 
consequent microvascular complications.13 Symptoms for hyperglycemia are e. g. polyphagia, 
polydipsia, polyuria, fatigue and weight loss.14 Diagnostic criteria for diabetes mellitus from the 
American Diabetes Association (ADA) are A1C ( HbA1C, glycated hemoglobin)  6.5%, fasting 
plasma glucose (FPG)  126 mg/dl, 2-h plasma glucose (2-h PG)  200 mg/dl or classical 
syndroms of hyperglycemia or hyperglycemic crisis together with a random plasma glucose level 
 200 mg/dl.15 Four different types of diabetes mellitus can be differentiated. Type I relies on a 
complete malfunction of the -cells of the pancreas. In type II a progressive insulin secretory 
deficiency develops due to an insulin resistance of the cells. Type III is the gestational diabetes 
which can break out in the second or third trimester of a pregnancy. In type IV several forms of 
diabetes due to other underlying causes are summarized. The former paradigm which classified 
the onset of type I diabetes in young age and the one of type II in older age seems not to be 
justified anymore since recent studies indicate that both types are present in both age groups.15, 16 
1.3.2 Prevalence of diabetes 
It is estimated that in 2013 382 million people worldwide suffered from diabetes. This means that 
8.3% of all adults suffered from this disease. Diabetes is no longer the disease of only the 
industrial countries since 80% of the cases are found in the low- to middle-income countries, 
making this disease a big threat for the health of the world population. Estimations predict an 
increase up to 592 million people living with diagnosed diabetes in 2035.17 Additionally, it 
implies a big significance for the health care systems which have to attend to such a huge amount 
of patients with a chronic disease. 
  
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1.3.3 Treatment of diabetes 
Type I diabetes has to be treated with insulin. The use of multiple dose injections which consists 
of basal and prandial insulins is recommended which should mimic physiological insulin 
secretion. The time of injection should be well coordinated with the carbohydrate intake, the 
blood level of glucose and the intended physical activity.18 For the treatment of type II diabetes 
metformin is the preferred pharmacological ingredient. If the single therapy with metformin is 
not effective enough a second and also a third substance could be added to the therapy. Therefore 
numerous further oral antidiabetic agents are available: Sulfonylureas, thiazolidinediones, DPP-4 
inhibitors, SGLT2 inhibitors and GLP-1 receptor agonists. In some cases the additional 
application of insulin is indicated for type II diabetes as well.18, 19 
1.3.4 Diabetic complications 
Patients who suffer from diabetes have a high risk of developing complications which are related 
to the underlying sickness. Cardiovascular diseases like angina, myocardial infarction, stroke, 
peripheral artery diseases and congestive heart failure might occur. Diabetes is one of the major 
causes of chronic kidney diseases and of blindness. Small blood vessels are damaged and thus the 
supply of the organs is disturbed. Peripheral neuropathies develop in the extremities, especially 
the feet.20-23 As a consequence pain, tingling and loss of feeling develop. Especially the latter 
constitutes a major problem in diabetic patients. Injuries are not noticed which can lead to serious 
infections and ulcerations. This can result in the development of the diabetic foot disease and 
lower limb amputations. Peripheral nerve damage develops in 25% of patients 10 years after 
diabetes is diagnosed and in 50% of patients after 20 years. This diabetic peripheral neuropathy 
influences walking speed, stability, balance and reaction time, negatively.22, 24 Since 30- 50% of 
type II diabetes remains undiagnosed the diabetic complications must be considered as even more 
meaningful because these patients have no possibility for preventive actions.25, 26 A recent review 
classified diabetes as the epidemic of the century and highlighted the need for extensive research 
especially to prevent the development of chronic complications.23, 27 
  
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In the first step, human aldose reductase (ALR2, EC 1.1.1.21) reduces glucose to sorbitol using 
the cofactor NADPH. In the second step of the pathway, sorbitol dehydrogenase oxidizes sorbitol 
to fructose using NAD+ as a cofactor. ALR2 reduces toxic aldehydes to inactive alcohols. 
However, in a diabetic patient the concentration of glucose in the cell becomes too high and 
ALR2 uses it as a substrate. Previously it was assumed that the elevated sorbitol levels would 
lead to a high osmotic pressure. But sorbitol does not reach such high concentrations. The 
depletion of NADPH is now regarded as the important pathological consequence of the sorbitol 
pathway. NADPH is additionally the cofactor for the regeneration of reduced glutathione. The 
latter is an important intracellular antioxidant. Thus, the activity of the ALR2 leads to a higher 
vulnerability for intracellular oxidative stress.21 Engerman et al. measured the effect of the aldose 
reductase inhibitor sorbinil on diabetic dogs over a treatment period of five years.29 The 
administration of sorbinil prevented the decline of the nerve conduction velocity which was 
observed in not treated diabetic dogs. This shows that ALR2 plays an important role in the 
development of diabetic complications.21  
Today we know that development of diabetic complications is a complex process. At least three 
additional mechanisms accompany the polyol pathway: increased formation of advanced 
glycation end products (AGEs), hyperglycemia-induced activation of protein kinase C (PKC) 
isoforms and increased hexosamine pathway flux.21 This might explain why the sole 
administration of an ALR2 inhibitor only shows moderate effects in clinical studies.30, 31 
Consequently, the combination of an ALR2 inhibitor with an inhibitor of one of the other three 
pathways is a promising therapeutic option.32 
1.3.6 Human aldose reductase as a target for drug design 
The ALR2 consists of 315 residues and contains a single peptide chain. It has a /-barrel motif 
which is built up by a central core of eight parallel -sheets (yellow in Figure 1-4) which are 
connected by eight -helices (red in Figure 1-4) running anti-parallel to the -sheets.33 The 
resulting TIM-barrel is an unique structural motif for an oxidoreductase since most reductases 
have a Rossman fold. The substrate binding site lies at the C-terminal end of the TIM-barrel 
which is bordered by several of the loops which connect the -helices to the -sheets. NADP+ is 
stabilized across the barrel. Its nicotinamide is located at the bottom of the binding site. The 
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protein is an excellent system to study the background of the process of bimolecular recognition 
between the protein and ligands.  
1.4 Human Carbonic Anhydrase II as a Model System for Biophysical Studies 
Carbonic anhydrases (CA) are present, as far as we know, in all organisms.46 Four families of 
carbonic anhydrases (CA) exist (-, -, - and -CAs). In mammals, 16 isoforms of -CAs or 
carbonic anhydrase related proteins (CARP) have been discovered.47 The human carbonic 
anhydrase II (hCAII, EC 4.2.1.1.) belongs to the -CAs and is a cytosolic enzyme. It functions as 
a zinc hydrolase which is catalyzing the simple reaction of CO2 and water to bicarbonate and a 
proton:48 
H20   +   C02 H+    +    HCO3-
 
This reaction is reversible and depends on the environmental pH value. hCAII is with a turn-over 
rate of 106 s-1one of the fastest working proteins.48, 49 Due to this simple reaction the protein is 
involved in several basic physiological processes, e.g. pH and CO2 homeostasis, respiration, 
transport of bicarbonate between different tissues and secretion of electrolytes.47 hCAII consists 
of one domain with 259 amino acids. The tertiary structure is dominated by a ten-stranded -
sheet which spans through the protein, dividing it into two halves. The beta sheets have an 
antiparallel orientatation with the exception of two sheets which are parallel. They are surrounded 
by several -helices (Figure 1-6).50 The binding pocket is conically shaped. At the bottom a Zn2+ 
ion is coordinated by three histidine residues (His94, His96 and His119) and a water molecule 
which is most likely present as a hydroxide ion.47 This Zn2+ ion catalyzes the reaction by ordering 
a hydroxide ion in a suitable position to undergo a nucleophilic attack on the CO2 molecule. The 
formed bicarbonate is subsequent displaced by a water molecule. To start a new reaction cycle 
this water molecule has to be deprotonated (Figure 1-7a).47 The fast transport of H+ is assumed to 
be conducted by a proton shuttle formed by His64, His4, His3; His10; His15 and His17.47, 51, 52 
The binding pocket is amphipihilic. Tyr7, Asn62, His64, Asn67, Gln92, Glu106, Thr199 and 
Thr200 are forming the hydrophilic area while Val121, Val143, Leu198 and Trp209 are 
hydrophobic residues (Figure 1-7b).46, 48 
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For this reason, several projects have been carried out in this work: 
The structural and thermodynamic characterization of an ALR2 inhibitor with a new 
scaffold: ALR2 is a promising target to prevent the development of diabetic complications. 
Epalrestat is the only ALR2 inhibitor which is currently marketed (Kinedak®, Eparel®) in Japan 
and India.64 A new type of inhibitor based on a carboxymethylated mercaptotriazinoindole 
(CMTI) scaffold showing high selectivity compared to aldehyde reductase and AKR1B10 was 
investigated in this work by protein crystallography. ITC measurements were used to determine 
the stoichiometry of the binding reaction. 
Determination of the thermodynamic profiles of two new compounds with affinity to ALR2 
and AKR1B10: ITC measurements of two inhibitors for ALR2 and a related protein, AKR1B10, 
which is presently discussed as a putative anticancer target, have been performed. The findings 
were correlated with the binding modes which were determined previously by X-ray 
crystallography. 
Carboxylic acids containing two or three aromatic systems as ALR2 inhibitors: A further 
design cycle to optimize an ALR2 inhibitor series originating from a virtual screening65 was 
performed by the group of Prof. Martin Schlitzer (Philipps University of Marburg). The crystal 
structures and thermodynamic profiles of these ligands were characterized using protein 
crystallography, IC50 value determination and ITC measurements. The influences of subtle 
differences in the binding modes on affinity and thermodynamic profiles have been elucidated. 
Investigating the specificity pocket of ALR2: A congeneric series of ligands based on the 
chemical structure of the previously published inhibitor IDD393 was used to induce different 
conformations of the specificity pocket of ALR2. The influence of different substituents on the 
aromatic ring system which addresses the specificity pocket was investigated. The 
thermodynamic parameters were determined and set in relationship to the conformation of the 
specificity pocket. 
SPR measurements to elucidate the mechanism of binding of sulfonamides to hCAII: The 
kinetic constants and the complex crystal structures of a series of five benzenesulfonamides 
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binding to hCAII were determined with the aim to propose a possible mechanism of the 
association process of this ligand series with hCAII. The results were compared with the findings 
from molecular dynamics (MD) simulations and with previously published data from stopped-
flow fluorescence (SFF) experiments.66, 67 
 
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2.2 Abstract 
Fifteen compounds, sharing an indole-1-acetic acid moiety as a common fragment, were selected 
from commercial databases for testing aldose reductase inhibition. 3-Mercapto-5H-1,2,4-
triazino[5,6-b]indole-5-acetic acid (13) was the most promising inhibitor, with an IC50 in 
submicromolar range and high selectivity, relative to aldehyde reductase. Crystal structure of 
aldose reductase complexed with 13 revealed an interaction pattern explaining its high affinity. 
Physicochemical parameters underline the excellent „lead-likeness“ of 13, as a promising 
candidate for further structure optimizations. 
2.3 Introduction 
In diabetic patients, under conditions of hyperglycemia, glucose becomes a substrate of aldose 
reductase (ALR2), the first enzyme of the polyol pathway. Increased flux of glucose through the 
polyol pathway results in overproduction of the organic osmolyte sorbitol. Depletion of NADPH 
cell stores by aldose reductase may eventually increase the susceptibility of cells to damage by 
reactive oxygen species. In addition, the polyol pathway contributes to the glycation process 
supplying fructose, a reactive glycation agent. Through these mechanisms glucose exerts its 
toxicity with diabetic complications as a consequence.68, 69 
Aldose reductase, due to its physiological role, metabolizes lipid peroxidation products, 
contributing in some settings to the inflammatory response. Inhibition of aldose reductase was 
found to prevent significantly the inflammatory signals induced by cytokines, growth factors, 
endotoxins, high glucose, allergens and auto-immune reactions in cellular as well as animal 
models.70, 71 
The binding pocket of aldose reductase consists of a rigid anion binding pocket and a flexible 
specificity pocket (Figure 2-1a). The anion binding pocket is formed mostly by His110, Tyr48, 
Trp111 and the positively charged NADP+. Different classes of inhibitors are described in 
literature which exhibit varying head groups such as carboxylic acids, succinimides, hydantoins 
and phenolic OH groups which bind with their negative charge to this pocket.45 This specificity 
pocket  may only  be opened  by inhibitors  that  offer the  right  interactions. Phe122 and Leu300  
Identificatio
Carboxy

serve as gatekeepers and can
Leu300 backbone and is best 
determines whether the pocke
with citrate (PDB: 1X96)34 w
structure of ALR2 complexed
fluorobenzyl)carbamothioyl]-5
specificity pocket in open conf
Figure 2-1(a) Schematic view on th
His110, Trp111 and NADP+. The sp
the backbone of the Ala299-Leu300
protein is shown in gray. Phe122 and
the oxygen atoms in red. Two confo
(c) ALR2 complexed with 20 (PDB
oxygen atoms in red. The protein sur
Leu300 is in a conformation that o
carboxylic acid function to the anion
 
n of Novel Aldose Reductase Inhibitors Base
methylated Mercaptotriazinoindole Scaffold
 seal the pocket. The main flexibility is s
visible in different conformations of the Leu
t is open or not.37 In Figure 2-1b the protein
ith the specificity pocket in closed conform
 with the highly potent aldose reductase inh
-fluorophenoxy acetic acid (20,40 Figure 2-
ormation (PDB: 1US0).  
e binding site of ALR2. The anion binding pocket is
ecificity pocket is opened and closed because of the 
 stretch. (b) ALR2 complexed with citrate (PDB code
 Leu300 are colored in red. The carbon atoms of citra
rmations of citrate are visible. The specificity pocket 
 code: 1US0). The carbon atoms of the inhibitor a
face is colored in gray. Phe122 and Leu300 are color
pens the specificity pocket. The ligand binds presum
 binding pocket. (d) Chemical structure of 20. 
d on 
 
 
39 
hown by the Ala299- 
300 side chain which 
 is shown complexed 
ation. In Figure 2-1c, 
ibitor 2-[(4-Bromo-2-
1d), is shown with the 
 
 mainly formed by Tyr48, 
conformational changes in 
: 1X96). The surface of the 
te are colored in green and 
is observed in closed state. 
re shown in blue and the 
ed in red. The side chain of 
ably with a deprotonated 
Identificatio
Carboxy
 
40 

Aldose reductase inhibitors (A
hydantoins (sorbinil), or the 
investigated for their role aga
sufficient  efficacy in human  c
Figure 2-2 (a) Compounds 1- 8. (b
n of Novel Aldose Reductase Inhibitors Base
methylated Mercaptotriazinoindole Scaffold
RIs), such as acetic acid derivatives (tolre
succinimide class of compounds (ranirestat
inst diabetic complications.72-74 None of th
linical trials without  undesirable side  effect
) Compounds 9 - 12. (c) Compounds 13 - 19. 
  
d on 
 
stat, zenarestat), spiro 
) have been primarily 
em has demonstrated 
s. The involvement of  
 
Identification of Novel Aldose Reductase Inhibitors Based on 
Carboxymethylated Mercaptotriazinoindole Scaffold 
 
41 

ALR2 in inflammatory pathologies apparently renewed the interest in the field of ARIs.75 In the 
search for better ARIs, the focus has been shifted towards novel chemotypes. Emphasis was 
given not only to the inhibitory activities but also to the physicochemical properties determining 
biological availability in target tissues.76, 77 Recently presented examples of a new generation of 
aldose reductase "differential" inhibitors were found to preferentially inhibit the reduction of 
either hydrophilic or hydrophobic substrates.78, 79 Substituted indole-1-acetic acids represent a 
group of ARIs of high activity and selectivity,80-83 with lidorestat as a promising candidate for 
clinical studies. Yet lidorestat was withdrawn from these studies owing to its side effects. 
Nonetheless, we still consider the indole-1-acetic acid moiety as a promising starting fragment 
for the design of efficient, selective and pharmacologically applicable ARIs. 
In line with the above findings, we used a ligand-based drug design strategy to search for novel 
ARIs in databases of commercially available compounds. Fifteen compounds with an indole-1-
acetic acid moiety as a common fragment in their structure were selected for experimental testing 
of their inhibitory potency against aldose reductase. Among the compounds studied, 3-mercapto-
5H-1,2,4-triazino[5,6-b]indole-5-acetic acid (compound 13) exhibited the highest biological 
activities both at the level of isolated enzyme and at organ level, in a model of isolated rat eye 
lenses. The stoichiometry of the binding reaction was determined by ITC. To identify crucial 
interactions within the aldose reductase binding site, the crystal structure of ALR2 in complex 
with 13 was determined. Selectivity in relation to the closely related rat kidney aldehyde 
reductase (ALR1) was evaluated. Structure–activity relationships along with a computer-based 
physicochemical profiling of the compounds are discussed. 
2.4 Results and Discussion 
2.4.1 Compounds 
ChemSpider database was screened for compounds exhibiting the structural requirements to 
embed an indole-1-acetic and indoline-1-acetic acid moiety. An initial database of 5813 
compounds was thus obtained. Coincidence of four additional requirements, namely 
experimental/ACD calculated logP = 0-3.5, free N-carboxymethyl group, up to 6 hydrogen bond 
donors and 2-6 hydrogen bond acceptors reduced the set to 1147 compounds. Then applying 
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LASSO similarity value of 0.99 for ALR2 inhibition in combination with commercial availability 
requirement gave 335 compounds. 
In our further search we focused on indole-1-acetic acids bearing a neutral substituent (compound 
3) or a basic substituent (compounds 4-8) in position 3 (structural analogues of lidorestat). In 
addition, we were interested in the effect of embedding the substituent into a fused ring 
(compounds 9-17). Vendor accessibility was taken into consideration in selection of the 
compounds for experimental evaluation. Their structures are shown in Figure 2-2. For 
comparison, two indole-1-propionic acid congeners (2, 5) were included into the experimental 
sample set. In addition, two structural variants lacking the indole-1-acetic acid moiety were 
selected (compounds 18, 19). 
2.4.2 ALR2 inhibition 
The compounds 1- 19 were evaluated for their potential to inhibit the in vitro reduction of D,L-
glyceraldehyde by partially purified ALR2 extracted from rat eye lenses, using zopolrestat and 
epalrestat as reference inhibitors (Table 2-1). It has been shown that human ALR2 exhibits 85% 
sequence homology to rat lens ALR2,84 while the catalytic active sites of both enzymes are 
considered identical.85 Unsubstituted indole-1-acetic acid (1) inhibited ALR2 in low micromolar 
range as suggested by the measured IC50 values. Insertion of a substituent at position 3 
(compounds 3,4, 6-8) resulted in reduced inhibitory power towards ALR2 compared to the 
unsubstituted indole-1-acetic acid (1). Variation of the basic substituents in compounds 4, 6-8 
had only mild effect on the inhibitory potential. For the propionic acid congeners 2 and 5, a 
profound decrease of inhibition was observed, with IC50 ~50 M for 2 and IC50>100 M for 5. 
The polycyclic derivatives 9 and 10, with one or two additional fused aromatic rings, 
respectively, revealed moderately increased inhibitory power compared to 1. Yet, the addition of 
a third ring in 11 resulted in a substantial drop of inhibitory potential. Increased polarity of the 
fused ring in 12 resulted in a similar reduction of the inhibitory power. On the other hand, 
profoundly increased inhibition was recorded for the mercapto triazine derivatives 13 and 17, 
with IC50 values in submicromolar range.  
 
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Table 2-1 Inhibitory Effect of Compounds 1-19 on rat ALR2 and ALR1. 
  
IC50 (µM)A 
compound MW ALR2 ALR1 
1 175.19 7.30 ± 0.03 80.16 ± 2.30 
2 189.22 53.54 ± 3.70 11.75 ± 0.96 
3 259.31 13.76 ±0.73 68.44 ± 3.48 
4 260.34 30.14 ± 0.67 38.05 ±2.13C 
5 274.37 19.85 ± 0.14C 6.65C 
6 246.31 42.16 ± 2.06 22.31 ± 1.93C 
7 258.32 46.48 ± 11.88 19.20 ± 0.27C 
8 274.32 34.52 ± 1.29 32.49 ± 1.26C 
9 215.25 2.87 ± 0.86 4.82 ± 0.40 
10 277.28 2.75 ± 0.78 24.79 ± 0.61 
11 317.3 9.95 ± 0.35 15.13 ± 2.84B 
12 243.22 11.46 ± 2.38 48.99 ± 9.04C 
13 260.28 0.097 ± 0.019 40.55 ± 2.05 
14 302.35 2.05 ± 0.05 14.13 ± 0.36 
15 368.39 2.24 ± 0.14 1.18 ± 4.34B 
16 435.5 4.06 ± 0.10 23.48 ± 2.11B 
17 373.43 0.32 ± 0.05 19.56 ± 5.38 
18 260.27 3.46 ± 0.53B n.d. 
19 202.24 4.41 ± 2.94C n.d. 
Zopolrestat 419.38 0.005 ± 0.001 0.049 ± 0.016 
Epalrestat 319.4 0.25 n.d. 
Sodium - Valproate 166.11 n.d. 56.1 ± 2.7 
A Results are mean values ± SD from at least three measurements.  
B %I at 10 µM concentration. 
C %I at 100 µM concentration. 
 
Values of IC50 in low micromolar range were recorded for the remaining mercapto triazine 
derivatives (14-16). The strongest inhibition of ALR2 was found for 13 with IC50 ~ 0.1 M. In 
addition, we obtained a closely related value (IC50 = 0.057 ± 0.002 M) for the inhibition of 
human recombinant AKR1B1 by 13, measured under identical reaction conditions as applied for 
rat ALR2 assay, with the protein concentration of 0.28 M. The structure-activity relationship in 
the series of 12, 13, 18 and 19 points to the necessity of a concurrent presence of both, the 
carboxymethyl group in position 5 and the terminal sulfur to achieve best affinity. Shifting of the 
carboxymethyl group from indole nitrogen to sulfur in 18 or its absence in 19 resulted in a loss of 
activity.  
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2.4.3 Selectivity 
An important feature of pharmacologically applicable ARIs is their high selectivity over other 
members of the aldo-keto reductase family. The co-inhibition of structurally related 
physiologically relevant oxido-reductases may create undesired side effects. To test for 
selectivity, the closely related aldehyde reductase (ALR1) is routinely studied.86 The ALR1 
inhibitory potencies, expressed as IC50 values for the inhibition of the reduction of the substrate 
D-glucuronate by partially purified ALR1 from rat kidney, are shown in Table 2-1. For 
comparison, the reference valproic acid is included. All tested compounds were found to be less 
active on ALR1 compared to ALR2. In the series of the most efficient ARIs, the selectivity 
indices were found to be the highest for the mercapto triazines. It should be noted that the most 
selective compound 13, with a selectivity factor above 400, is also the most potent ARI in this 
series.  
For compound 13, AKR1B10 inhibition was assayed yielding an IC50 value of 21.4 ± 2.0 M and 
the corresponding selectivity factor with respect to ALR2 was above 200. 
2.4.4 Enzyme kinetics 
In the next step, the enzyme kinetics for the most efficient ARI 13 was analyzed. Uncompetitive 
inhibition was observed in relation to D,L-glyceraldehyde as a substrate (Figure 2-3) with a 
corresponding inhibition constant Ki(13) = 0.089 ± 0.018 mol/L. 
2.4.5 Conformation analysis 
For the most efficient ALR2 inhibitor 13, tautomeric forms were first estimated by the Marvin 
calculator25 in the range of pH = 6.2 – 8.0. As a result, three tautomers were selected (Figure 2-4) 
and investigated by means of quantum-chemical calculations. The most preferred tautomer in 
solution was found to be 13-1 followed by the forms 13-2 and 13-3 with relative energy 
stabilities of 16.4 kJ/mol and 72.9 kJ/mol, respectively (see Section 2.6.4).  
 
Identificatio
Carboxy

Figure 2-3 Inhibitory effect of com
initial enzyme velocity versus the co
() no inhibitor; (	) 0.05 M; (
) 0.1
 
Figure 2-4 Tautomeric forms of co
 
2.4.6 Crystal structure and
The crystal structure of ALR2
1.26 Å. Two molecules of the
one as expected in the binding
-10 -5
n of Novel Aldose Reductase Inhibitors Base
methylated Mercaptotriazinoindole Scaffold
pound 13 on rat lens aldose reductase. Typical do
ncentration of substrate (D,L-glyceraldehyde) in the 
 M of 13 (uncompetitive type of inhibition). 
mpound 13. 
 isothermal titration calorimetry (ITC) me
 in complex with 13 was determined at pH 8
 inhibitor are visible in the determined diffe
 pocket and a second in the vicinity of the 
0
1
2
0 5 10
Glyceraldehyde (mM)  1/c
1/
v
d on 
 
 
45 
 
uble reciprocal plots of the 
presence or absence of 13: 
 
asurements 
.0 with a resolution of 
rence electron density, 
entrance of the pocket 
15 20
Identification of Novel Aldose Reductase Inhibitors Based on 
Carboxymethylated Mercaptotriazinoindole Scaffold 
 
46 

(Figure 2-5a). The latter is in contact with the binding site inhibitor molecule (first molecule) and 
refines to an occupancy of 70% whereas the active site molecule shows 100% occupancy. The 
oxygen atom of the carboxylate group of the second inhibitor molecule and N2 of the first one 
form an H-bond (2.8 Å, Figure 2-5c). The proton is most likely contributed by the nitrogen of the 
triazine ring of the first molecule of 13, as we assume that the carboxylate is deprotonated under 
the applied conditions.  
In our structure (Figure 2-5b), the first inhibitor molecule which occupies the anion binding 
pocket forms similar interactions as described for related inhibitors exhibiting a carboxylate head 
group, for example the inhibitor 20 (IDD594), with which the so far best resolved crystal 
structure of an ALR2-inhibitor complex could be determined.40 One carboxylate oxygen atom of 
the inhibitor forms an H-bond to NE2 of His110 (2.7 Å) and to the Tyr48OH group (2.7 Å), 
while the second oxygen is in contact with NE1 of Trp111 (3.0 Å). The most likely negatively 
charged carboxylate group of 13 makes an electrostatic interaction with the oxidized and then 
positively charged NADP+ (3.1 Å). A water molecule is connected to ND1 of His110 (3.0 Å). 
One further water molecule is interacting with N1 of the triazine ring of the inhibitor (3.0 Å). The 
remaining contacts to the protein are of hydrophobic nature, e.g. to Trp219 (3.5 Å), Trp20 
(3.5 Å), Trp111 (4.0 Å), Trp79 (5.0 Å), Val47 (3.8 Å), Phe122 (4.2 Å). Presumably the inhibitor 
binds favorably to this aromatic environment due to its own aromatic character.  
We analyzed the crystal structure to rationalize the good selectivity of 13 for ALR2 compared to 
ALR1. The conformation adopted in the binding pocket is surprising. Previously it has been 
proposed that addressing the protein with the specificity pocket in open state is a prerequisite for 
a high selectivity index,39 however we found in the present complex this pocket to be closed 
(Figure 2-5a). The distance of the sulfur atom of 13 to the backbone nitrogen of Leu300 (3.2 Å) 
indicates a putative H-bond to this residue (Figure 2-5b) even though the geometry of this 
interaction is not ideal for an H-bond. This requires the sulfur atom to be in the tautomeric state 
to act as an H-bond acceptor. To obtain accurate values for the bond lengths and angles with 
corresponding standard deviations in order to support our assumption about the tautomeric state 
actually adopted for binding to ALR2, we performed a refinement with SHELXL without 
imposing any geometry restraints for 13. However, no conclusive results could be obtained.  
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that tautomer 13-2 is present as it would allow to establish the observed H-bond to the second 
molecule of 13. In tautomer 13-1, N2 cannot serve as an H-bond donor to interact with the most 
likely deprotonated carboxylate group of the second molecule of 13 (pH 8.0). The quantum-
chemical calculations however suggested the tautomer 13-1 to be the most likely one in water. 
The energies of 13-1 and 13-2 in vacuum were very similar, slightly shifted in favor of 13-2 
(Table 2-6 in Section 2.6.4). We even assume the equilibrium between different tautomers might 
be changed upon ligand binding to the protein as the inhibitor molecule in the anion binding 
pocket is largely desolvated. The second inhibitor molecule binds (Figure 2-5c) via the described 
H-bond to the first one and the other carboxylate oxygen atom is in H-bond distance to the 
backbone nitrogen of Ser302 (2.8 Å). Furthermore, the aromatic core skeleton makes a face to 
face -stacking to Trp219 (3.4 Å).  
We perfomed ITC measurements to determine the stoichiometry of the binding reaction, which 
reveals a value in agreement with a 1:1 binding, similarly observed for other inhibitors. 
Accordingly, the second inhibitor molecule is only weakly bound and possibly results from the 
applied concentrated crystal soaking conditions. It is well accommodated in the protein structure 
and likely suggests an additional binding position that could intermediately be adopted during the 
penetration of the inhibitor into the catalytic center. Also the occupancy of 70% indicates that the 
second molecule is only weakly bound. In agreement with the first molecule of 13, we decided to 
build it as tautomer 13-2. Our ITC experiments were performed from three buffer conditions 
(Table 2-2) suggesting a proton entrappment upon protein binding (Figure 2-6).  
Table 2-2 Hobs for 13 in the corresponding buffer system.  
 
buffer G0 H0ionA H0obs 
 
[kJ/mol] [kJ/mol] [kJ/mol] 
HEPES 35.9 +/- 0.3 21.07 -51.2 +/- 1.4 
Tricine 34.9 +/- 0.4 31.97 -38.7 +/- 0.6 
TRIS 35.9 +/- 0.2 48.07 -33.1 +/- 0.8 
    A
 Values for Hion were taken from literature.87, 88 
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present in lidorestat. Lidorestat makes several interactions in the specificity pocket which 
explains the higher IC50 value (5 nM) compared to 13.21,22 
2.4.8 Physicochemical properties 
Values of logP and log D7.4 calculated by the ACD/Labs software89 for 13 were found to be 1.68 
and -2.03, respectively. The distribution ratio of 13 was also determined experimentally by a 
standard shake-flask technique which gave a closely similar value of log D7.4 =-1.90 ± 0.03. 
 
Table 2-3 Molecular obesity indices calculated for mercapto-triazino-indoles 13-17. 
Compound pIC50 logPA logDA LEB LLEC LELPD BEIE 
number  ACD/Labs ACD/Labs     
13 7.01 1.68 -2.03 0.55 5.33 3.08 26.94 
14 5.69 2.68 -1.05 0.38 3.01 7.07 18.81 
15 5.66 3.63 -0.11 0.31 2.03 11.93 15.36 
16 5.39 2.06 -1.68 0.24 3.34 8.44 12.38 
17 6.49 2.2 -1.54 0.35 4.29 6.3 17.38 
 
       
A Log P and log D were calculated with ACD/Labs software24,  
B LE = -1.4log(IC50)/N, N:number of heavy atoms,  
C LLE = pIC50 – logP,  
D LELP = logP/LE,  
E BEI = pIC50/MW (kDa) 
 
 
Considering the high inhibition efficacy/selectivity along with the structural parameters fitting 
„the rule of three“, (MW<300 Da, clogP<3), compound 13 appears as a promising lead. 
Therefore, molecular obesity indices, considering potency, size and lipophilicity in the same 
index,90-92 were calculated for 13 and for related mercapto-triazino-indoles 14-17 (Table 2-3). 
Indeed the calculated values of the corresponding parameters (LE = 0.55, LLE = 5.33, 
LELP = 3.08 and BEI = 26.94) point to an excellent „lead-likeness“ of 13, rendering this 
compound suitable for further optimization. Another aspect that enhances „lead-likeness“ of 13 is 
its good water solubility (10 mM water solution of 13 could easily be prepared under neutral pH 
conditions).  
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2.4.9 Eye lens sorbitol 
The inhibitory effect of compound 13 with respect to sorbitol accumulation in isolated rat eye 
lenses was determined. As shown in Table 2-4, increased sorbitol levels were recorded in the 
isolated rat eye lenses incubated with glucose, in comparison with control incubations without 
glucose, reflecting increased flux of glucose through the cytosolic lens ALR2. Similarly other 
authors93 observed a more than 10-fold increase of sorbitol levels in the isolated eye lenses 
incubated with glucose under comparable conditions (50 mM glucose, 4 h incubation). Sorbitol 
accumulation was significantly and in a concentration-dependent way inhibited by compound 13, 
starting at a concentration as low as 10 M. This finding indicates the ready uptake of compound 
13 by the eye lens tissue followed by inhibition of the cytosolic ALR2. Obviously, the final 
response observed at the organ level of isolated lenses is the result of an interplay of well-suited 
physicochemical properties of 13 (namely lipophilicity and ionization) with good inhibition 
efficacy. 
Table 2-4 Effect of compound 13 on sorbitol accumulation in isolated rat eye lenses cultivated with high 
glucoseA 
   
  
Incubation Sorbitol (nmol/g)  n 
-  Glucose 233.99 ± 7.80 B 15 
+ Glucose 772.90 ± 19.70 17 
+ Glucose  +  13 (1.0 M) 668.66 ± 54.15 4 
+ Glucose  +  13 (10 M) 536.01 ± 25.90 C 7 
+ Glucose  +  13 (50 M) 478.71 ± 30.99 C 4 
+ Glucose  +  13 (100 M) 395.06 ± 23.83 C 10 
 
A Glucose, 50 mM; time of incubation, 3 hours; 37 °C. Results are mean values ± SEM from n independent 
incubations. 
B p <0.001 vs. (+)Glucose (Student´s t-test) 
C p <0.001 vs. (+)Glucose (Student´s t-test) 
 
2.5 Conclusions 
By applying a ligand-based search for novel ARIs in databases of commercially available 
compounds, fifteen compounds exhibiting an indole-1-acetic acid moiety as common parent 
scaffold in their structure were selected to experimentally assess their inhibitory potency against 
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aldose reductase. 3-Mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid (13) with an IC50 in 
submicromolar range and a selectivity discrimination relative to ALR1 about 400 and to 
AKR1B10 above 200, was identified as promising scaffold for development of efficient, selective 
and pharmacologically applicable ARIs. The crystal structure determination performed on 13 
revealed an interaction pattern explaining its high affinity. The ALR2 inhibitory potential of 13 
was demonstrated at the organ level in isolated rat eye lenses incubated with high glucose. 
Molecular obesity indices, in addition to the structural features matching „the rule of three“, 
along with good water solubility, point to an excellent „lead-likeness“ of compound 13, as a 
promising candidate for further structure optimizations. 
2.6 Description of Experimental Procedures 
2.6.1 Expression and purification, ITC measurements, crystallization and structure 
determination 
The expression and purification of ALR2 are described in Section 9.2.1, the ITC measurements 
in Section 9.2.5, the crystallization in Section 9.2.3, the soaking in Section 9.2.3.7 and the 
structure determination in Section 9.2.4. 
2.6.2 Chemicals 
To control the purity of the tested compounds we used LC-MS technique, Agilent 1100 HPLC-
MSD SL Ion Trap mass spectrometer with a multi-mode ion source (ESI, APCI) (Agilent 
Technologies, USA), mostly under following conditions: Column Zorbax SB-C18 1.8 µm 
4.6x15mm, Rapid Resolution cartridge (PN 821975-932), mobile phase  – acetonitrile, – 
water (0.1% formic acid); flow rate 3 mL/min; gradient: 0 min – 0% ; 0.01 min – 0% ; 0.5 
min – 100% ; 1.00 min –100% ; 1.01 min – 0% ; injection volume 1µl; ionization mode - 
atmospheric pressure chemical ionization (APCI; Scan range m/z 80-1000). For the sample 
preparation ~0.7 mg of the compound was commonly dissolved in DMSO. A purity of 95% has 
been established for all compounds studied (compounds 1-19). Sorbitol dehydrogenase, 
diaphorase, -NAD+, resazurin, M-199 medium (M 3769), D,L-glyceraldehyde, sodium D-
glucuronate, sodium valproate, NADPH, D-glucose, -mercaptoethanol, epalrestat and HClO4 
were obtained from Sigma-Aldrich (St. Louis, MO, USA). AKR1B10 was from Acris 
Antibodies, Herford Germany. Zopolrestat (lot # 43668-12-7F) was supplied as a gift sample by 
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Pfizer (Groton, CT, USA). Diethylaminoethyl cellulose DEAE DE 52 was from Whatman 
International Ltd. (Maidstone, England). Other chemicals were purchased from local commercial 
sources and were of analytical grade quality. 
2.6.3 Animals  
Male Wistar rats 8- 9 weeks old, weighing 200- 230 g, were used as organ donors. The animals 
came from the Breeding Facility of the Institute of Experimental Pharmacology Dobra Voda 
(Slovak Republic). The study was approved by the Ethics Committee of the Institute and 
performed in accordance with the Principles of Laboratory Animal Care (NIH publication 83-25, 
revised 1985) and the Slovak law regulating animal experiments (Decree 289, Part 139, July 9th 
2003).  
2.6.4 Computational methods 
Calculator Plugins were used for the prediction of the distribution of the compound 13 
tautomers.86 For the most probable tautomers for the range of pH= 6.2 – 8.0, the low energy 
conformations were obtained by equilibrium conformer systematic search (MMFF94) and 
subsequent optimization in DFT B3LYP 6-31G* method, all performed in the program 
SPARTAN’08 (Wavefunction, Inc., Irvine, CA, 2009). To search for the most probable tautomer 
of 13, the effect of solvation was also taken into account and the values of total energies Eaq94 of 
the solvated tautomers were calculated, along with the energies E in vacuum.  
Table 2-5 Energies of tautomers of compound 13 calculated in vacuum (E) and in water (Eaq). 
 
 
 
2.6.5 Preparation of rat ALR2 
ALR2 from rat lens was partially purified using a procedure adapted from Hayman and 
Kinoshita95 as follows: lenses were quickly removed from rats following euthanasia and 
homogenized in a glass homogenizer with a teflon pestle in 5 volumes of cold distilled water. 
The homogenate was centrifuged at 10 000 g at 0-4°C for 20 min. The supernatant was 
E (kJ/mol) Eaq (kJ/mol) 
13-1 -3127206.7 -3127489.4 
13-2 -3127207.1 -3127473.0 
13-3 -3127173.3 -3127416.5 
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precipitated with saturated ammonium sulfate at 40%, 50% and then at 75% salt saturation. The 
supernatant was retained after the first two precipitations. The pellet from the last step, 
possessing ALR2 activity, was dispersed in 75% ammonium sulfate and stored in smaller 
aliquots in liquid nitrogen container. 
2.6.6 Preparation of rat ALR1 
ALR1 from rat kidney was partially purified according to the reported procedure of Costantino et 
al.96 as follows: kidneys were quickly removed from rats following euthanasia and homogenized 
in a knife homogenizer followed by processing in a glass homogenizer with a teflon pestle in 3 
volumes of 10 mM sodium phosphate buffer, pH 7.2, containing 0.25 M sucrose, 2.0 mM EDTA 
dipotassium salt and 2.5 mM -mercaptoethanol. The homogenate was centrifuged at 16,000 g at 
0-4°C for 30 min and the supernatant was subjected to ammonium sulfate fractional precipitation 
at 40%, 50% and 75% salt saturation. The pellet obtained from the last step, possessing ALR1 
activity, was redissolved in 10 mM sodium phosphate buffer, pH 7.2, containing 2.0 mM EDTA 
dipotassium salt and 2.0 mM -mercaptoethanol to achieve total protein concentration of 
approximately 20 mg/mL. DEAE DE 52 resin was added to the solution (33 mg/mL) and after 
gentle mixing for 15 min removed by centrifugation. The supernatant containing ALR1 was then 
stored in smaller aliquots in liquid nitrogen. No appreciable contamination by ALR2 in ALR1 
preparations was detected since no activity in terms of NADPH consumption was observed in the 
presence of glucose substrate up to 150 mM.  
2.6.7 ALR1 and ALR2 enzyme assays 
ALR1 and ALR2 activities were assayed spectrophotometrically as described before97 by 
determining NADPH consumption at 340 nm and were expressed as decrease of the optical 
density (O.D.)/s/mg protein. To determine ALR2 activity, the reaction mixture contained 4.67 
mM D,L-glyceraldehyde as a substrate, 0.11 mM NADPH, 0.067 M phosphate buffer, pH 6.2 and 
0.05 mL of the enzyme preparation in a total volume of 1.5 mL. The reference blank contained 
all the above reagents except the substrate D,L-glyceraldehyde to correct for oxidation of NADPH 
not associated with reduction of the substrate. The enzyme reaction was initiated by addition of 
D,L-glyceraldehyde and was monitored for 4 min after an initial period of 1 min at 30 °C. ALR1 
activity was assayed analogically using 20 mM D-glucuronate as a substrate in the presence of 
Identification of Novel Aldose Reductase Inhibitors Based on 
Carboxymethylated Mercaptotriazinoindole Scaffold 
 
55 

0.12 mM NADPH in 0.1 M phosphate buffer pH 7.2 at 37 °C. Enzyme activities were adjusted 
by diluting the enzyme preparations with distilled water so that 0.05 mL of the preparation gave 
an average reaction rate for the control sample of 0.020 ± 0.005 absorbance units/min. The effect 
of compounds on the enzyme activity was determined by including in the reaction mixture each 
inhibitor at required concentrations dissolved in water or DMSO at 1% final mixture 
concentration. The inhibitor at the same concentration was included in the reference blank. IC50 
values (the concentration of the inhibitor required to produce 50% inhibition of the enzyme 
reaction) were determined both from the least-square analysis of the linear portion of the semi-
logarithmic inhibition curves and non-linear regression analysis. Each curve was generated using 
at least four concentrations of inhibitor causing an inhibition in the range from at least 25 to 75%.  
2.6.8 AKR1B1 and AKR1B10 enzyme assays 
The aforementioned procedure for rat ALR2 assay was employed, with the final protein 
concentrations of 0.28 µM. In AKR1B10 assay, 0.1 M phosphate buffer pH 7.0 was used instead 
of 0.067 M phosphate buffer, pH 6.2. 
2.6.9 Eye lens sorbitol assay 
The animals in light ether anesthesia were killed by exsanguinations of the carotid artery and the 
eye globes were excised. The lenses were quickly dissected and rinsed with saline. The 
compound 13 dissolved in water was added into the tubes containing freshly dissected eye lenses 
(1 lens per tube) in M-199 medium at pH 7.4, bubbled at 37 °C with pneumoxid (5% CO2, 95% 
O2), to the final concentrations as reported, 30 min before adding glucose. The incubation was 
initiated by adding glucose to the final concentration of 50 mM and then continued at 37 °C with 
occasional (in about 30-min intervals) bubbling the mixture for approximately 30 s periods with 
pneumoxid. The incubations were terminated after a 3 h period by cooling the mixtures in an ice 
bath, followed by washing the lenses three times with ice-cold phosphate buffered saline (1 mL). 
The short term cultivations were preferred to avoid substantial permeability changes of the eye 
lenses. The washed lenses were kept deep-frozen for sorbitol determination which was performed 
as described before.98 In brief, the frozen lenses were let to melt at the ambient temperature. Then 
distilled water (0.2 mL/1 lens) was added. The lenses were disrupted by a glass rod. The rod was 
washed twice with distilled water (0.1 mL) and the suspension was ultra-sounded for 5 min. 
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Thereafter, ice cold HClO4 (9%, 0.4 mL) was added and mixed thoroughly. The mixture was 
ultra-sounded for another 5 min and then kept on ice for 30 min to let proteins precipitate. The 
precipitated protein was spun off (15 min at 3 000 rpm) at 4° C. The supernatant was neutralized 
with concentrated K2CO3 (4 M). The neutralized supernatant was used for determination of 
concentration of sorbitol by modified enzymatic analysis.99 In brief, sorbitol was oxidized to 
fructose by sorbitol dehydrogenase (SDH) with concomitant reduction of resazurin by diaphorase 
to the highly fluorescent resorufin. The final concentrations of the assay solutions were: 
diaphorase (11.5 U/25 mL triethanolamine buffer), NAD+ (25 mg/25 mL triethanolamine buffer), 
resazurin (0.025 mL 2 mM resazurin solution in 25 mL of triethanolamine buffer), SDH (15.025 
U/1 mL triethanolamine buffer). Reaction mixtures were incubated for 60 min at room 
temperature with an opaque cover. The sample fluorescence was determined at excitation 544 
nm, emission 590 nm. After the appropriate blanks were subtracted from each sample, the 
amount of sorbitol in nmol per gram of lens wet weight in each sample was determined by 
comparison with a linear regression of sorbitol standards. 
2.6.10 Partitioning 
The distribution ratios D in 1-octanol/buffer systems, defined by total concentration of a solute in 
organic phase divided by that in aqueous phase, were measured using the shake-flask 
technique100 at room temperature. The organic and aqueous phases were mutually saturated. 
Compound 13 was dissolved in aqueous buffer solution (0.1 M phosphate buffer pH 7.4) in final 
concentration of 100 M; the solutions were shaken with 1-octanol for 3 h. Both aqueous and 
organic phase volumes were 3 mL. The phases were separated by centrifugation for 1 h. The 
organic layer was removed with a Pasteur pipette. The concentration of the solute was determined 
in both phases by UV spectrophotometry. 
 
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3 Structural Determinants of the Selectivity of  
3-Benzyluracil-1-Acetic Acids towards Human Enzymes Aldose 
Reductase and AKR1B10 
3.1 Introductory Remarks 
The following chapter is an excerpt of a manuscript which was prepared for submission to a 
scientific journal. This project was a collaboration with Dr. Francesc Xavier Ruiz, Alexandra 
Cousido-Siah, Dr. André Mitschler and Prof. Dr. Alberto Podjarny (CNRS, Illkirch, France), 
Dres. Marta Domínguez and Ángel R. de Lera (Universidade de Vigo), Dres. Maria Jesús Martin 
and Jesús Ángel de la Fuente (Biomar Microbial Technologies S. A., León), Dres. Sergio Porté, 
Isidro Crespo, Jaume Farrés and Xavier Parés (Universitat Autònoma de Barcelona). The author 
of this thesis contributed the ITC measurements along with the discussion of the corresponding 
results to this work. 
3.2 Abstract 
Human enzymes aldose reductase (ALR2) and AKR1B10 have been thoroughly related to 
diabetes, inflammation disorders and cancer. Here we have identified two new lead compounds, 
JF0048 (23) and JF0049 (24), that selectively target these enzymes. Although 23 and 24 share the 
3-benzyluracil-1-acetic acid scaffold, they have different substituents in their aryl moieties. 
Inhibition, thermodynamic and structural characterization of both enzymes reveals that the 
chloronitrobenzene moiety of 23 can open the ALR2 specificity pocket but not the AKR1B10 
cognate. In contrast, the larger atoms at ortho and/or meta positions of 24 prevent the ALR2 
specificity pocket from opening due to steric hindrance and provide a tighter fit to the AKR1B10 
inhibitor binding pocket. 
3.3 Introduction 
Human aldose reductase (ALR2 or AKR1B1) and AKR1B10 are enzymes of biomedical interest 
because of their involvement in diabetes (ALR2) and in cancer (ALR2 and AKR1B10). They 
belong to the aldo-ketoreductase superfamily (AKR) and are NADPH-dependent enzymes 
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In the search of novel ligands selective for AKR1B10, we focused our attention on compound 
JF0048 (23), which was previously shown to be selective for rat lens ALR2 versus rat kidney 
aldehyde reductase.116 We surmised that the modification of the 3-benzyluracil-1-acetic acid 
scaffold through the incorporation of additional substituents at the (poly)halogenated aryl moiety, 
reminiscent of the sponge natural products, might shift the selectivity of the designed compound 
to target AKR1B10 instead. In the present work, this assumption was indeed confirmed, since 
compound JF0049 (24) (Figure 3-1) was found to be selective for AKR1B10. In addition, 
structural insights were gained from several X-ray structures of the corresponding complexes. 
The selectivity of 23 for ALR2 was justified by its ability to open the specificity pocket of the 
enzyme. On the other hand, the selectivity of 24 for AKR1B10 is probably due to the inability of 
its bulkier aryl moiety to occupy the specificity pocket of ALR2 and its better fitting into the 
larger active site of AKR1B10, including a subpocket defined by loop A. This study paves the 
way for future efforts in structure-guided drug discovery, directed to both ALR2 and the 
relatively unexplored AKR1B10.  
3.4 Results and Discussion 
3.4.1 Inhibition assays of ALR2/AKR1B10 complexes with 23 and 24  
Kotani and coworkers116 had previously assayed 23 against rat lens ALR2 and rat kidney 
aldehyde reductase, which were purified from the corresponding tissues. They found that 23 was 
one of the best hits for rat ALR2, with more than 4000-fold selectivity versus rat aldehyde 
reductase. We confirmed that 23 exhibits strong inhibition against human ALR2 (IC50 = 170 
nM),117, 118 and is 127-fold and >4000-fold more potent than for AKR1B10 and ALR1, 
respectively. On the other hand, 24 inhibits AKR1B10 with an IC50 value of 450 nM, being 
8-fold and >200-fold more potent than for ALR2 and ALR1, respectively (Table 3-1). We have 
also performed ITC measurements to study the binding of 23 and 24 to both enzymes. As shown 
in Table 3-3, the Gibbs free binding energy (G°) and the dissociation constants (KD) obtained 
by ITC are in agreement with the inhibition assays for the binding of 23 and 24 to ALR2. Only 
for the binding of 24 to AKR1B10, the KD value is slightly higher in comparison to the 
corresponding IC50 value.  
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Table 3-1 IC50 values and selectivity ratios.  
 
Inhibitor 
ALR2 
IC50 
 (µM) 
AKR1B10 
IC50  
(µM) 
ALR1 
(100 µM)A 
AKR1B10 /  
ALR2 
ALR2 / 
AKR1B10 
23 0.17 ± 0.02 21.6 ± 1.7 5.6% 127 0.008 
24 3.6 ± 0.4 0.45 ± 0.04 27.3% 0.1 8 
     
 
A Percentage of inhibition of a 100 µM solution of the respective inhibitor. 
 
 
3.4.2 Crystal Structures of 23 and 24 complexed with ALR2 and 
       24 complexed with AKR1B10 
With the aim to understand the rationale behind the inhibitory properties of 23 and 24 towards 
ALR2 and AKR1B10, we sought to determine the X-ray structures of the ternary complexes. We 
were able to obtain all of them, except that of the AKR1B10-23 complex. The structures fold into 
the expected (/)8-TIM barrel, with the cofactor position being conserved.  
The X-ray structure of ALR2-NADP+-23 complex was obtained at the atomic resolution of 1.0 Å, 
with the Fo−Fc omit map showing clearly the inhibitor electron density (Figure 3-2a). The 
carboxylic acid of 23 is assumed to be deprotonated, as observed before for 20,40, 119 and the 
oxygen atoms act as hydrogen bond (H-bond) acceptors to Tyr48OH (2.7Å), His110NE2 (2.7 Å) 
and Trp111NE1
 
(3.0 Å) and display electrostatic contact with the charged nicotinamide N of 
NADP+ (4.1 Å). 
The uracil-1-acetic acid moiety is performing hydrophobic contacts with Trp20, Trp111, Trp219 
and Cys298. Its aryl moiety is sandwiched between the indole moiety of Trp111, through a face-
to-face oriented – stacking interaction (with a distance of approximately 3.4 Å between the two 
planes) and the side chains of Phe122, Leu300 and Cys303 lining the specificity pocket. One of 
the oxygen atoms of the nitro group forms an H-bond with the Leu300 main chain nitrogen atom 
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(2.9 Å) while the Cl atom undergoes a halogen bond with Thr113OH (2.9 Å, Figure 3-2a). 
Furthermore, two “non-classical H-bonds” are formed between the oxygen atoms of the nitro 
group and the Tyr309 C1 and C1 (3.5 Å for both, Figure 3-2a), as observed for other nitro-
containing ARIs.8 Apparently, the sum of the halogen bond and the interactions provided by the 
nitro substituent at the meta position are not triggering a stronger binding. This is not surprising, 
taking into account that molecular interactions behave in a highly non-additive fashion.120 
The X-ray structure of ALR2-24 complex was obtained at 2.45 Å resolution. It has to be noted 
that crystals were obtained by co-crystallization with 5 mM 24 in a rarely applied reservoir 
condition for ALR2 crystallization, replacing the habitual buffer ammonium citrate (pH 5.0) with 
TRIS-HCl (pH 8.0). This is the second ALR2 structure obtained by co-crystallization at this pH 
value, after the ternary complex of ALR2 with the inhibitor IDD552 (Protein Data Bank (PDB) 
code 1T41).121 In addition, the crystal grew in a very unusual space group, I222, only observed 
before in one ALR2 X-ray crystal structure, a holo-enzyme complex (PDB: 1ABN).122 The Fo−Fc 
omit map shows unequivocally the inhibitor electron density in two different conformations (A 
and B), where the neighbouring residue Phe122 adopts two different conformations in 
concordance with the inhibitor positioning (Figure 3-2b and Figure 3-2c). Both conformations of 
24 are stabilized by crystallographic contacts with the complex in the neighbouring asymmetric 
unit. Conformation A of 24 (60% occupancy) is stabilized by the neighbouring conformation A 
molecule, with a Br –Br contact between the two Br atoms in para, while conformation B of 24 is 
stabilized through halogen bonds with the main chain of the residues of loop A of the complex in 
the neighbouring asymmetric unit (Figure 3-2d). Therefore, the observed interaction of 24 with 
the ALR2 holo-enzyme confirms that the conformation adopted by 23 in the cognate complex is 
not possible for the former compound. 
In this regard, we have superimposed 24 in the position of 23 in its ALR2 complex, with the 
methoxy group oriented towards Ala299 or Phe122 (Figure 3-3). In each case, one of the Br 
atoms at the meta position (ortho to the methoxy group) would clash against the CH2 group of 
Trp79 (2.4 Å distance). For the ortho  substituents,  in case  the methoxy would be facing Phe122  
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Figure 3-2 X-ray structures of ALR2-23 and ALR2-24 complexes. a) Atomic representation of the inhibitor 
binding site for the ALR2-23 complex, with the electron density of the inhibitor shown as a Fo-Fc omit map 
contoured at 6 level in a grey mesh and the protein residues, the cofactor and 23 in stick representation (white, 
orange and cyan, respectively); b) Atomic representation of the inhibitor binding site for the ALR2-24 complex 
conformation ensemble, with the inhibitor electron density shown as a Fo-Fc omit map contoured at 3 level in a 
grey mesh (with both conformations showing the inhibitor bound (top) and separated (down)) and the protein 
residues in white sticks (except for Phe122, which follows the coloring of 24), the cofactor in orange sticks and 24 in 
cyan for conformation A and green for conformation B; c) Atomic representation of the inhibitor binding site for the 
ALR2-24 complex with each conformation shown in a separate drawing (for color coding see legend to panel b); 
d) Atomic representation of the inhibitor binding site for the ALR2-24 complex conformation ensemble including the 
intermolecular crystallographic contacts with the symmetry-related molecules, in pink lines or sticks for the protein 
and in blue sticks for the symmetry-related 24, following the same color code as for the remaining panels. H-bond 
distances are shown as green-dotted lines. 
 
(Figure 3-3a), a clash would occur with the latter residue (2.1 and 2.2 Å distance with Phe122 C2 
and CZ, respectively). If the methoxy group was in the other orientation (Figure 3-3b), there 
would be clashes with the nitrogen and carbon atoms of the backbone of Ala299 (2.5 Å distance). 
In the case of AKR1B10, albeit new structures of AKR1B10-inhibitor have been solved in the 
last two years,123, 124 we only succeeded to obtain the ternary complex with 24 of the methylated 
AKR1B10 K125R/V301L mutant (from now on, named as AKME2MU). The same procedure 
was applied for the determination of the complex structure of inhibitor 22 with AKR1B10.101, 125 
The AKME2MU holo-enzyme complexed with 24 was obtained at 1.70 Å resolution, with the 
Fo−Fc omit map showing the inhibitor and the anomalous difference map confirming the position 
of the four Br atoms of compound 24 (Figure 3-4a). The carboxylic acid oxygen atoms display 
H-bonds with Tyr49OH (2.9 Å), His111NE2 (2.8 Å) and Trp112NE1
 
of the conformer A (3.0 Å) 
(Figure 3-4a). The electron-deficient uracil ring is also involved in further interactions: (i) with 
Trp21 aromatic moiety through a parallel-displaced stacking (3.5 Å distance) and (ii) the 
carbonyl oxygen atoms are H-bonded to Phe123 C1 and to Trp220 CH2, the two being “non-
classical H-bonds”8, 126 (Figure 3-4a, atomic distances not shown, being 3.2 Å for both 
interactions). The methylene bridge and the tetrabromomethoxy aryl moiety are surrounded by a 
hydrophobic subpocket formed by Trp80, Trp112, Phe116, Phe123, Ala131, Leu301 (Val301 in 
the wild-type enzyme) and the aliphatic part of Arg125 (Lys125 in the wild-type form) and 
Gln303 (Figure 3-4b). The most significant interactions are the edge-to-face stacking that the aryl 
moiety performs with the side chain of Phe123 (3.8Å distance, data not shown) and the 
interactions of two of the Br atoms of 24 with the aromatic ring systems of Trp80 and Phe116,  
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Figure 3-3 Steric hindrance of 24
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water molecule (W116) interacting with two of the Br atoms of 24 (3.3 and 3.2 Å, respectively) 
and with NE1 (2.9 Å) of the conformation A of Trp122 (Figure 3-4c). This water molecule is also 
present in the conformation B, as it displays 100% occupancy and does not experience any 
clashes with the residues of the protein or with the ligand. 
3.4.3 ITC experiments 
ITC experiments were perfomed to gain insights into the thermodynamic profiles of the binding 
events of the inhibitors to ALR2 and AKR1B10. The binding of the carboxylate-type inhibitors 
to ALR2 is accompanied by an uptake of 0.7-0.9 protons per mole formed complex by 
Tyr48.42, 127 To correct for buffer dependencies, we performed the measurements in three 
different buffer systems (HEPES, Tricine and TRIS) and plotted the measured enthalpy (H°obs) 
against the heat of ionization (H°ion) of the corresponding buffer system. This procedure was 
previously described in literature.88 The binding of 23 to ALR2 could be measured in all three 
buffer systems (Table 3-2). The corrected thermodynamic profile shows a strong favourable 
enthalpic contribution (-59.7 kJ/mol) while the entropic term is unfavourable (+19.3 kJ/mol, 
Table 3-3). An entrapment of 0.6 protons per mole is detected (Figure 3-5) which is in good 
agreement with previous results for similar ARIs. As already mentioned, the formed contacts of 
the nitro group in the specificity pocket are linked to a strong exothermic enthalpic signal.8 
Presumably, these interactions are responsible for the strong enthalpic binding contribution of 23 
to ALR2.  
The binding of 24 to ALR2 could only be measured in HEPES since the enthalpic signal was too 
low to be evaluated in the other two buffer systems (Figure 10-3 in the Appendix). However, a 
buffer dependency for the binding of 24 to ALR2 could be detected. In HEPES, the binding of 24 
to ALR2 is much less driven by the enthalpy than the binding of 23 (-10.7 kJ/mol compared 
to -46.7 kJ/mol). The measurements of the binding of other carboxylate-type inhibitors to ALR2 
which were performed in our laboratory (unpublished results) showed that the enthalpic portion 
which is corrected for the protonation effect is approximately -11.5 to -14.0 kJ/mol more 
exothermic than in HEPES buffer. Both types of ligands, those which address and open the 
specificity pocket and those which do not address it, show this amount of overlaid buffer 
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dependence in HEPES. It can only be assumed that the binding of 24 is accompanied by a similar 
proton uptake by the protein. Even if a similar influence on the enthalpic signal due to the proton 
uptake is assumed as for 23 the enthalpic term of 24 would be much smaller as that of 23. Thus, 
the different binding modes of 23 (addresses the specificity pocket) and 24 (leaves the specificity 
pocket unoccupied) with ALR2 have a significant influence on the thermodynamic profile.  
Table 3-2 Hobs for 23 and 24 in the corresponding buffer system.  
 
  
23 with ALR2 24 with AKR1B10 
Buffer HionA Hobs Hobs 
 
[kJ/mol] [kJ/mol] [kJ/mol] 
HEPES 21.07 -46.7 -38.7 
Tricine 31.97 -38.6 -38.2 
TRIS 48.07 -29.3 -35.5 
    A Values for Hion were taken from literature.87, 88 
 
As 24 binds to ALR2 in two alternative orientations the interpretation of its thermodynamic 
profile is even more complicated. The following aspects can be seen: in conformation A of 24, a 
water molecule is fixed due to H-bonds to the oxygen atom of the benzyluracil-scaffold of 24 
(3.2 Å), to the nitrogen atom of the Leu300 backbone (2.6 Å) and to the nitrogen of the Ala299 
backbone (2.9 Å). In conformation B, an H-bond between the methoxy substituent of 24 and 
Trp20 (3.1 Å) can be found. The Br atoms of 24 form contacts to polar groups of ALR2 
(Figure 3-2c). In conformation A, such an interaction is visible to the oxygen of Ser302 and, in 
conformation B, to the nitrogen of Gln49. However, all these interactions do not sum up to a 
similar contribution to the enthalpy as the (4-chloro-3-nitro-phenyl)-moiety of 23 can account for. 
For AKR1B10, only the binding of 24 could be measured since 23 has a too low affinity towards 
AKR1B10 to be characterized by a direct ITC experiment. Surprisingly, the measurement of 24 
with AKR1B10 in the three different buffers revealed that the enthalpic signal of this binding 
event is much less buffer dependent than it was detected for the binding of 24 to ALR2. A 
negligible pickup of only 0.1 protons per mole formed complex is detected (Figure 3-5). As 
described above, Trp112 changes from conformation B to A during the binding of 24 compared  
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Figure 3-5 Plot of heat ionization 
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Table 3-3 Thermodynamic data of
Complex KD (nM) 
ALR2-23 91.1 ± 3
ALR2-24 8894.2 
AKR1B10-23C n.d. 
AKR1B10-24 2313.3 
 
n.d.: not determined. 
A Given is the thermodynamic data fo
B If possible, the values were correct
C The binding of 23 to AKR1B10 co
  
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G0 H0obsA H0bindB 
(kJ/mol) (kJ/mol) (kJ/mol) 
9.8 -40.4 ± 1.3 -46.7 ± 0.5 -59.7 
± 1451.6 -28.8 ± 0.4 -10.7 ± 1.9 n.d. 
n.d. n.d. n.d. 
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 the corresponding buffer 
inhibitors which exhibit a 
 line), the binding of 24 to 
4 with AKR1B10. 
-TS0obsA -TS0bindB 
(kJ/mol) (kJ/mol) 
6.1 ± 0.6 19.3 
-18.1 ± 1.5 n.d. 
n.d. n.d. 
6.0 ± 0.6 9.3 
rds AKR1B10. 
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to the holo-enzyme. This is accompanied by the rupture of the internal H-bond network including 
Gln114 and Ser304 (Figure 3-4c).123 A more profound study of the electrostatic properties of the 
binding pocket of AKR1B10, especially with regard to the structural changes upon ligand 
binding, is required to quantify the pKa values of the local residues and their putative changes 
upon ligand binding to better understand this different behaviour of AKR1B10 compared to 
ALR2. However, this example underlines the importance of the investigation of buffer 
dependencies in ITC experiments. The thermodynamic profile of the binding of 24 to AKR1B10, 
which is corrected for the protonation effect, shows a strong dominance by the enthalpic binding 
portion (-41.6 kJ/mol) while it is accompanied by an unfavourable entropic term (+9.3 kJ/mol). 
The enthalpic gain of the newly formed interactions between 24 and the protein residues is 
obviously overcompensating the enthalpic penalty due to the rupture of the internal H-bond 
network. As discussed above, we estimate the thermodynamic profile of the binding of 24 to 
ALR2 to be much less dominated by the enthalpy as is the case for the binding of 24 to 
AKR1B10 even if the binding profile of 24 to ALR2 would be corrected for the protonation 
effect. Accordingly, the above described binding mode which 24 adopts with AKR1B10 leads to 
a more favourable enthalpic contribution. Summarizing both cases, first the comparison of the 
binding of 23 and 24 to ALR2 and second the comparison of the binding of 24 to ALR2 and 
AKR1B10, indicate that the opening and occupying of the respective specificity pocket lead to an 
increase in the enthalpic portion.  
3.5 Conclusions 
A large number of ARIs have been developed for the treatment of diabetic complications. Indeed, 
huge amounts of preclinical and clinical data have been collected through academic and industrial 
programs, including a deep structural characterization of the ALR2 binding pocket, which is 
highly flexible and susceptible to induced fit adaptations. In the last ten years, AKR1B10 has 
been characterized as a protein related to cell proliferation and shown to be overexpressed in a 
plethora of different cancers, such as liver, breast, pancreas and lung cancer. ALR2 has also been 
shown to be involved in processes other than diabetic complications. In fact, it has been 
established as an important mediator in oxidative stress and inflammation-related processes, 
including cancer (e.g. colon cancer).128 Both ALR2 and AKR1B10 siRNA knockdown or drug 
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inhibition decreased tumor growth of several cell line xenografts (from different tissues) 
transplanted into immunodeficient mice.129-133 Therefore, ALR2 and AKR1B10 inhibitors may 
represent a novel class of antitumor agents and the clinical data assembled in diabetes clinics may 
help the transition of these inhibitors to cancer chemotherapy. 
The AKR1B10 structure has been kept fairly uncharacterized until a couple of years ago and only 
several new AKR1B10 structures have been deposited in the PDB. Starting from the structure of 
the uracilacetic acid 23, we have developed compound 24, which differs from the former one in 
the aryl moiety substitution pattern, inspired in this case by the halogenated biaryls and diaryl 
ethers present in natural products. The inhibition assays, ITC experiments, X-ray crystallographic 
determinations and in silico structural analysis of holo-enzyme-23/24 complexes have allowed 
dissecting ALR2 and AKR1B10 selectivity and potency.  
Several conclusions can be extracted from this work. Starting from the structure of the ARI 
compound 23 and keeping its uracil-acetic acid unmodified, it has been possible to design and 
synthesize compound 24, with an increased volume of the aryl moiety of the N3-benzyl 
substituent, shifting the selectivity to AKR1B10. The aryl group of 23 is able to open the ALR2 
buried specificity pocket located between Trp111 and Leu300, but the bulky substituents at the 
ortho and meta positions of 24 prevent its binding into the specificity pocket of ALR2. On the 
other hand, the large aryl moiety of 24 binds into a more remote hydrophobic subpocket in 
AKR1B10, located between loops A and C. The nitro group of 23 prevents a proper binding to 
AKR1B10, as shown by its high IC50 value (~20 µM).  
The ITC data show that the binding of 24 to AKR1B10 is accompanied by an uptake of 
0.1 protons per mole of formed complex, while 0.6 protons per mole are incorporated during the 
binding of 23 and most likely of 24, to ALR2, unveiling the difference in electrostatic properties 
between the two enzyme active sites. The binding of both 23 to ALR2 and 24 to AKR1B10 
display a large enthalpic signature while the binding of 24 to ALR2 is more driven by the 
entropic portion.  
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3.6 Description of Experimental Procedures 
3.6.1 Site-directed mutagenesis, enzyme expression and purification 
The cDNAs of ALR2 and ALR1 were subcloned into the pET15b plasmid, while that of 
AKR1B10 was subcloned into the pET16b plasmid (pET30-Xa/LIC was used for the 
K125R/V301Lmutant). ALR2, wild-type and mutant AKR1B10 and ALR1 were recombinantly 
expressed in the E. coli BL21(DE3) strain (Novagen) and were purified using the procedures 
described previously for ALR2,134 AKR1B10108 and ALR1.135 Purity was confirmed by SDS-
PAGE and protein concentration was determined using a NanoDrop ND-1000 (Thermo 
Scientific). 
3.6.2 Inhibition screening 
The IC50 activity assays were carried out according to the quantification of NADPH consumption 
which takes place when the enzyme catalyses the conversion of D,L-glyceraldehyde into glycerol. 
The assays were performed at 298 K in 100 mM sodium phosphate buffer, pH 7.0, with protein 
amount to reach Vmax and 0.2 mM NADPH. The final reaction volume was 500 L. All 
compounds assayed were dissolved in dimethyl sulfoxide (DMSO), with the corresponding 
solution added to 2% (v/v) DMSO final concentration. They were incubated for 5 min at 25°C 
prior to addition of the substrate. The reaction was initiated by addition of 1, 60 and 5 mM D,L-
glyceraldehyde (for ALR2, AKR1B10 and ALR1, respectively) and the decrease in optical 
density at 340 nm was monitored for 3 min at 25°C in a UV–Vis spectrophotometer (UV-1700 
PharmaSpec, Shimadzu). The IC50 value was determined as the compound concentration that 
inhibits enzymatic activity by 50% and was calculated using the Grafit program (version 5.0; 
Erithacus Software). Values were given as the mean ± standard error of three experiments.  
3.6.3 Crystallization and structure determination 
Regarding the ALR2-23 complex, crystals were obtained by co-crystallization under the 
published condition:134, 136 hanging drop method at 298 K, reservoir with 50 mM ammonium 
citrate, pH 5.0, 20% polyethylene glycol (PEG) 6000, with 5 mM of 23. Neither co-
crystallization nor soaking was successful for the ALR2-24 complex using the previous 
condition. Later on, co-crystals were obtained using the following condition: 10 mM TRIS-HCl, 
Structural Determinants of the Selectivity of  
3-Benzyluracil-1-Acetic Acids towards Human Enzymes Aldose Reductase and AKR1B10 
 
72 

pH 8.0, 20% PEG 6000, with 5mM of 24. Regarding the AKR1B10 complexes, all crystals were 
obtained with the AKME2MU system (reductive lysine methylation plus K125R/V301L 
mutations), except for the methylated AKR1B10 holo-enzyme. Co-crystals of the AKME2MU-
24 (30 mM inhibitor) complex and of both mutant holo-enzymes were obtained by the hanging-
drop vapour diffusion method at 298K. The protein solution was mixed with an equal volume of 
precipitating solution consisting of 100 mM sodium cacodylate, pH 9.0, 30% PEG 6000. A 
detailed protocol is explained elsewhere.101 X-ray data were collected on the home source for 
AKME2MU-24 complex, at the Swiss Light Source on the X06SA beamline for ALR2-23 
complex and on X06DA for the methylated AKR1B10 holo-enzyme and for ALR2-24. All data 
sets were processed with the program HKL2000.137 The structures were solved by molecular 
replacement with Phaser138 and finalized sets of atomic coordinates were obtained after iterative 
rounds of model modification with the program Coot139 and refinement with REFMAC5 140 and 
PHENIX.141 Generation of ligand coordinates and restraints were created as previously reported 
101
 or using eLBOW.142 The coordinate data for the structures were deposited in the PDB: ALR2-
23: 4XZH, ALR2-24: 4XZI, AKME2MU-24: 4XZL, methylated AKR1B10 holo-enzyme: 
4XZM, AKME2MU holo-enzyme: 4XZN. Related figures were prepared with PyMOL (v.1.3; 
Schrödinger). 
3.6.4 ITC experiments 
The ITC experiments are described in Section 9.2.5. Representative example curves and fitted 
regression curves are shown in Figure 10-3 in the Appendix. 
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4 Crystallographic and Thermodynamic Characterization of 
Carboxylic Acids Containing Two or Three Aromatic Systems as 
Inhibitors of Human Aldose Reductase  

4.1 Introductory Remarks 
The following chapter was prepared for submission to a scientific journal. The synthesis of the 
compounds was done by Dr. Regina Ortmann and Dr. Michael Eisenmann from the group of 
Prof. Dr. Martin Schlitzer (Philipps University Marburg). The author of this thesis performed the 
complex crystal structure determinations, ITC and IC50 measurements. Furthermore, he drafted 
the following manuscript. 
4.2 Abstract 
The human aldose reductase is involved in the development of diabetic complications. Here we 
present newly synthesized inhibitors bearing a carboxylic acid head group. High-resolved 
complex crystal structures along with the thermodynamic characterization are presented. 
Furthermore, we present the first complex crystal structure of an inhibitor of this series 
possessing an acrylic acid head group and of an inhibitor containing a third aromatic moiety. The 
findings provide valuable input for a further optimization cycle of this group of inhibitors.  
4.3 Introduction 
382 million people worldwide were afflicted with diabetes in 2013. Up to the year 2035 the 
estimated number of cases could rise to 592 million.17 As long-term complications neuropathy, 
nephropathy and retinopathy can occur.45 Due to its role in the polyol pathway the human aldose 
reductase (ALR2, EC 1.1.1.21) is an interesting target for drug design. It catalyzes the reduction 
of glucose to sorbitol, using NADPH as cofactor. The following depletion of NADPH results in a 
too low level of reduced glutathione, for which regeneration this cofactor is needed as well. 
Consequently, the cell experiences a higher risk to suffer from intracellular oxidative stress which 
leads to the development of diabetic complications.21 The binding pocket of ALR2 is depicted in 
Figure 4-1a. The anion binding pocket is formed by Tyr48, His110, Trp111 and the nicotinamide 
moiety of NADP+. 
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micromolar range (26: 2.4 +/- 0.5 µM, 27: 4.1 +/- 1.0 µM). In a subsequent optimizing cycle 
further derivatives were synthesized with the aim of replacing the oxadiazole moiety of 26 and 27 
by a thiophene or furan moiety since the heteroatoms of the oxadiazole ring were not involved in 
polar interactions. This resulted in a series of further compounds between which 28 (0.17 +/- 
0.03 µM) and 29 (0.26 +/- 0.05 µM) showed an improved affinity for ALR2. Furthermore the 
crystal structure of 28 complexed to ALR2 could be determined by cocrystallization in the space 
group P1.143 36 is the side chain analogue of 29 with an acrylic acid head group instead of a 
propionic acid head group. It showed a significantly decreased affinity (19.0 +/- 0.9 µM) 
compared to the latter one. Here we present the results of a subsequent optimization cycle. The 
aromatic moieties and the substituents of the terminal aromatic moiety have been varied to 
understand their contribution to the affinity and thermodynamic profile. Derivatives containing 
an acrylic acid function are investigated to further probe the ability of the latter to address the 
anion binding pocket. Finally, it is evaluated wether the binding pocket of ALR2 can 
accommodate members of this inhibitor series which comprise a third aromatic moiety. The IC50-
values are determined. The complex crystal structures of 30, 31, 37 and 43 could be determined. 
Furthermore the complex crystal structure of ALR2-28 could be determined at high resolution in 
space group P21 and is compared with the formerly published structure in space group P1. 
Additionally the thermodynamic profiles of 26, 28, 29, 30 and 31 could be measured and 
compared relatively to each other.  
4.4 Results and Discussion 
4.4.1 IC50-value determination 
The IC50 values of ligands 26-43 are shown in Figure 4-2. 30 (IC50: 2.2 +/- 0.6 µM) possesses as 
28 and 29 a terminal meta nitro phenyl side chain but as a central aromatic moiety it exhibits a 
phenyl ring instead of a thiophene or a furan moiety. This replacement corresponds to an 
approximately tenfold decreased affinity compared to the aforementioned which are nearly 
equipotent. In turn the exchange of the terminal phenyl residue by a furan ring is not 
accompanied by a significant drop in affinity as shown by the comparison with 31 (IC50= 2.1 +/- 
0.5 µM). With the exception of 39 (IC50= 76.6 +/- 19.9 µM) all ligands possessing a meta nitro 
substituent attached to the terminal aromatic moiety exhibit submicromolar to single digit 
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micromolar affinity. The favorable contribution to the affinity of the attached meta nitro group is 
in good agreement with previous results.143 Owing to the obvious importance of this group we 
decided to probe the influence of an exchange of the nitro group by the isostructural but 
permanently charged carboxylic acid group. The latter group should be able to form similar 
interactions in the specificity pocket as the nitro group. Interestingly the IC50 value is about fifty 
times higher for 32 (96.3 +/- 3.7 µM) compared to 30 (2.2 +/- 0.6 µM). Either the carboxylate 
group forms far less efficient interactions in the specificity pocket or the adopted binding mode of 
the ligand is entirely different. Since the complex structure of 32 could not be determined due to 
the low affinity of the ligand a structural validation of the latter hypotheses cannot be provided. 
The exchange of the propionic acid head group to an acrylic acid function leads to inconsistent 
results. The propionic acid derivative 33 (IC50= 38.6 +/- 1.8 µM) has a slightly higher affinity 
than its acrylic acid derivative 41 (IC50= 52.2 +/- 4.6 µM) which is in agreement with former 
studies.143 On the other hand 37 (IC50= 3.1 +/- 0.8 µM) which possesses an acrylic acid head 
group shows nearly the same affinity as 30 (IC50= 2.2 +/- 0.6 µM) which comprises a propionic 
acid head group instead. The explanation for these deviating results appears quite controversal. 
As will be explained later a change of the configuration of the double bond from E- to Z- for 37 is 
found while analyzing the corresponding complex crystal structure with ALR2. It could not be 
resolved whether this configurational transition occurs for all the ligands containing an acrylic 
acid head group prior to binding to ALR2. In case the configurational transition takes place to 
deviating extent for the different ligands investigated here, this might explain why in some cases 
the replacement of the propylene side chain by the double bond comes with a decreased affinity 
and in other cases not. A similar drop of affinity due to the exchange of the meta nitro group by a 
meta carboxylate group as described above for the ligands bearing a propionic acid head group is 
observed for a member with an acrylic acid head group: 37 with a terminal nitro group (IC50= 3.1 
+/- 0.8 µM) exhibits much higher affinity compared to the carboxylate derivative 38 
(IC50 >100 µM). 43 contains a third aromatic ring system. The additional phenyl portion and the 
fixed headgroup arrangement are well tolerated by ALR2 since the IC50 value rates the compound 
as high affinity binder (0.34 +/- 0.05 µM). This finding suggests that the ligand adopts a binding 
mode with ALR2 similar to the other highly potent members of this ligand series despite its 
spatially more demanding shape. This hypothesis will be further investigated by crystallography. 
Crystallographic and Thermodynamic Characterization of Carboxylic Acids Containing Two or 
Three Aromatic Systems as Inhibitors of Human Aldose Reductase 
 
78 

4.4.2 Crystallographic determination of the binding modes of 30, 31, 37 and 43 
4.4.2.1  Similarities in the binding modes of 26, 28, 30, 31, 37 and 43 
The overall binding modes of 26, 28, 30, 31, 37 and 43 are similar. Figure 4-3a shows the 
superposition of the inhibitor molecules obtained by mutual alignment of the complex crystal 
structures. Two anchoring points can be defined which correspond to the two important 
interactions accomplished by the potent ligands in the binding site. On the one hand it can be 
observed that the carboxylic acid function aligns almost perfectly for 30, 31, 37 and 43 while it is 
orientated slightly different for 26 and 28. This part of the ligands binds to the anion binding site. 
On the other hand the position of the terminal nitro group matches exactly for all studied ligands. 
The remaining ligand scaffolds arrange in a way to accomplish these key interactions. The 
alignment of all complex structures shows that all ligands adopt a very similar spatial occupancy 
(Figure 4-3a, Figure 4-4a). All inhibitors open the specificity pocket with their terminal nitro 
phenyl moiety. The IC50 values show that the introduction of the nitro group leads to a 
significantly higher binding affinity. As shown in Figure 4-3b and Figure 4-4c in ALR2-30 the 
nitro group forms via one of its oxygen atoms an H-bond to the backbone nitrogen of Leu300 
(3.0 Å). Similar H-bonds are established by 26 (3.3 Å, Figure 4-1b), 28 (3.0 Å in space group 
P21, Figure 4-4b), 31 (3.1 Å, Figure 4-4d), 37 (3.1 Å, Figure 4-4e) and 43 (3.1 Å, Figure 4-4f). 
Interestingly in syn direction the distance between the two oxygen atoms of the nitro group of the 
ligands and the carbon atoms of the phenyl ring of Tyr309 are surprisingly short in all mentioned 
ALR2-ligand complexes. As shown exemplarily in Figure 4-3b for ALR2-30 the distances 
between the oxygen atoms of the nitro group of 30 to the carbon atoms of Tyr309 are only 3.3 Å 
and 3.4 Å, respectively. It was discussed previously that these short distances indicate so-called 
non-classical hydrogen bonds between the oxygen atoms of the nitro group and the hydrogen 
atoms attached to the phenyl ring.8 No water molecules are directly bound to 30, 31, 37 and 43. 
The complex structures of 30 and 37 were obtained at pH 5.5, the complex structures of 28, 31 
and 43 at pH 8.0. At both pH values the carboxylic acid function is presumably deprotonated and 
should carry a negative charge. As known from a former study with the carboxylate-type ligand 
25 (IDD594, PDB: 1US0)40 the cofactor is bound in its oxidized form and is thus present with a 
positive charge. When a similar situation is assumed in the here described ligand series a charge-
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Figure 4-4 Stick representation of the binding pocket of ALR2 complexed with 28, 30, 31, 37 and 43. a) 
Superposition of the binding pockets of the complexes ALR2-26, ALR2-28-P21, ALR2-30, ALR2-31, ALR2-37 and 
ALR2-43. The carbon atoms of the protein residues of ALR2-26 are colored in grey, the carbon atoms of the residues 
of the remaining protein-ligand complexes are colored corresponding to the colors of the carbon atoms of the ligands 
in b)-f). All residues of the binding site align very well. In consequence, all the ligands induce a very similar binding 
site conformation. b) Binding mode of 28 in space group P21 (ALR2-28-P21, PDB: 4YU1, 1.02 Å). The carbon 
atoms of the protein residues are shown in grey and of NADP+ in purple. This will be maintained during the 
following representations. The carbon atoms of 28 are shown in purple. c) Binding mode of 30 (PDB: 4PR4, 1.06 Å). 
Carbon atoms of 30 are colored in blue. d) Binding mode of 31 (PDB: 4PRR, 1.01 Å). Carbon atoms of 31 are 
colored in orange. e) Binding mode of 37 (PDB: 4NKC, 1.12 Å). Carbon atoms of 37 are colored in green. 
f) Binding mode of 43 (PDB: 4PRT, 0.96 Å). Carbon atoms of 43 are colored in cyan.  
 
This long linker between the carboxylic acid function and the central aromatic moiety prevents a 
direct H-bond between the carboxylic acid group and Trp111 which is found for many of the 
other ALR2 inhibitors (Figure 4-4).40, 127 Instead a water molecule (W1 in Figure 4-1b) is 
captured which mediates the contact to Trp111NE1 (2.8 Å) and to one of the oxygen atoms of the 
carboxylate group of 26 (2.3 Å). The water molecule is further stabilized by an H-bond to one of 
the nitrogen atoms of the central oxadiazol ring of the ligand (3.0 Å).8 The crystal structure was 
obtained at pH 5.0 at which the carboxylic acid group is assumed to be mainly deprotonated. A 
charge-assisted interaction between the negatively charged carboxylic acid group and the 
positively charged NADP+ is detected (2.8 Å). The ALR2-26 structure was obtained by soaking 
preformed ALR2 crystals, crystallized in space group P21, in a solution containing 26. In contrast 
the structure of 28 complexed to ALR2 (in the following referred to as ALR2-28-P1) was 
obtained by co-crystallization. In the latter case the ternary complex of ALR2, NADP+ and 28 
crystallized in space group P1.143 One of the oxygen atoms of the carboxylate group of 28 forms 
H-bonds to Tyr48OH (2.6 Å) and His110NE2 (2.7 Å). Furthermore, the carboxylic acid group 
forms with the latter oxygen atom the charge-assisted interaction to NADP+. Similarly as in the 
ALR2-26 structure the carboxylate group of 28 does not form a direct H-bond to Trp111. Instead 
one of the oxygen atoms of the carboxylate group of 28 establishes an H-bond to a water 
molecule (W2 in Figure 4-1c). To better understand the role of this water molecule and to 
estimate whether its position is influenced by the space group change observed for the latter 
crystal structure an additional structure determination was attempted. This time an uncomplexed 
ALR2 crystal, obtained in space group P21, was soaked in a saturated solution of 28 in TRIS 
buffer at pH 8.0  (in the following referred to as ALR2-28-P21).  
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Figure 4-5 Comparison of the complex crystal structures of 28 in space groups P1 (ALR2-28-P1) and P21 (ALR2-
28-P21). a) Alignment of ALR2-28-P1143 and ALR2-28-P21. The carbon atoms of the residues 116-134 are shown in 
grey for ALR2-28-P21 and in orange for ALR2-28-P1. The carbon atoms of 28 are colored in purple in ALR2-28-P21 
and in salmon in ALR2-28-P1. In ALR2-28-P21 the loop consisting of residues 116-134 is shifted compared to 
ALR2-28-P1, which is followed by a different orientation of the side chain of Phe122. The spatial orientation of 28 
aligns perfectly well in both structures and thus the adopted binding pose is not influenced by the space group. 
b) Representation of the Fo-Fc difference density map at 3.0  after five cycles of simulated annealing for residues 
298-302 in ALR2-28-P21. The carbon atoms of the ligand are shown in purple, the carbon atoms of the protein 
residues corresponding to the specificity pocket in open conformation, are depicted in yellow and the ones 
corresponding to the closed conformation are displayed in grey. The occupancy of the ligand was refined to 70%. 
The specificity pocket is presumably only opened when the ligand has bound. Accordingly 30% of the the protein 
residues 298-302 are found in the conformation which corresponds to the closed conformation of the specificity 
pocket. c) Water structure in ALR2-28-P1.143 The water molecules W2 and W6 which are in H-bonding distances to 
28 and Val 47 are shown as green spheres, further water molecules are shown as red spheres. W2 does not form 
further interactions apart from the H-bond to 28. d) Water structures in ALR2-28-P21. The carbon atoms of the 
protein residues are colored in grey, those which belong to the protein residues of the next symmetry mate are shown 
in blue. The water molecules W2, W3 and W6 which are in H-bond distances to 28 and Val47 are shown as green 
spheres. The water molecules W4 and W5 which are stabilized by the amino acid residues of the next symmetry 
mate are shown as blue spheres. Further water molecules are shown as red spheres. e) and f): Alignment of ALR2-30 
and ALR2-28-P21. A superimposition of the two ligands is shown. Due to the different central aromatic ring systems 
the positions of the carboxylate groups of both ligands vary. The - oxygen atoms align well but the positions of the 
- oxygen atoms differ.  
 
The binding modes of 28 in both structures align perfectly well (Figure 4-5a). Koch et al. 
described previously the influence of crystal packing on the positioning of the loop consisting of 
the amino acids 116-134. They found that Lys119 and Phe121 form H-bonds to Gln283 of the 
next symmetry mate in the P21 crystal packing. In P1 these residues are not involved in any 
crystal contacts.145 This leads to a shift of the loop consisting of residues 116-134 in crystals 
which were obtained in space group P21 with respect to those obtained in space group P1. This 
affects mainly the position of the side chain of Phe122. In the present comparison of ALR2-28-
P1 and ALR2-28-P21 we observe the same finding (Figure 4-5a). Surprisingly, in ALR2-28-P21 
the ligand showed only an occupancy of 70%. After initial placement of the ligand into the 
electron density the structure was refined. Afterwards still some Fo-Fc difference electron density 
at the 3.0  level in agreement with the closed conformation of the specificity pocket is visible. 
The coordinates of the protein residues 298-303 which are mainly involved in the flexibility and 
opening of the specificity pocket were built in two conformations into the density. The 
occupancy of conformation of the latter residues corresponding to the open conformation of the 
specificity pocket was fixed to 70% in agreement with the occupany of 28 which induces through 
binding the opening of the pocket. The closed conformation of the specificity pocket was fitted 
into the difference electron density at the 3.0  level. The refinement resulted in a 2Fo-Fc density 
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electron map at 1.0  which was in good agreement with the coordinates of the closed 
conformation. To exclude a major model bias, both conformations of the residues 298-303 were 
deleted from the model and five cycles of simulated annealing were performed. The resulting Fo-
Fc difference electron density map at 3.0  is shown in Figure 4-5b. It shows density both for the 
specificity pocket in closed and in open state. Consequently, ALR2-28-P21 was deposited with 
the specificity pocket modeled in both conformations. The position of water W2 which was 
already visible in ALR2-28-P1 (Figure 4-5c) could be confirmed in the P21 complex. 
Interestingly here it is connected to a further water molecule (W3 in Figure 4-5d, 3.1 Å). 
Furthermore both W2 and W3 are stabilized by H-bonds to the water molecules W4 (2.4 Å) and 
W5 (3.0 Å), respectively. Both W4 and W5 are stabilized themselves by H-bonds to Ser282 of 
the next symmetry mate. W4 forms an H-bond to the OH group of Ser 282 (3.2 Å) and W5 to the 
backbone oxygen (3.2 Å) of the same residue. Whether the occupancy of W3 in ALR2-28-P21 is 
mainly stabilized by the remote contacts to the next symmetry mate remains difficult to answer. 
In both structures another water molecule (W6) is in H-bond contact to the carbonyl oxygen atom 
of Val47 (2.8 Å and 2.7 Å, respectively). In ALR2-28-P1 the location of W3 remains unoccupied 
but no sterical repulsion with adjacent protein residues or other water molecules would argue 
against the presence of a water molecule. The higher resolution of the ALR2-28-P21 (1.02 Å 
compared to 1.45 Å) structure might be a reason why W3 was actually not detected in the P1 
structure. As W3 is in additionally connected to the backbone oxygen atom of Val47 (3.1 Å ) in 
ALR2-28-P21 the latter structure shows that 28 uses W2 and W3 to establish a water network to 
form a bridge to Val47.  
4.4.2.3 Binding mode of the carboxylic acid head group in 
      the anion binding pocket of ligands 30, 31, 37 and 43. 
The carboxylic acid head groups of 30, 31, 37 and 43 bind as assumed in the anion binding 
pocket. They all form H-bonds between one of the oxygen atoms of the carboxylate group and 
Tyr48OH (2.6-2.7 Å) and His110NE2 (2.6-2.7 Å) while the other oxygen atom of the carboxylate 
group forms H-bonds to His110NE2 (2.6-3.0 Å) and Trp111NE1 (2.9-3.1 Å). Thus, in contrast to 
ALR2-26 and ALR2-28-P21, a direct contact to Trp111 is formed. All ligands are involved in the 
already discussed charge-assisted interaction between one of the oxygen atoms of the 
deprotonated carboxylic acid group and the positively charged NADP+ (2.9-3.0 Å). 
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Figure 4-6 Surface representation of the binding pocket of ALR2 complexed with ligands 26, 28, 30, 31, 37 and 
43. The solvent-accessible surface of the protein is shown in grey. Only water molecules are shown which are 
involved in an H-bond network with the ligand. All ligands address with their meta nitro phenyl moiety the 
specificity pocket. All structures are shown from the same viewing direction. a) Binding mode of 26 (ALR2-26, 
PDB: 2IKG, 1.43 Å).8 The carbon atoms of ligand 26 are colored in green. The water molecule W1 mediates an H-
bond between one of the oxygen atoms of 26 and the Trp111NE1. b) Binding mode of 28 in space group P21 (ALR2-
28-P21, PDB: 4YU1, 1.02 Å). The carbon atoms of 28 are shown in purple. Two water molecules (W2 and W3) 
mediate an H-bond network between one of the oxygen atoms of 28 and the OH group of Ser282. c) Binding mode 
of 30 (PDB: 4PR4, 1.06 Å). Carbon atoms of 30 are colored in blue. d) Binding mode of 31 (PDB: 4PRR, 1.01 Å). 
Carbon atoms of 31 are colored in orange. e) Binding mode of 37 (PDB: 4NKC, 1.12 Å). Carbon atoms of 37 are 
colored in green. f) Binding mode of 43 (PDB: 4PRT, 0.96 Å). Carbon atoms of 43 are colored in cyan.  
 
4.4.2.4 Binding mode of 30 
The structure of 30 complexed to ALR2 was refined to a resolution of 1.06 Å. 30 possesses 
similar to 37 and 43 a terminal meta phenyl moiety which addresses the specificity pocket. The 
central aromatic moiety consists here of a phenyl ring which is connected via a linker of two 
carbon atoms to the carboxylic acid function. The terminal phenyl ring forms a face-to-face --
stacking to Trp111 (3.6 Å) in the specificity pocket. The central phenyl ring and the C2-linker 
establish hydrophobic interactions to Trp20 (3.5 Å), Trp219 (3.6 Å), Cys298 (3.8 Å), Leu300 
(3.5 Å) and Trp111 (3.7 Å, Figure 4-4 c).  
4.4.2.5 Binding mode of 31 
The complex crystal structure ALR2-31 was refined to a resolution of 1.01 Å. 31 possesses in 
comparison to 30 a terminal 5-nitro-2-furan ring. Similar to 30 it contains a central phenyl ring 
and a C2-linker to the carboxylic acid function. The binding modes of 30 and 31 are very similar. 
The same hydrophobic contacts of the central part of 31 consisting of the phenyl ring and the C2 
linker are established as for 30. In detail, these are hydrophobic interactions to Trp20 (3.6 Å), 
Trp219 (3.7 Å), Cys298 (3.8 Å), Leu300 (3.5 Å) and Trp111 (3.7 Å). The oxygen of the furan 
ring of 31 does not form any H-bonds. The backbone of Leu300 forms an H-bond to the nitro 
group of 31 (3.1 Å) and is too far away (3.9 Å) to form another H-bond with the furan ring of 31. 
The furan ring makes a face-to-face --stacking to Trp111 (3.8 Å) in the specificity pocket. 
Regarding the required prize to spend for desolvation effect it appears not favorable to use a furyl 
moiety to address the specificity pocket. The oxygen atom of the furan ring has to be desolvated 
when bound to the protein but as the structure shows it is not compensated by forming any polar 
interactions with the protein (Figure 4-4d). 
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4.4.2.6 Binding mode of 37 
The complex crystal structure ALR2-37 was refined to a resolution of 1.12 Å. 37 is the only 
compound of this series with an acrylic acid head group for which a complex crystal structure 
could be determined. As a terminal group it posseses as 30 and 43 a meta nitro phenol moiety. 37 
was initially synthesized as the E-isomer. Suprisingly, in ALR2-37 only the Z-isomer is visible. It 
was shown by 1H-NMR analysis that the geometry of the double bond of 37 is liable to 
isomerization (see Section 4.6.2). This surprising observation clearly indicates that ALR2 
strongly favors the ligand with the double bond in Z-configuration at this position. The 
rigidification of a ligand with a double bond in the required binding site geometry will enhance 
the free energy of binding. The entropic portion to binding will be favorably influenced since a 
more rigidified ligand loses less degrees of freedom compared to a more flexible ligand. This 
experience can be used as a strategy for the development of further ALR2-inhibitors. We 
considered the possibility to synthesize 37 with the double bond in Z-configuration. However, 
since the configuration of this bond seems not to be stable in solution we discarded this attempt. 
The terminal phenyl ring makes in the specificity pocket a face-to-face --stacking to Trp111 
(3.7 Å). The central part of 37 which consists of the phenyl ring and the Z-configurated double 
bond C2 linker makes hydrophobic contacts to Trp20 (3.5 Å), Trp219 (3.4 Å), Leu300 (3.5 Å), 
Cys298 (3.6 Å) and Trp111 (3.5 Å). Since the molecule possesses a limited flexibility due to its 
double bond, the central phenyl ring deviates from the plane which is defined by the 
corresponding phenyl rings of 30 and 31. The superposition of 30 and 37 is shown in Figure 4-3c. 
It is obvious that 37 binds to ALR2 in a way that the interactions of the carboxylic acid group and 
of the meta nitro group are possible adopting a geometry highly similar to that of 30. In contrast 
the central part of 37 shifts compared to 30 (Figure 4-4e).  
4.4.2.7 Binding mode of 43 
The crystal structure of 43 complexed to ALR2 was refined to a resolution of 0.96 Å. 43 is the 
only member of this group of aldose reductase inhibitors which exhibits a third aromatic moiety 
and for which crystal structure determination was successful. An additional phenyl ring serves as 
a linker between the central furan ring and the acetic acid function which binds in the anion 
binding site. 43 possesses as 30 and 37 a terminal meta nitro phenyl moiety. The oxygen atom of 
the central furan ring of 43 is not involved in any H-bonds and it is directed towards the 
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hydrophobic residues Trp79 and Phe122. This oxygen atom cannot compensate for shedding its 
solvation shell by any newly formed polar contacts to the protein. The phenyl ring next to the 
acetic acid group forms hydrophobic contacts to Trp79 (4.1 Å), Tyr48 (3.7 Å) and Trp20 (4.2 Å). 
A -- stacking is here not observed, nevertheless the phenyl moiety should be well 
accommodated in this predominantly aromatic environment. The furan ring forms hydrophobic 
interactions to Leu300 (3.4 Å) and Trp111 (3.3 Å). In the specificity pocket the terminal phenyl 
ring undergoes a face-to-face --stacking to Trp111 (3.5 Å, Figure 4-4f). 
4.4.3 Further crystallographic experiments 
The initial aim of this study was to elucidate the complex crystal structures of numerous 
members of this ligand series and measure the corresponding thermodynamic signature. At the 
beginning of this project ALR2 complex structures were either obtained by cocrystallization or 
by ligand soaking in citrate buffer. The complex crystal structures of ALR2-26, ALR2-27 and 
ALR2-28-P1 were obtained under these conditions.8, 143 One example was known for which it 
was possible to cocrystallize the protein with an inhibitor in TRIS buffer at pH 8.0121 but these 
conditions were difficult to reproduce. Unfortunately, in none of the various collected datasets of 
cocrystallized or soaked ALR2 crystals in citrate buffer sufficient difference electron density for 
the accomodation of the bound ligand molecule could be found. The description of a new 
crystallization condition in MES-buffer, pH 5.5, by Cousido-Siah et al.101 was a very valuable 
asset for our crystallographic study. Cousido- Siah et al. discussed the absence of citrate in the 
MES condition as crucial since citrate is known to be an aldose reductase inhibitor itself38 and 
thus it always competes with a ligand to be bound in the crystallographic analysis. Plenty of 
datasets of ALR2 crystals either cocrystallized or soaked under the citrate condition were 
collected. In fact often not enough difference electron density for a bound ligand was visible 
whereas still some difference electron density indicated the presence of a carboxylic acid group 
in the anion binding pocket. This could result from the occupancy with disordered molecules of 
citrate as described in literature34 and supports the hypothesis that citrate is blocking the binding 
of the inhibitors. Since it required some time to establish the crystallization in MES in our 
laboratory an alternative approach was tested. The protein was crystallized under the known 
condition in citrate buffer at pH 5.0. Afterwards the crystals were transferred into several droplets 
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in a step-wise fashion which contained the initial citrate condition with 25% (w/v) PEG 6000 at 
pH 5.0 in decreasing concentration and the MES condition with 25% (w/v) PEG 6000 at pH 5.5 
in increasing concentrations. The latter solution was saturated with the inhibitor in order to 
increase its concentration. For several ligands this protocol was applied. In fact, this procedure 
gave access to the complex structures of 30 and 37. Still in several crystals soaked with other 
ligands of this series, for example 31, not sufficient difference electron density for the bound 
ligand was detected. In the mean time the crystallization of ALR2 under the MES conditions was 
established in our laboratory. To our surprise a dataset of the holo-enzyme of this condition still 
showed density for a carboxylic acid function in the anion binding site. Since the protein had 
never been in contact with citrate there must some other molecule be present showing a similar 
functional group topology. Presumably the difference electron density is created by another 
unknown carboxylic acid, obviously picked-up by the protein during the expression or 
purification. However, since the exchange of citrate to MES as buffer compound seems not to be 
the essential discriminating factor, the modified pH value of the applied conditions attracted our 
attention. While at pH 5.0 or 5.5 the carboxylic acid function of the studied ligand molecules 
could still be partly protonated, it should be fully deprotonated at more basic pH values. Thus the 
soaking experiments described above were repeated. This time the droplets consisted of 
decreasing concentrations of citrate buffer with 25% (w/v) PEG 6000 at pH 5.0 and increasing 
concentrations of TRIS buffer with 25% (w/v) PEG 6000 at pH 8.0, saturated with the inhibitor. 
In fact 31 did successfully bind under this condition to ALR2. Unfortunately it was the only 
ligand for which these new soaking conditions brought the expected achievement. Indeed also the 
complex structure of 43 could be successfully determined in TRIS buffer. However it is possible 
that this ligand would also bind under different conditions since it possesses a high potency. 
Interestingly, using the latter described soaking procedure 29, 34 and 35 lead to datasets where in 
addition to the missing Fo-Fc difference electron density for the ligand molecule also the protein 
residues next to Leu300 were disordered and thus not visible in the density. Apparently these 
ligands are not binding in an ordered fashion under these conditions and are so far only able to 
disturb the crystal packing in this area of the protein. Two factors should be mentioned that may 
explain the pH dependency of the binding of 30, 31 and 37 to ALR2 crystals. At higher pH a 
larger portion of ligand molecules will exhibit a deprotonated carboxylic acid function. This 
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should increase the binding since the negative charge enhances the binding to the anion binding 
pocket which contains the positively charged NADP+. On the other hand the deprotonated 
carboxylate group should lead to higher solubility of the compounds. Since saturated solutions of 
the inhibitors are used under the soaking buffer conditions the basic pH value will lead to higher 
concentrations of the ligands which facilitate the binding to ALR2. To further increase the 
solubility of the compounds up to 10% (v/v) DMSO was added to the soaking solution, but this 
did not further increase the hit rate. However, these experiments indicate that the success of 
protein soaking experiments can be improved by careful choice of the soaking conditions.  
4.4.4 Thermodynamic characterization of 26 and 28-31. 
All ITC measurements were performed in HEPES buffer, pH 8.0 (Figure 10-2 in the Appendix). 
Steuber et al. could show that the binding of carboxylate-type ALR2 inhibitors, among them 26, 
is accompanied by an entrapment of 0.8-0.9 protons due to the protonation of Tyr48.42 The 
thermodynamic profile of 26 was measured with a MCS-ITC instrument of MicroCal. The 
reported data for the titration in HEPES buffer were G0= -35.4 kJ/mol, H0= -25.6 kJ/mol and 
-TS0=-9.8 kJ/mol.8 The values corrected for the protonation step were G0= -35.4 kJ/mol, 
H0= -45.1 kJ/mol and -TS0= +9.7 kJ/mol42 (-TS0 was calculated from the reported data using 
the equation -TS0 = G0 - H0). Due to the small structural variations we assume a similar 
protonation behavior for all ligands of which the thermodynamic profile will be discussed in the 
following. Since the aim of this study was to compare the different ligands relative to one 
another, we relinquished to perform the measurement in different buffer systems to correct the 
enthalpy for the constantly superimposed protonation step. The thermodynamic data are shown in 
Figure 4-7 and in Table 4-1. Representative thermograms and the fitted regression curves are 
shown in Figure 10-2 in the Appendix. Since all new compounds were measured with an ITC200 
we repeated the measurements for 26 with the latter instrument. The enthalpy could be 
reproduced whereas the KD-value and thus the free energy of binding and the entropic term data 
deviate slightly more (G0= -31.5 kJ/mol, H0= -27.2 kJ/mol and -TS0= -4.3 kJ/mol8). For 37 
only ITC curves of poor quality were obtained. As explained above the ligand changed its 
configuration from E- to Z-conformer prior to binding to ALR2. This process occurs apparently 
too slowly to be measured by an ITC experiment. Since the change of configuration could be 
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induced by UV light we exposed a solution of 37 overnight by UV light. However, the following 
ITC measurement resulted again in a curve of insufficient quality. Presumably still a significant 
portion of 37 was present in E-configuration which disturbed the measurement.  
Table 4-1 IC50- values and thermodynamic data for compounds 26, 28, 29, 30 and 31 
 
IC50 KD G0 H0 -T*S0 
 
[µM] [µM] [kJ/mol] [kJ/mol] [kJ/mol] 
26 2.4 ± 0.5 3.1 ± 0.3 -31.5 ± 0.3 -27.2 ± 0.7 -4.3 ± 0.9 
28 0.17 ± 0.03 0.82 ± 0.1 -34.8 ± 0.1 -33.5 ± 0.1 -1.3 ± 0.0 
29 0.26 ± 0.05 2.2 ± 0.1 -32.3 ± 0.1 -23.4 ± 0.1 -8.9 ± 0.1 
30 2.2 ± 0.6 1.7 ± 0.1 -32.9 ± 0.0 -27.4 ± 0.1 -5.5 ± 0.1 
31 2.1 ± 0.5 1.9 ± 0.1 -32.6 ± 0.1 -24.4 ± 0.4 -8.2 ± 0.4 
               
 
 
The thermodynamic signature of the binding of a ligand to a protein is composed of different 
factors. Each polar interaction e. g. H-bond or charge-assisted contact contributes favorably to the 
enthalpic portion. It can be assumed that especially the charge-assisted interaction between the 
negatively charged carboxylate group of this ligand series and the positively charged NADP+ has 
a strong favorable influence on the enthalpic portion. The binding pocket of ALR2 contains 
several hydrophobic residues (e.g. Trp20, Trp111, Phe122, Pro218, Ala299, Leu300) even with 
the specificity pocket in its closed state. Prior to the accommodation of a ligand, water molecules 
will likely fill the binding pocket. These water molecules can be assumed to be entropically 
unfavored compared to the situation in the bulk water phase and their release should lead to a 
favorable signal in the entropic portion of the thermodynamic profile. This would be in line with 
the classical hydrophobic effect.146-148 This general consideration should be valid for all here 
investigated ligands since they all undergo van der Waals interactions with the non-polar residues 
of the binding pocket and consequently are displacing water molecules from this hydrophobic 
environment. Since no highly resolved structure of the holo-enzyme of ALR2 is available it is 
impossible to estimate how many water molecules are displaced by the ligand. In terms of their 
molecular volume the studied ligands fall into the same range (221.0-239.4 A3, V= 18.4 A3, 
calculated with Molinspiration property engine)149 making the hypothesis of the replacement of 
similar amount of water molecules at least reasonable. 
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has due to its oxygen atom an enhanced electron density compared to the phenyl ring of 30. Since 
Trp111 possesses an electron-rich indole ring an electron-deficient system will be preferred as 
interaction partner, also indicated by the fact that electron-withdrawing substituents of this ring 
such as nitro-groups, fluorine and chlorine are beneficial for binding.43 Electron deficiency is 
better fulfilled for 30 as for 31 which could additionally explain the slight enthalpic advantage of 
30 compared to 31. 26 shows a very similar thermodynamic profile as 30. The enthalpic portion 
(-27.2 kJ/mol compared to -27.4 kJ/mol) and the entropic portion (-4.3 kJ/mol compared -5.5 
kJ/mol) are nearly identical despite remarkable changes in the binding modes. Steuber et al.8 
discussed several factors which influence the thermodynamic profile of 26. For the relative 
discussion of 26 and 30 these assumptions were taken into account. Several factors influence the 
enthalpic contribution of the binding of 26 to ALR2. The formed H-bonds between 26 and the 
captured water W1 and between W1 and Trp111 are contributing favorably to the enthalpic 
portion. In ALR2-30 no similar interaction to a water molecule can be detected. Accordingly 26 
should have an enthalpic advantage compared to 30. A small enthalpic advantage arises from the 
H-bond between one of the oxygen atoms of the carboxylic acid group of 26 and the Tyr48OH. It 
is in ALR2-26 shorter in comparison to the other complexes, possibly due to the fact that this 
oxygen atom is in contrast to the other complexes not involved in any further H-bonds. 
Therefore, it can be assumed that it is accompanied by a stronger favorable enthalpic contribution 
compared to the comparable contact in ALR2-30. On the other hand, some characteristics of the 
chemical structure and the binding mode of 26 influence the enthalpy unfavorably. In all other 
complexes except ALR2-28-P21 and ALR2-28-P1 an H-bond (2.9-3.1 Å) between one of the 
oxygen atoms of the carboxylate group of the inhibitor and Trp111NE1 is observed. Indeed these 
distances indicate a rather weak interaction. Nevertheless, this missing interaction in ALR2-26 
should be accompanied by a loss in the enthalpy and has to be overcompensated by the 
interactions involving W1. Furthermore, the central oxadiazol ring of 26 will be well solvated in 
solution. The situation can be compared to that of the furan ring in 31. An unfavorable effect on 
the enthalpy can be assumed since the heteroatoms of the oxadiazol moiety of 26 are not 
compensated for the lost interactions to the solvent water molecules by polar contacts to the 
protein residues. Regarding the entropy the following assumptions should be regarded. The 
degrees of freedom of water W1 are decreased which contributes unfavorable to the entropic 
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profile. On the other hand the water molecules which are part of the solvation shell of 26 are 
released when 26 binds to the protein. This in consequence leads to a favorable entropic 
contribution and compensates, at least in parts, for the unfavorable entropy loss accompanied 
with the capturing of the water molecule W1. Altogether the comparison of 26 and 30 is an 
example where significant differences in the binding mode finally display a very similar 
thermodynamic signature. 28 shows a more favorable enthalpic (-33.5 kJ/mol) and a less 
favorable entropic portion (-1.3 kJ/mol) than 30. This is in line with the deviating binding modes. 
In ALR2-28-P21 two water molecules (W2 and W3) are captured. Again, as discussed for 26, the 
formed H-bonds between 28, W2, W3 and the protein residue will result in a gain in enthalpy 
compared to 30 whereas the entropic part is reduced owing to the fixation of the water molecules. 
The established H-bond network of 28 involving W2 and W3 leads to such a large gain in 
enthalpy most likely overcompensating the missing interaction between the carboxylate group of 
28 and Trp111. Both effects, the gain in the enthalpic contribution and the loss in the entropic 
contribution are more distinct for 28 than for 26 since 28 captures two waters instead of one. 
Surprisingly, 28 and 29 deviate strongly in their thermodynamic profiles. The enthalpic portion is 
-33.5 kJ/mol for 28 while it is -23.4 kJ/mol for 29. The entropic portion is -1.3 kJ/mol for 28, but 
it amounts to -8.9 kJ/mol for 29. Despite several trials we were not able to obtain the complex 
structure of 29. In consequence we can only hypothesize about a possible explanation of its 
deviating thermodynamic signature. It was previously discussed that the carboxylic acid group of 
29 might adopt a different orientation compared to the one of 28.143 However, the comparison of 
ALR2-28-P21 and ALR2-30 indicates moreover that the different central aromatic ring systems 
lead to deviating interactions of the carboxylic acid functions of both ligands. As shown in 
Figure 4-5e-f, the relative positions of the C2-linker between the respective aromatic ring system 
and carboxylic acid function differ strongly since a phenyl and thiophenyl ring do not allow for 
the attachment of the C2 linker with the same geometry. Consequently, only the -oxygen atoms 
of both ligands align while the -oxygen atoms differ in their positions. Since 29 contains similar 
to 28 a five-membered central aromatic moiety the binding geometries of the carboxylic acid 
group should be similar for both ligands. Although no explanation for the deviating 
thermodynamic profiles of 29 and 28 can be provided this example demonstrates how 
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significantly the exchange of a thiophene ring to a furan ring can influence the thermodynamic 
profile.  
4.5 Conclusions 
Due to its role in the polyol pathway ALR2 is a promising target to prevent the development of 
diabetic complications. Here, a series of closely related carboxylic acid type ligands bearing two 
or three aromatic ring moieties were evaluated as inhibitors of ALR2. It could be confirmed that 
the introduction of the meta nitro group to the terminal aromatic ring system is accompanied by a 
potency enhancement which is in concordance with previous studies. Surprisingly, the exchange 
of this nitro group by a carboxylic acid group leads to a significantly decreased affinity. 37 is 
with an IC50-value of 3.1 +/- 0.8 µM an interesting derivative bearing an acrylic acid group while 
43 is with an IC50-value of 0.34 +/- 0.05 µM144 a potent member of the compound class 
containing a third aromatic ring system. The soaking protocol was improved so that the pH value 
facilitates the binding of the inhibitors. Solving the complex crystal structure of 28 complexed to 
ALR2 in space group P21 (ALR2-28-P21) showed that the binding mode of 28 is in good 
agreement with the previously described corresponding structure in P1. Furthermore, an 
additionally captured water molecule (W3) is visible in the ALR2-28-P21 complex which might 
influence the thermodynamic profile. The binding mode of four new ALR2-inhibitor complexes 
(ALR2-30, ALR2-31, ALR2-37, ALR2-43) were determined. ALR2-37 is the first complex 
structure of an ALR2 inhibitor complex which contains an acrylic acid head group. Since the 
conformation of the double bond of 37 changed from E-to Z-configuration prior to binding it can 
be deduced that ALR2 prefers inhibitors with the acrylic acid group in Z-configuration. ALR2-43 
is the first complex structure of ALR2 with an inhibitor of this compound class which exhibits 
three aromatic moieties. The structure shows that ALR2 can accommodate such a bulky ligand.  
Additionally, the thermodynamic profiles could be measured in HEPES buffer. The enthalpic 
binding portion across the studied ALR2- inhibitor series varies between the lowest and largest 
value over a range of 10.1 kJ/mol. This is remarkably large since the binding modes of the 
ligands to the target protein ALR2 are closely comparable. In two cases captured water molecules 
could explain the differences in the thermodynamic profiles. Different interaction patterns of the 
carboxylic acid head group have been observed. In some cases the burial of polar groups of the 
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inhibitors in a hydrophobic environment of the protein provide an explanation for a reduced 
enthalpic signature. The relationship between the thermodynamic binding patterns and the 
adopted binding modes described here can serves as a valuable input for further design cycles. 
4.6 Description of Experimental Procedures 
4.6.1 Expression, purification, ITC measurements, crystallization and structure 
determination 
The expression and purification of ALR2 are described in Section 9.2.1, the ITC measurements 
in Section 9.2.5, the crystallization in Section 9.2.3, the soaking in Section 9.2.3.6 and 9.2.3.7 
and the structure determination in Section 9.2.4. 
4.6.2 1H-NMR analysis of 37 
No sign of the Z-isomer of 37 was visible within the compound´s 1H-NMR spectrum when it was 
measured immediately after the synthesis. The doublet at 6.69 ppm with a coupling constant of 
16.0 Hz clearly shows the presence of the E-isomer. However, a doublet at 6.02 ppm with a 
coupling constant of 12.6 Hz and an integral of 0.02 (integral of the E-isomer doublet = 1.00) 
appeared in the spectrum after three years. This signal with its typical coupling constant belongs 
to the Z-isomer.150 Therefore we concluded that an isomerization of the double bond had taken 
place during storage. The compound was stored undissolved in a box, but no additional measures 
were taken to protect it from light. An attempt to separate the isomers chromatographically (silica 
gel and dichloromethane / methanol mixtures) was unsuccessful. Instead the Z-isomer was 
enriched. The NMR spectrum showed the Z-isomer doublet at 6.02 ppm with an integral of 0.15 
(integral of the E-isomer doublet = 1.00). Whether the enrichment of the Z-isomer was only due 
to isomerization under the conditions of chromatography or whether a more favorable elution of 
the Z-isomer played a part could not be determined. The NMR sample of the mixture (dissolved 
in deuterated DMSO) was exposed to ultraviolet light (254 nm) and subsequently spectra were 
taken. After 8 h exposure the spectrum showed the Z-isomer doublet at 6.02 ppm with an integral 
of 0.39.The E-isomer doublet at 6.69 ppm was superimposed with the second doublet of the Z-
isomer in a way that made separate integration impossible. The combined signal was set to 1.00. 
This means the ratio of E to Z was around 3:2 at this time and continued to increase during 
exposure to ultraviolet light. The doublet of the Z-isomer was integrated to 0.44 after 16 h 
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exposure and to 0.52 after 31 h (signal at 6.69 ppm was always set to 1.00). Therefore it seems 
clear that the geometry of the double bond is liable to isomerization and especially unstable in 
solution, under exposure to ultraviolet light as well as during chromatography while even the 
undissolved solid is not completely stable. 
 
  
98 

 
 
Thermodynamic and Structural Investigation of  
the Opening of the Specificity Pocket of Human Aldose Reductase 
 
99 

5 Thermodynamic and Structural Investigation of  
the Opening of the Specificity Pocket of Human Aldose Reductase 
5.1 Introductory Remarks 
The following chapter was prepared for submission to a scientific journal. This study was done in 
collaboration with Dr. Frithjof Scheer, Felix Terwesten, Dr. Philipp Toth, Prof. Dr. Andreas 
Heine and Prof. Dr. Wibke Diederich (Philipps University Marburg). The author of this thesis 
determined the complex crystal structures, performed the ITC measurements and drafted the 
following manuscript. 
5.2 Abstract 
For drug design a profound understanding of the process of molecular recognition between the 
binding site of a protein and small molecules which have the ability to inhibit this protein is 
essential. Here, we present insights into the thermodynamic background of the opening of a 
subpocket of a protein when addressed by a suitable moiety of a ligand. As a model protein the 
human aldose reductase was chosen, which is involved in the development of diabetic 
complications. The opening of its specificity pocket, which is highly significant for the design of 
selective inhibitors for this protein, is studied by high-resolved X-ray crystallography, isothermal 
microcalorimetry and surface plasmon resonance measurements, using a ligand series based on a 
2-carbamoyl-phenoxy-acetic acid scaffold.  
5.3 Introduction 
For drug design a detailed understanding of the thermodynamic behavior of the binding process 
of a ligand to a protein is essential.6, 7 This appears even more important if for the 
accommodation of the ligand a transient subpocket has to be opened. Little is known about the 
influence of the opening process of such a subpocket on the thermodynamic profile. To gain 
further insights into this process the choice of human aldose reductase (ALR2, EC 1.1.1.21) as a 
model protein appears promising. Due to its involvment in the development of diabetic 
complications this protein has medicinal relevance. In 2013, 382 million people worldwide 
suffered from diabetes. This number is predicted to increase to 592 million cases up to the 
year 2035.17 The disease is related to some long-term complications like neuropathy, nephropathy 
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and retinopathy.45 ALR2 is a NADPH-dependent oxidoreductase. It reduces glucose to sorbitol 
which is the first step of the polyol pathway. The consumption of NADPH leads to decreased 
levels of reduced glutathione21 which makes the cells more vulnerable for intracellular oxidative 
stress. This is a confirmed mechanism which leads to the development of diabetic 
complications,28, 29 making ALR2 an interesting target for drug design. This made ALR2 to a 
well characterized protein. Ultrahigh resolved crystal structures40 and thermodynamic data of 
protein ligand complexes, giving insights into key interactions8 and overlaid protonation effect42 
are described in literature. This knowledge served as a starting point for the current study. 
The binding pocket of ALR2 is depicted in Figure 5-1a. One subpocket consists of an anion 
binding pocket which is formed by Tyr48, His110, Trp111 and the nicotinamide moiety of 
NADP+.38 Inhibitors address this subpocket with a negatively charged group, e.g. their 
carboxylate, hydantoin or succinimide functions.45 Adjacent, an additional subpocket can be 
formed in the active site. The C-terminal loop, especially the region around Leu300, possesses a 
high flexibility, which allows the opening of the so-called specificity pocket. Phe122 and Leu300 
serve as gatekeepers which either seal or give access to this pocket.37 In Figure 5-1b the binding 
mode of fidarestat (44, PDB: 1PWM)151 is shown. It does not address the specificity pocket 
which remains in the closed state. In Figure 5-1d the binding mode of minalrestat (45, 
PDB: 1PWL)151 is depicted. The latter compound addresses the specificity pocket with its 
halogenated phenyl substituent. The side chain of Leu300 (colored in red) shifts its position in 
space and opens the entrance of the pocket. In Figure 5-1c the different conformations of Phe122 
and the Ala299 to Ser302 sequence stretch in both structures are compared. The image shows that 
not only the side chain of Leu300 but the entire attached protein backbone changes its 
conformation. Accommodation of ligand portions in this pocket by inhibitors which exhibit 
suitable moieties is a promising strategy to gain specificity compared to the human aldehyde 
reductase (EC 1.1.1.2). For the latter enzyme the formation of such a pocket is less favorable 
since it would involve the rupture of a salt bridge.39 The crystal structure of the ALR2 holo-
enzyme shows the closed conformation of the specificity pocket (PDB: 1ADS).33 In the 138 
complex crystal structures which are deposited in the PDB (August 2015) the specificity pocket 
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is only opened if addressed by an inhibitor. Consequently, the closed conformation appears to be 
the thermodynamically more stable one.  
A previously published class of ALR2 inhibitors possess 2-arylcarbamoyl-phenoxy-acetic acid 
scaffold as the core structure.43 In the present work, we use derivatives of this group with varying 
moieties (R in Figure 5-2) to induce different binding site conformers. The chemical structures of 
the studied inhibitors are presented in Figure 5-2. The resolution of the here described complex 
crystal structures ranges from 0.98- 1.20 Å which allows for a detailed analysis of the binding 
modes of the inhibitors, the induced conformation of the binding pocket and water structures. 
Isothermal microcalorimetry (ITC) and surface plasmon resonance (SPR) measurements were 
used to study the thermodynamic background of the addressing and consequently opening of the 
specificity pocket.  
5.4 Results 
5.4.1 Introductory remarks regarding the crystallization and soaking conditions 
The complex structures ALR2-47, ALR2-49, ALR2-50, ALR2-52 and ALR2-53 were obtained 
by soaking the ligands in TRIS buffer at pH 8.0 into holo-protein crystals. ALR2-51 was 
obtained by soaking in citrate buffer at pH 5.0. ALR2-48 was obtained by cocrystallization in 
citrate buffer at pH 5.0 since this ligand destroyed the crystals during the soaking process in 
TRIS buffer. Since the differences which we found in this study between the binding modes of 
the different ligands can be explained by conformational adaptions on the protein side or by 
displacement of water molecules due to sterical reasons we consider the influence of the different 
crystallization and soaking conditions as negligible.  
5.4.2 Different protein conformers 
Three different conformers of the residues which border the specificity pocket were found in the 
here described crystal structures. Figure 5-1e-j, Figure 5-4 and Figure 5-7 give an overview about 
the induced protein conformers of ALR2-47- ALR2-52. First, ALR2-47, ALR2-48 and ALR2-52 
represent complex crystal structures where the specificity pocket is found in its closed state. 
Here, the side chain of Leu300 points towards Phe122 which blocks the access to the pocket.  
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Figure 5-1 (a) Schematic view of the binding pocket of ALR2. (b) Binding mode of 44 with the specificity pocket in 
closed conformation. The protein surface is colored in gray, the carbon atoms of 44 are colored in cyan, the oxygen 
atoms in red and the nitrogen atoms in blue. Phe122 and Leu300 are colored in red. This color scheme is maintained 
during the following images. (c) The view direction is perpendicular compared to the remaining figures. The carbon 
atoms of the protein residues which correspond to ALR2-44 (specificity pocket is closed) are colored in green, those 
which correspond to ALR2-45 (specificity pocket is opened) are colored in blue. The entire backbone next to Leu300 
performs conformational changes when the specificity pocket is opened. This is best visible when the positions of the 
side chain of Leu300 are compared (red arrow). (d) Binding mode of 45 with the specificity pocket in open 
conformation. Carbon atoms of 45 are shown in purple. (e)-(j) Binding modes of the ligands which are investigated 
in this study. 47, 48 and 52 leave the specificity pocket closed while 49, 50 and 51 open the specificity pocket. 
(e) ALR2-47, carbon atoms of 47 are shown in light-red. (f) ALR2-48, carbon atoms of 48 are shown in green. 
(g) ALR2-49, carbon atoms of 49 are shown in yellow. (h) ALR2-50, carbon atoms of 50 are colored in orange. 
(i) ALR2-51, carbon atoms of 51 are colored in blue. (j) ALR2-52, carbon atoms of 52 are colored in purple. This 
figure and the following representations were prepared using PyMOL.36 
 
As a consequence of the position of Leu300 the protein surface forms a cleft between the 
backbone of Leu300 and the side chain of Trp219 (Figure 5-1e, f and j). Secondly, ALR2-49 and 
ALR2-51 exhibit the specificity pocket in an open conformation. The loop around Leu300 
performs conformational changes to open the specificity pocket. The side chain of Leu300 moves 
away from the phenyl ring of Phe122. Leu300, Cys298 and Trp219 form a kind of wall which 
limits the binding pocket at the lower side (Figure 5-1g, i). 53 induces with the meta nitro phenyl 
moiety the same conformation of the residues of the specificity pocket as 49 and 51 (not shown 
in Figure 5-1). Thirdly, in ALR2-50 the specificity pocket is similarly opened, but here the 
carboxamide group of the Ala299- Leu300 backbone is orientated differently (Figure 5-3a). An 
H-bond between the nitrogen of the benzothiazole ring and the nitrogen of the Ala299-Leu300 
amide bond leads to this rearrangement of the backbone of the specificity pocket (Figure 5-4d). 
Figure 5-3b shows an alignment of Ala299-Ser302 of the obtained complex crystal structures. 
The conformational changes result in the largest repositioning of the side chains of Leu300 and 
Leu301. The transformation from the closed to the opened state of the pocket is accompanied by 
the rupture of one and the formation of two new internal H-bonds between the residues which 
border the specificity pocket. In Figure 5-3c an overlay of ALR2-47 (carbon atoms are colored in 
salmon, specificity pocket is in closed state) and ALR2-51 (carbon atoms are colored in blue, 
specificity pocket is in open state) is presented. In the closed state, an H-bond between the 
oxygen atom of the carbonyl group of the peptide bond between Ala299 and Leu300 and the 
Tyr309OH group is established. The short distance of 2.5 Å indicates a strong interaction. In the 
open state the peptidic carbonyl oxygen is turned away from Tyr309 (Figure 5-3d).  
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Figure 5-4 Stick representation of the binding modes of 47-52. Carbon atoms are colored in gray, nitrogen atoms 
are colored in blue, sulfur atoms in yellow and oxygen atoms in red for protein residues. Carbon atoms of NADP+ 
are colored in magenta. Water molecules which are interacting with the ligand are shown as green spheres, H-bonds 
are depicted as black-dotted lines. (a) ALR2-47, carbon atoms are shown in light red. (b) ALR2-48, carbon atoms are 
shown in green. (c) ALR2-49, carbon atoms are shown in yellow. (d) ALR2-50, carbon atoms are shown in orange. 
(e) ALR2-51, carbon atoms are shown in blue. The non-classical H-bond between one of the oxygen atoms of the 
nitro function of 51 and one of the hydrogen atoms of the phenyl ring of Tyr309 is displayed as a green-dotted line. 
(f) ALR2-52, carbon atoms are shown in purple.  
 
In a previous study the cofactor was described as being bound in its oxidized form NADP+.40 
Figure 5-4 shows stick representations of ALR2-47 to ALR2-52 along with the polar interactions 
formed between ligand, protein residues and water molecules, Figure 5-7 the same complexes 
with corresponding water networks. The complex structures were obtained at pH 8.0 and pH 5.0, 
respectively. At pH 8.0 the carboxylate group should be deprotonated during the entire binding 
process. At pH 5.0 it should be deprotonated in bound state, however prior to protein binding it 
should be partly protonated. Therefore it will carry a negative charge on the acetic acid group by 
which it interacts with the positively charged nicotinamide moiety of NADP+. The distance 
between the carboxylate oxygen which falls near to the cofactor and the endocyclic nitrogen of 
the nicotinamide of NADP+ is 4.2 Å. Furthermore, the acetic acid carboxylate oxygen forms H-
bonds to Tyr48OH (2.7-2.8 Å) and His110NE2 (2.7Å) while the other oxygen of the carboxylate 
group establishes an H-bond to Trp219N1 (3.0-3.1 Å). The central peptide bonds of 47-51 
position in a way that an internal H-bond between the amide nitrogen NH to one of the oxygen 
atoms of the carboxylate group of the inhibitor (3.0-3.4 Å) can be formed. Solely 52 does not 
form this interaction. All investigated ligands (except 52) form an H-bond contact (2.5-2.9 Å) 
between the carbonyl oxygen of the central peptide bond and water W1. Additionally the central 
fluoro-substituted phenyl ring makes van der Waals contacts to Trp79 (4.6 Å), Trp20 (3.8 Å) and 
Phe122 (3.9 Å). In the following Section the differences between the binding modes of ligands 
47-53 are explained in detail.  
5.4.4 Binding mode of 47 
Since 47 carries no further substituent at the amide nitrogen the doubly protonated nitrogen can 
undergo an additional H-bond contact to the additionally recruited water molecule W2 (3.2 Å, 
Figure 5-4 a) which in turn is H-bonded via an additional water molecule W3 with the nitrogen of 
the amide bond between Ala299/Leu300 (2.9 Å). Consequently, using W2 and W3 as mediating 
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water molecules, 47 forms additional polar contacts to the protein. In the here investigated ligand 
series it is the only ligand besides 52 which forms an H-bond via this amide nitrogen in addition 
to the intramolecular H-bond to the terminal acetic acid carboxylate group. 
5.4.5 Binding mode of 48 
48 contains a propynyl side chain which is attached to the amide function. The propynyl side 
chain contains a -electron system and fills the cleft next to the unopened specificity pocket 
formed between Leu300 and Trp219 which has a rather hydrophobic character. This binding 
mode enables the propynyl side chain of 48 to form van der Waals contacts to Trp111 (3.4 Å), 
Phe122 (4.8 Å), Trp219 (3.6 Å) and Leu300 (3.5 Å). To accommodate the side chain of 48 
Ala299–Tyr309 have to shift slightly compared to the ALR2-47 structure (Figure 5-5a). Using 
the McLachlan algorithm152 as implemented in the program ProFit153 an RMSD across the 
residues 299-309 of 0.67 Å was calculated which is 3.6 times larger than the RMSD of the 
remaining protein residues (0.19 Å) in this comparison. For this calculation and the additional 
calculations referenced further down with ProFit the protein molecules were aligned based on the 
C atoms. Similar to 47 also 48 forms a direct H-bond to W2 (2.7 Å), however, here the ligand 
uses its carbonyl oxygen of the central amide bond to establish this contact (Figure 5-4b). 
5.4.6 Binding mode of 49 
49 could be built into the Fo-Fc difference electron density map at a  level of 3.0. It was refined 
to an occupancy of 80%. Still unassigned significant difference electron density remained in the 
specificity pocket. An overlay with ALR2-47, in which the specificity pocket keeps the closed 
conformation, shows a univocal match between the backbone and side chain positions of the 
residues of the specificity pocket and the unexplained difference electron density (Figure 5-5b). 
This observation strongly supports the presence for a second conformation of the specificity 
pocket in ALR2-49. Predominantly the open conformation is visible which is induced by 49 
binding. It was adjusted to the same occupany as the ligand (80%). The protein residues which 
correspond to the open conformation of the specificity pocket adopt a similar geometry as in 
ALR2-51. Because the corresponding Fo-Fc electron density is not fully visible we restrained 
from inserting the closed conformation of the specificity pocket as a second conformation. The 
question  remains  whether  49  binds  in  two conformations, in agreement with the observed two  
Therm
the Opening of

Figure 5-5 (a) Alignment of ALR2
Cys303 and of the ligands are shown
ALR2-48 and ALR2-52 the residues
corresponding ligand. (b) 49 is show
correspond to the open conformatio
conformation was included in the f
sigma which corresponds to the clos
This can be attributed to 20% o
molecule of 49.  
 
conformers of the specificity 
ligand conformer with respec
entrance of the binding pocke
suggesting the occupancy of 
average B-factor of the termin
the attached fluorophenoxyace
pocket. If a second orientation
phenyl ring should show muc
that supposedly no second or
specificity pocket is opened. T
pocket and performs a --
undergoes van der Waals cont
and to the side chain of Leu
odynamic and Structural Investigation of  
 the Specificity Pocket of Human Aldose Red
-47, ALR2-48 and ALR2-52. The carbon atoms of 
 in light red for ALR2-47, in green for ALR2-48 and
 Ala299 to Cys303 are pushed aside to accommodat
n together with Ala299- Ser302. The residues with c
n of the specificity pocket which was refined to an
inal model. Some Fo-Fc difference electron density w
ed conformation of the specificity pocket (carbon ato
f the protein molecules where the specificity po
pocket. In such case, the difference electron
t to the terminal phenyl ring of 49 should 
t. However, we did not find any Fo-Fc diffe
the phenyl ring in this area at a  level of 
al phenyl ring of 49 (13.1 Å2) is only sligh
tic acid scaffold (10.4 Å2) which binds tight
 of the terminal phenyl moiety of the ligan
h higher B-factors. Consequently, the avera
ientation of the ligand is present and that
here, the terminal phenyl ring of 49 accomm
stacking with Trp111 (~3.5 Å). Furtherm
acts to the aromatic systems of Trp79 (3.7 Å
300 (3.6 Å). Up to now this is the only kn
uctase 
 
109 
 
protein residues Ala299 to 
 in purple for ALR2-52. In 
e the bulky moieties of the 
arbon atoms shown in gray 
 occupancy of 80%. This 
as found at a level of 3.0 
ms are shown in light red). 
cket is not opened by a 
 density for a second 
be visible next to the 
rence electron density 
3.0. Additionally, the 
tly higher than that of 
ly to the anion binding 
d existed the terminal 
ged B-factors suggest 
 49 only binds if the 
odates the specificity 
ore, the phenyl ring 
) and Phe122 (3.7 Å) 
own complex crystal 
Thermodynamic and Structural Investigation of  
the Opening of the Specificity Pocket of Human Aldose Reductase 
 
110 

structure which shows the binding of an unsubstituted aromatic system in the specificity pocket 
of ALR2. With a KD= 7.5+/-1.4 µM it is one of the weakest binders, confirmed by X-ray 
crystallography, to open the specificity pocket of ALR2 (Figure 5-4c).  
5.4.7 Binding mode of 50 
An H-bond is formed between the amide nitrogen of the Ala299-Leu300 bond and the nitrogen 
atom of the benzothiazolyl moiety of 50 (3.1 Å, Figure 5-4d). Therefore, the backbone changes 
its position to enable the formation of this H-bond compared to ALR2-51 (Figure 5-3a). The 
benzothiazolyl moiety of 50 forms a face to face --stacking with the side chain of Trp111 
(approximately 3.5 Å). Furthermore, it forms van der Waals contacts to Trp79 (4.2 Å), Phe122 
(4.0 Å) and Leu300 (3.4 Å). The sulfur atom of the benzothiazolyl moiety is not involved in any 
polar interactions. 
5.4.8 Binding mode of 51 
51 possesses a nitro group attached in meta position to its terminal phenyl ring. The latter moiety 
of 51 opens the specificity pocket (Figure 5-4 e and Figure 5-7e). Its binding mode is very similar 
to that of its Cl-analogue IDD393 (46).8 The phenyl ring of the side chain performs a --
stacking with the aromatic system of Trp111 (~3.5 Å). Additionally, it forms van der Waals 
contacts to the side chains of Trp79 (3.8 Å) and Phe122 (3.8 Å). Thus, the hydrophobic 
interactions of the phenyl ring of 51 are similar as already described for the corresponding moiety 
of 49. The nitro group forms an H-bond to the NH of the Leu300 backbone (3.2 Å). Furthermore, 
one of the oxygen atoms of the nitro group is positioned close to one of the carbon atoms of the 
phenyl ring of Tyr309 (3.3 Å, Figure 5-4 e). This distance is surprisingly short. It was previously 
discussed to be a non-classical secondary H-bond between the C-H dipole at the phenyl ring and 
the negatively polarized oxygen of the nitro group.8  
5.4.9 Binding mode of 52 
The occupancy of 52 was refined to 77%. Compared to 51 the nitro function is replaced in 52 by 
an isosteric carboxylic acid function. Unfortunately, the terminal carboxylic acid function at the 
phenyl ring is not visible in the Fo-Fc difference electron density at a  level of 3.0 and was 
consequently not included in the deposited structure. The NMR, mass-spectrometric and 
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dataset was collected with our inhouse source (Incoatec IS microfocus,  = 1.5418 Å). Also in 
this dataset the carboxylic acid group was already missing in the resulting Fo-Fc difference 
electron densitiy at a  level of 3.0. Consequently, radiation damage can be excluded. The 
exchange of the nitro function by a carboxylic acid group leads to a surprising change in the 
binding mode. 51 addresses the specificity pocket and forms an H-bond with its nitro group to the 
Leu300 backbone. On the contrary, 52 directs the benzoic acid side chain towards the 
surrounding solvent area and fills the hydrophobic cleft adjacent to the unopened specificity 
pocket (Figure 5-4f, Figure 5-7f). Accordingly, the specificity pocket remains in its closed 
conformation even though the carboxylate group should be better suited to establish the H-bonds 
in the specificity pocket compared to the nitro group which is often classified as a weak H-bond 
acceptor. To enable this changed binding mode the bond between the central phenyl ring and the 
peptide bond is flipped over compared to 51. In consequence, the intraligand H-bond between the 
amide nitrogen and one of the oxygen atoms of the acetic acid carboxylate group of 52 is 
ruptured. This internal H-bond was discussed in literature as crucial for high affinity binding.43 
The acetic acid head group of 52 adopts two different conformations in the anion binding pocket. 
Conformation A occurs with the minor occupancy (28%). It aligns well with the conformation 
found for the carboxylate group in all the other members of this series, accordingly a similar H-
bonding pattern is established. Conformation B is the predominant one (49%). Here the 
carboxylate head group is shifted and forms an H-bond with one of its oxygen atoms to Tyr48OH 
(2.6 Å) whereas the other one contacts to His110NE2 (2.7 Å). At this position the second oxygen 
atom is too remote to make a direct H-bond to Trp111. Instead water W17 is captured (2.8 Å) and 
mediates such a contact. The existence of two conformations of the carboxylate group of the 
inhibitor and the entrapment of a water molecule at similar position was described previously for 
the binding mode of 52a (Figure 5-2) at pH 8.0.121 Owing to a sterical repulsion with W17 caused 
by one of the oxygen atoms of the carboxylate group in conformation A, the ligand can only 
entrap the water in conformation B. Its occupancy was therefore set to the same value as that of 
conformation B of the carboxylate group. W17 forms in turn an H-bond to Trp111NE1 (2.7 Å). 
Furthermore, W17 is in H-bond distance to the carbonyl oxygen atom of the central amide bond 
of 52 (2.8 Å). Supposedly, the generated interaction network by one of the carboxylate oxygens 
of 52 in conformation B, entrapment of W17 and the involvement of the peptidic oxygen of 52 
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can, at least in parts, compensate for the loss of the internal H-bond between the carboxylate and 
the peptidic group of 52. W2 is visible with conformations A and B. In both cases it makes H-
bonds to the oxygen atom of the central amide bond (A: 3.3 Å, B: 2.5 Å). The amide nitrogen of 
52 forms an H-bond to W16 (2.9 Å). W16 is found in an adjacent position in all the other 
described complexes, however, without establishing an H-bond to the ligand (not shown in 
Figure 5-7a-e). Thus, compared to the other described ligands, no additional water is trapped to 
establish this network. The terminal phenyl ring of the benzoic acid moiety of 52 undergoes an 
aromatic edge to face contact with the phenyl ring of Phe122 (~4.6 Å). Additionally, it forms a 
van der Waals contact to the aromatic moiety of Trp219 (3.8 Å). Compared to ALR2-47 the 
residues 299-309 are slightly repositioned as similarly observed in ALR2-48. Here the RMSD, 
calculated with ProFit,152, 153 for the residues 299-309 is 0.56 Å which is 4.4 times larger than the 
RMSD of the remaining protein residues. As shown in Figure 5-5a, this loop adopts a similar 
position as in ALR2-48.  
5.4.10 The water networks around the surface of the specificity pocket 
For the analysis of the water networks around the binding pocket of ALR2 the water molecules in 
contact with the adjacent symmetry mates in the packing were included. All water molecules with 
a distance not larger than 10 Å to 50 which was used as a reference ligand were included. Only 
those water molecules which are influenced by the binding of the different ligands are shown for 
the sake of clarity in Figure 5-7. For the same reason we focus on the first solvation shell. The 
oxygen atoms of the central peptide bond of the ligands 47-51 and 53 form an H-bond to water 
W1 (2.3-2.9 Å, Figure 5-4a-f). The latter is connected to a water cluster which consists of two 
connected five-membered ring systems next to the surface of Phe122, including W4, W5, W6, 
W7, W8, W9, W10 and W11. This cluster is fully visible in ALR2-48 and ALR2-51 
(Figure 5-7b and e). The water molecules are stabilized by H-bonding contacts to residues of the 
protein (Phe122, Ser302). All here described complex structures crystallize in the spacegroup 
P21. Due to the spatial packing in the crystal a close symmetry mate of ALR2 comes close to the 
active site of the protein. The described water network in the crystal structures is stabilized by the 
OH and the amide group of Ser282 contributed by the next symmetry mate. Since the changes in 
the water networks which are induced by the different ligands are found more distal from the 
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latter residue the stabilization by the next symmetry mate should not take significant influence on 
the discussed water structures. In ALR2-47 (Figure 5-7a) and ALR2-48 (Figure 5-7b) W2 and 
W3 are mediating an H-bonding network to the amide nitrogen of Ala299 and the ligand. 
Remarkably in ALR2-47 the NH of the peptide bond is used for the interaction to W2, whereas in 
ALR2-48 the carbonyl oxygen of the peptide bond is used for the same interaction. In 
consequence in ALR2-47 the water chain is deeper buried in the cleft between Trp219 and 
Leu300, in ALR2-48 it is pushed upwards because the propynyl side chain of 48 fills the cleft. In 
the final refinement cycle of the complex structure of 47 we decided to not assign a water 
molecule at the position corresponding to that of W11 of ALR2-48 and ALR2-51. Nevertheless, 
difference electron density suggests that W11 is at least partially occupied in ALR2-47. The Fo-Fc 
difference electron density for W14 is shown in Figure 5-7c at a sigma level of 3.0. Reasonable 
difference electron density was visible but placing a water molecule led to sterical repulsions 
with the side chain carbon of Ser302. Summarized the binding modes of 47 and 48 induce a 
water pattern which involves a similar number of water molecules next to the surface of the 
specificity pocket. However, significant changes in the water structures are observed.  
The terminal phenyl ring of 52 interferes with the water network next to Phe122 and Leu300. 
Nevertheless, the water molecules present in ALR2-47 and ALR2-48 can also be found in ALR2-
52, however at shifted positions to avoid steric repulsions with the terminal phenyl ring of 52 
(Figure 5-7f). W13, which is visible in ALR2-50 and ALR2-51, but not in ALR2-47 and ALR2-
48, can also be assigned in ALR2-52. It forms H-bonds to Ser302OH (3.1 Å) and the amide 
nitrogen of the same residue (3.0 Å). Furthermore, W13 establishes an H-bond with W3 (3.0 Å) 
and van der Waals contacts (3.5 Å) to the terminal phenyl ring of 52. W13 and W17, as already 
described above, are water molecules not detectable in the water networks around 47 and 48, but 
in complex with 52. All three ligands do not address the specificity pocket.  
In ALR2-51 (Figure 5-7e) W1, W12, W2 and W3 mediate a contact between the oxygen atom of 
the central peptide bond of 51 and the amide nitrogen of Ala299. W12 is additionally recruited to 
the network to bridge across the hydrophobic cleft formed by the side chain of Leu300. W13 is 
stabilized by H-bonds to the amide NH of Leu301 and to W11. It cannot be detected in ALR2-47 
and 48. 
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Figure 5-7 Representation of the binding mode of 47-52. The protein surface is shown in gray. Nitrogen atoms are 
colored in blue, sulfur atoms in yellow and oxygen atoms in red. Carbon atoms of the protein residues are shown in 
gray. H-bonds distances between 2.3 and 3.3 Å are drawn as black-dotted lines. (a) ALR2-47: Carbon atoms of 47 
are shown in light red. The Fo-Fc density at the position which corresponds to W11 is shown as a green mesh at a 
sigma level of 3.0 sigma. (b) ALR2-48: Carbon atoms of 48 are shown in green. (c) ALR2-49: Carbon atoms of 49 
are shown in yellow. Water molecules which were placed in this structure are shown as green spheres. The water 
molecules from ALR2-51 are shown as blue spheres. The Fo-Fc difference electron densities from the ALR2-49 
dataset which correspond to the positions of water molecules W2, W3 and W10-W13 of ALR2-51 is shown as a 
green mesh at a level of 3.0 . (d) ALR2-50: Carbon atoms of 50 are shown in orange. The water molecules from 
ALR2-51 are shown as blue spheres. (e) ALR2-51: Carbon atoms of 51 are shown in blue. (f) ALR2-52: Carbon 
atoms of 52 are shown in purple. 
 
In summary, the structures showing the specificity pocket in closed conformation, entrap two 
additional water molecules (W12, W13) which become involved in the H-bond network next to 
the specificity pocket compared to the complexes in open state. The partial occupancy of the 
ligand in ALR2-49 along with the superimposed conformer of the holo-enzyme reduce the 
accuracy of the electron density and make it difficult to fully place the water molecules which 
would correspond to W2, W3, W10, W11, W12 and W13 in ALR2-51. Figure 5-7c shows apart 
of reliably assigned water molecules in ALR2-49 (green spheres) the residual Fo-Fc difference 
electron density in this complex together with the positions of the water molecules as formed in 
the ALR2-51 complex (blue spheres) at a 3.0  level. The image shows that water molecules of 
ALR2-51 coincide well with the residual difference electron density peaks in ALR2-49. 
Consequently, the water network observed for ALR2-49 can be assumed to be identical to that of 
ALR2-51. 
As discussed above, 50 induces an open conformer deviating from that found with 49 and 51. As 
a consequence also the water network changes slightly (Figure 5-7d). The corresponding water 
molecules from ALR2-51 are shown as blue spheres. Due to the different orientations of the side 
chain of Leu300 in ALR2-50 the water molecules W4 and W11 are shifted compared to ALR2-
51. A direct H-bond between W4 and W11 cannot be formed any longer . As a consequence W10 
moves its binding position and forms in ALR2-50 H-bonds to W4 (2.4 Å) and W11 (2.3 Å). The 
pivotal water W5 in ALR2-51 is no longer stabilized. Instead W14, not observed in the other 
complexes, is recruited in ALR2-50. It seals a five-membered water cluster consisting of W1, 
W4, W10, W12 and W14 (Figure 5-7d). Furthermore, in this complex the backbone 
conformation next to Leu300 allows stabilization of W15 via H-bonds to the carbonyl oxygen of 
Ala 299 and the amide NH of Leu301 (Figure 5-7d). Overall, despite significant changes in the 
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water network, only one additional water molecule is involved in the H-bonding network to fix 
50 compared to 51.  
5.4.11 Discussion of the binding mode and the surrounding water molecules of 53  
Compared to 51, 53 has an additional 4-phenyl substituent attached to the 2-(2-carbamoyl-
phenoxy)acetic acid scaffold and the 5-F-substituent is missing (Figure 5-2). Figure 5-8a and b 
show the binding mode of 53. The alignment of 53 and 51 shows very similar binding geometry 
for both ligands (Figure 5-8c). Consequently the main interactions with the protein residues are 
similar to the those found for 51. Two main differences are detected. First, the side chain of 
Phe122 shifts in ALR2-53 compared to ALR2-51 to enable an edge-to-face stacking (3.8 Å) with 
the additional 4-phenyl ring of 53. Secondly, this additional phenyl ring of 53 interferes with the 
water network which is detected in ALR2-51. For comparison purposes, the binding mode of 51 
is shown in Figure 5-8d along with some selected water molecules which are represented as green 
spheres. In ALR2-51 a contiguously connected chain of the water molecules (W1, W16, W18, 
W19, W20, W21 and W6) could be detected. W20 and W21 in the ALR2-51 complex have been 
displaced in ALR2-53 owing to the placement of the bulky 4-phenyl ring. 
5.4.12 Differences in mean B-factors of the residues 299-309 of the C-terminal loop 
The temperature factor (B-factor) reflects to some degree the residual mobility of an atom in a 
crystal structure.154 Since the specificity pocket of ALR2 exhibits remarkable flexibility the 
temperature factors of the residues 299-309 were analyzed. These residues are part of the flexible 
loop region which borders the specificity pocket. The residues 310-315 were not included since 
they represent the C-terminus, which is known to possess a high flexibility independent of the 
conformational state of the pocket. In case of ALR2-50, ALR2-51 and ALR2-53 H-bonds 
between the ligand and the latter residues are formed which may take influence on their mobility. 
To consider the difference in the overall mobility of the involved residues across the series of 
structures the B-factors of the residues 299-309 were normalized with respect to the overall B-
factor of the entire proteins and the B-factor ratio was mutually compared (Table 10-3 in the 
Appendix, numbers in brackets). This correlation was previously applied to compare residual 
mobilities.155, 156 The B-factor ratios of the residues 299-309 show remarkable differences 
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Table 5-1 Thermodynamic data of the measurements performed in HEPES buffer. 
 
  KD G0 H0 -T*S0 
  
[µM] [kJ/mol] [kJ/mol] [kJ/mol] 
  Direct Titration 
47 6.6 ± 0.4 -29.6 ± 0.2 -35.4 ± 0.3 5.8 ± 0.4 
48 2.8 ± 0.1 -31.5 ± 0.5 -46.2 ± 0.7 14.7 ± 1.1 
49 7.5 ± 1.4 -29.3 ± 0.4 -29.9 ± 0.4 0.6 ± 0.4 
50 0.054 ± 0.008 -41.5 ± 0.4 -54.0 ± 1.0 12.5 ± 1.1 
  Displacement Titration with 50 as high affinity ligand 
47 7.2 ± 0.9 -29.4 ± 0.3 -39.0 ± 1.0 9.6 ± 1.2 
49 9.1 ± 0.7 -28.8 ± 0.2 -30.6 ± 0.5 1.8 ± 0.7 
52 36.2 ± 11.4 -25.4 ± 0.7 -36.4 ± 2.9 11.0 ± 3.6 
  Displacement Titration with 47 as low affinity ligand 
50 0.050 ± 0.005 -41.7 ± 0.2 -50.6 ± 0.7 8.9 ± 0.8 
51 0.018 ± 0.003 -44.3 ± 0.5 -65.6 ± 0.5 21.3 ± 0.9 
53 0.024 ± 0.003 -43.5 ± 0.3 -55.8 ± 0.2 12.3 ± 0.6 
 
 
 
 
5.5 Discussion 
5.5.1 ITC experiments  
5.5.1.1 Comparison of structural and thermodynamic data of 47 and 48 
The crystal structure analyses reveal very similar binding modes for 47 and 48. In both structures 
the specificity pocket is found in the closed state. Even though differences in the surface water 
layer are found, the same amount of water molecules is involved in the interaction pattern 
between the ligands and the residues adjacent to the specificity pocket. The main difference 
between both ligands is the accommodation of the propynyl side chain of 48 in the rather 
hydrophobic cleft formed between Leu300 and Trp219. Furthermore, the latter ligand pushes the 
Ala299-Tyr309 loop out of way so that its hydrophobic propynyl substituent can be 
accommodated. 48 shows a slightly more favorable Gibbs free energy (G0= -1.9 kJ/mol) than 
47. The G0 difference is the result of a significantly higher exothermic binding of 48 
(H0= -10.8 kJ/mol) which is not fully compensated for by an entropically less favorable 
binding of 48  (-TS0= +8.9 kJ/mol) compared to 47. The B-factor ratio of the Ala299-Tyr309 
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stretch is much lower for 48 than for 47 (1.3 compared to 2.0). Presumably this is the 
consequence of the displacement of residues 299-309 which seem to be relocated to a less 
flexible state, leading to an unfavorable increase in the entropic binding portion. ALR2-47 was 
obtained by soaking, ALR2-48 by cocrystallization. Unlikely the different crystallization 
procedures provide an explanation for the deviating B-factor ratios of Ala299-Tyr309 stretch of 
these two complex crystal structures. For example, ALR2-51 was, similarly to ALR2-47, 
obtained by soaking but in contrast to ALR2-47 it exhibits a very low B-factor ratio for the latter 
residues. The binding of the propynyl side chain in the cleft is accompanied by a strong favorable 
increase of -10.8 kJ/mol of the enthalpy. On first glance this is surprisingly since the molecular 
portion only forms hydrophobic interactions. In this comparison it should not be neglected that 
also significant changes in the water structures are observed. 
5.5.1.2 Comparison of structural and thermodynamic data of 49 and 47 
49 exhibits with its unsubstituted phenyl ring the simplest moiety of all ALR2 inhibitors that 
succeeds in opening the specificity pocket. As discussed, the terminal phenyl ring of 49 does not 
form any other interactions in the specificity pocket apart from the --stacking. In consequence 
with respect to 47, which does not open the specificity pocket, 49 should allow to investigate the 
changes of the thermodynamic profile directly linked with the opening of the pocket. As 
discussed above, the Fo-Fc difference electron density at 3.0  suggests that 49 entraps two 
additional water molecules (W12, W13) in surface network compared to 47. The nitrogen of the 
terminal amide group of the latter ligand allows an H-bond to be formed to W2, a contact 
impossible to realize with 49. Since W2 participates in a water-mediated H-bond to the amide 
group of the Ala299/Leu300-backbone, 47 establishes an additional contact to the protein 
residues, which 49 most likely compensates via W12. The predominant interaction formed by 49 
in the specificity pocket is the --stacking to Trp111. The affinity data show that both 
compounds bind with similar KD values (47: 6.6 µM, 49: 7.5 µM) and Gibbs free energies 
(G0= +0.3 kJ/mol). We therefore conclude that the opening of the specificity pocket and 
stacking interaction inside this pocket is not reflected by an increase in potency. 47 displays a 
more favorable enthalpic portion (H0= -5.5 kJ/mol) nearly compensated by a less favorable 
entropic portion (-TS0= +5.2) than 49. The B-factor ratios of Ala299-Tyr309 of both 
complexes (1.9/2.0) are in the same range, indicating that these residues possess in both crystal 
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structures similar residual mobility. Thus, the sole opening of the specificity pocket does not 
restrain the flexibility of the 299-309 loop. First, the two different water networks should be 
contrasted with respect to the thermodynamic profiles. Even though the contact to W2 differs on 
first glance for 47, in ALR2-49 the corresponding W2 is stabilized via the water chain W1-W12-
W2-W3. As a result for both complexes the contacts reach out to the backbone amide group of 
Leu300/Leu301. We therefore believe that W2 has similar influence on the thermodynamic 
profiles of both ligands and hardly discriminates the deviating thermodynamic profiles. The 
entrapment of W12 and W13 in ALR2-49 should lead in contrary to ALR2-47 to an increase in 
the enthalpic signal and a loss in the entropic portion, however, the opposite is observed. Thus, 
either the effect of the water fixation is very weak or additional effects compensate the water 
contribution. 
The specificity pocket of ALR2 is presumably in its closed state before being addressed and 
opened by the attached phenyl substituent of an inhibitor. This assumption is supported by the 
crystal structure ALR2-49. The residual Fo-Fc difference electron density in this complex shows 
the ligand 80% populated but superimposed density for the closed conformation of the specificity 
pocket is indicated. We therefore suppose that this subpocket opens upon binding of the phenyl 
side chain of 49 during the soaking. If the specificity pocket is closed before a ligand binds, no 
solvent molecules will be bound inside this pocket. Accordingly, the classical hydrophobic 
effect,146-148 which involves the displacement of ordered water molecules from a hydrophobic 
environment to the bulk water phase cannot be the explanation for the more favorable entropic 
portion of 49. In contrast, the phenyl ring of the inhibitor forming most likely unfavorable 
contacts to water molecules in the bulk phase is favorably buried in the rather hydrophobic 
specificity pocket. Since the enthalpic signal of 49 is smaller than that of 47 the desolvation of 
the aromatic ring and the formed --stacking with Trp111 takes overall an unfavorable influence 
on the binding enthalpy.  
As the unsubstituted 47 and the analog phenyl derivative 49 exhibit nearly identical affinity, the 
opening of the pocket along with the accommodation of the phenyl ring is linked to a tiny change 
in Gibbs free energy. A partitioning in compensating enthalpically unfavorable and entropically 
beneficial contributions is found overall. Further splitting into individual contributions is difficult 
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as 49 (i) entraps two additional water molecules (usually an enthalpically favorable but 
entropically unfavorable step), (ii) has to drive the protein into a different protein conformation 
(possibly linked to a small energy barrier as the closed form is more stable), (iii) will require a 
contribution to desolvate the aromatic portion (a step which might be enthalpically unfavorable 
but entropically beneficial) and (iv) weak but energetically favorable - stackings are 
experienced. Clearly arguments can be found to relate these steps to a more enthalpic or entropic 
signature, however it appears impossible to quantify them relative to each other to reveal the 
profile for the entire step of the pocket opening.  
5.5.1.3 Comparison of structural and thermodynamic data of 50 and 49 
The increased potency of 50 compared to 49 (G0= -12.2 kJ/mol) is the result of the much more 
favorable enthalpic contribution (H0= -24.1 kJ/mol) which is only partly compensated by a 
higher entropic price (-TS0= +11.9 kJ/mol). The favorable increase in the enthalpic portion 
can be related to the formed H-bond between the nitrogen of the benzothiazolyl ring of 50 and the 
backbone of Leu300, even though this gain appears surprisingly large. This formed H-bond 
restraints the flexibility of the residues 299-309, leading to a significant smaller B-factor ratio for 
these residues (1.4 compared to 2.0) which supposedly explains the more unfavorable increase in 
the entropic portion of 50.  
5.5.1.4 Comparison of structural and thermodynamic data of 51 and 49 
The comparative analysis of 51 and 49 allows to dissect the influence on the thermodynamic 
parameters of the meta nitro group of the phenyl ring which addresses the specificity pocket of 
ALR2. ALR2 inhibitors bearing this group have been described previously as strong enthalpic 
binders8 but the portion which can be contributed to the attached meta nitro group could not be 
quantified so far. The thermodynamic profile of 51 could only be measured in a displacement 
titration. In a recent study157 we could show that displacement titrations can involve a more 
complex behavior making the assumption of a full additivity in all steps of the displacement 
process questionable. In the current case we could titrate 47 and 49 directly and by displacement 
with a strong binding ligand, whereas 50 could be studied directly and by displacing a weak 
ligand used to preincubate the protein. As reported in Section 5.7.2, the Gibbs free energy is well 
reproduced (0.5 kJ/mol), the partitioning in enthalpy and entropy is affected by larger 
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modulations but below 4 kJ/mol. Compared to 49, 51 forms an additional H-bond via its nitro 
function to the backbone of Leu300 and a non-classical H-bond to the CH of the phenyl ring of 
Tyr309. The formation of these interactions are accompanied by a surprisingly large gain in 
affinity (G0= -15.0 kJ/mol), overwhelmingly due to an enthalpic gain (H0= -35.7 kJ/mol). 
The deviating B-factor ratios for Ala299-Tyr309 (ALR2-49: 2.0, ALR2-51: 1.2) indicate that the 
formed H-bond strongly decreases the flexibility of the residues 299-309. This explains the loss 
in the entropy of 51 compared to 49.  
5.5.1.5 Comparison of structural and thermodynamic data of 50 and 51 
50 and 51 are both forming H-bonds in the specificity pocket to the backbone of Leu300 with 
similar distances (3.1 Å/ 3.2 Å). The thermodynamic profiles of both ligands slightly differ in 
affinity (G0= -2.6 kJ/mol) and factorize quite strongly in H0= -15.0 kJ/mol and 
-TS0= +12.4 kJ/mol. Obviously, the formed H-bond between the oxygen of the nitro group of 
51 and the Ala299-Leu300 backbone NH is accompanied by a stronger increase in the enthalpic 
signal compared to the H-bond between the basic nitrogen of the benzothiazolyl moiety of 50. 
Furthermore, the nitro group of 51 forms a non-classical H-bond to a hydrogen of the phenyl ring 
of Tyr309 which may further increase the exothermic signal. Presumably the enthalpic 
desolvation costs for the nitrophenyl group, heavily involved in contacts to the protein, are less 
than for the benzothiazolyl moiety. The B-factor ratio of Ala299-Tyr309 (51: 1.2, 50: 1.4) 
indicates that 51 locks the residues 299-309 more firmly in their position as 50 does. This is also 
supported by the entropic portion which is less favorable for 51 than for 50. Additionally, in 
ALR2-50 the backbone next to Ala299 adopts a slightly different conformation as in ALR2-51. 
This conformation might be energetically less favorable which would additionally decrease the 
enthalpic signal for ALR2-50. The stabilization of water molecule W15 in ALR2-50, which 
should be accompanied by a favorable increase in the enthalpic signal and a loss in the entropic 
part, is obviously overcompensated by the different interactions of both ligands in the specificity 
pocket. Furthermore, the deviating arrangements of the water networks next to the specificity 
pocket which were discussed above could lead to deviating thermodynamic signatures.  
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5.5.1.6 Comparison of structural and thermodynamic data of 52 and 47 
The less potent 52 and 47 show different thermodynamic profiles (G0= +4.0 kJ/mol with 
H0= +2.6 kJ/mol and -TS0= +1.4 kJ/mol). The decrease in the enthalpic term for 52 results, 
at least partially, in the loss of the internal H-bond between the amide nitrogen of the ligand and 
one of the oxygen atoms of its acetic acid carboxylate group. Furthermore, the altered binding 
mode of the polar head group of 52 in the anion binding pocket should also be reflected in the 
thermodynamic signature. Two additional water molecules are involved in the water network 
stabilizing 52 compared to that of 47 (W13, W17). Furthermore, the terminal phenyl ring of the 
latter ligand contributes with favorable contacts to Phe122. The B-factor ratio for the 299-309 
stretch (1.7/ 1.9) suggests that 52 decreases flexibility of this loop slightly stronger than 47. As 
described above, 52 displaces the residues 299-309 similarly to 48, thus reducing mobility, but 
less dominantly as ALR2-48. This could explain the unfavorable entropic contribution of 52.  
Surprisingly is the fact that 52 places its terminal benzoic acid moiety in direction of the 
surrounding solvent and not into the specificity pocket as found for the isosteric nitrophenyl 
group of 51. A possible explanation could provide the much more costly desolvation of acidic 
benzoic acid group. At the adopted position it remains partly solvent exposed whereas 
accommodation in the specificity pocket would require complete desolvation.  
5.5.1.7 Comparsion of the structural and thermodynamic data of 51 and 53  
The IC50 values for 51 and 53 were reported as similar (8 nM).43 Our ITC study comes to 
comparable results since the KD values (53: 0.024 µM; 51: 0.018 µM, G0= -0.8 kJ/mol) show 
only a slightly decreased affinity for 53 compared to 51. Interestingly, the thermodynamic 
profiles of both ligands, which we obtained in a displacement titration using 47 as a weak, 
competing ligand, differ significantly: G0= -0.8 kJ/mol, H0= -9.8 kJ/mol and -TS0= 
+9.0 kJ/mol. The data published by Van Zandt et al.43 allow to estimate the influence of a 
halogen substituent in 5-position at the 2-(2-carbamoyl -phenoxy)acetic acid scaffold. A ligand 
which carries a 5-chlorine substituent (53a, IC50: 30 nM, Figure 5-8e) has an IC50 value which is 
about six times smaller as the analogue without a halogen substituent at this position (53b, IC50: 
176 nM, Figure 5-8f). On the other hand, the exchange of a clorine atom at this position (46, IC50: 
6 nM) by a fluorine atom (51, IC50: 8 nM) does not influence the affinity significantly.43 
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Obviously, in the here described case the additional phenyl ring in 4-position of 53 can largely 
compensate for the missing halogen atom in 5-position regarding the free energy of binding, even 
if the enthalpic and entropic partitioning differs for both ligands. As already mentioned the 
additional phenyl ring of 53 replaces the water molecules W20 and W21. These water molecules 
are released to the bulk solvent phase and thus their degrees of freedom will increase resulting in 
a more favorable entropic term compared to 51. In contrast, the enthalpic portion is less favorable 
presumably as a result of the disturbed water structure leading to a loss of H-bond contacts in the 
system. This might lead to a more unfavorable enthalpic portion for 53 compared to 51 which 
cannot be compensated for by the additional edge-to-face stacking of the attached 4-phenyl ring 
of 53.  
5.6 Conclusions 
Addressing the specificity pocket of ALR2 may provide the opportunity to design ALR2 
inhibitors with pronounced selectivity over binding to ALR1. In this study we provide for the 
first time insights into the thermodynamic properties involved in the opening of this pocket. We 
determined high-resolution crystal structures of a narrow series of inhibitors which induce three 
different binding site conformers. The ITC data reveal large differences in Gibbs free energy, 
enthalpy and entropy. The comparison of 47 and 48 shows that ligands which possess similar 
binding modes can still show strongly deviating thermodynamic profiles. Thus, such profiles do 
not provide straightforward a conclusive answer whether the specificity pocket is opened or not. 
The comparison of 49 and 51 allowed to quantify the enthalpic and entropic contributions of the 
attachment of a meta nitro group. Facing the isosteric ligands 51 and 52, only differing in a 
COOH by NO2 exchange, the consequences of this displacement on the thermodynamic profile 
could be studied. The exchange leads surprisingly to an alternate binding mode of the ligand 
portion. 52 directs its terminal benzoic acid toward the surrounding solvent while the nitro-
phenyl ring of 51 is deeply buried in the specificity pocket. This suggests that the desolvation 
penalty for a nitro group is significantly lower than for a carboxylic acid group. The comparison 
of 47 and 49 shows that the enthalpic signal is significantly reduced when part of the ligand 
addresses the specificity pocket without forming H-bonds inside the pocket. This suggests that 
some energy is needed to transform the protein residues into the open specificity pocket 
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conformer. The presented case study provides some insights into the thermodynamic properties 
involving the opening of a protein pocket. They will afford valuable input for other drug design 
projects with proteins also exhibiting pockets of transient nature. 
5.7 Description of Experimental Procedures 
5.7.1 Expression, purification, crystallization and structure determination 
The expression and purification of ALR2 are described in Section 9.2.1, the crystallization in 
Section 9.2.3, the soaking in Section 9.2.3.7 and the structure determination in Section 9.2.4. 
5.7.2 ITC experiments 
The measurements were performed with an ITC200 (GE Healthcare) at 298 K. For the direct 
titrations of 47-50 the cell was filled with a solution containing ALR2 (10 µM-190 µM), an 
excess of NADP+ and 3% (v/v) DMSO in 10 mM HEPES buffer at pH 8.0. The syringe was 
filled with the same concentration of NADP+ and DMSO and with the inhibitor (0.075-1.2 mM) 
in 10 mM HEPES at pH 8.0. 20-25 injections with a volume from 1.6–2.0 µL were done. An 
initial injection of 0.3-0.5 µL was excluded from the analysis.  
It was shown previously that the enthalpic signals of carboxylate-type ALR2 inhibitors display a 
buffer dependency due to an uptake of approximately 0.8-0.9 mol protons per mol formed 
complex.42 The latter data were measured with a MCS-ITC instrument of MicroCal in 
pyrophosphate, HEPES, Tricine and TRIS buffer. Recently we determined with the ITC200 
instrument a proton uptake of 0.6-0.7 per mole of formed complex for different types of ALR2 
inhibitors bearing a carboxylate head group (unpublished results and Stefek et al.127) using 
HEPES, Tricine and TRIS buffer each at concentrations of 10 mM and at pH 8.0. The 
thermodynamic profile of two of the here investigated compounds, 48 and 50, were measured 
exemplarily in the latter three buffer systems. The resulting enthalpies (H0obs) were plotted 
against the heat of ionization of the corresponding buffer system (H0ion). The values for H0ion 
were taken from literature.87, 88 A line of best fit was drawn and its interception with the y-axis 
indicated the enthalpy to be corrected for the protonation effect (H0bind). The slope denoted the 
molar quantity of protons that are entrapped or released according to the formation of one mole 
of complex. A positive slope, as observed here, indicates proton uptake. The resulting diagram 
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for the binding of 48 and 50 is
Table 5-2.  
 
 
Figure 5-10 Plot of the heat of io
TRIS) against the measured entha
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Consequently, we refrained from correcting the enthalpy for the superimposed protonation effect 
since we are only interested in the relative differences between the investigated ligands. All 
measurements which led to the discussed thermodynamic profiles were performed in HEPES 
buffer. 
The strong affinity of 51 and 53 and the weak affinity of 52 made the direct titration of these 
ligands difficult. Consequently, displacement titrations were chosen to obtain the thermodynamic 
data for the latter ligands. For the displacement titration of 51 and 53 the protein was saturated 
with 47 as a competing ligand with a weaker affinity. The same concentration of 47 was added to 
the syringe. The data for 47 (Ka, weak ligand, H°weak ligand) were obtained by direct titrations of this 
ligand. Using equations 5-1 and 5-2, which were adapted from Sigurskjold,158 Ka, strong ligand and 
H°strong ligand for the high-affinity binder could be calculated.  
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The protein concentration varied between 23-42 µM. The required concentration of 90 µM 47 
was determined in a preceding direct titration of this ligand. This concentration exceeds 2-4x the 
concentration of the protein and approximately 15x the KD. To validate the experimental set up, 
50, which could also be measured in a direct titration previously, was titrated under the same 
condition. The KD value found for 50 by the direct titration (0.054 µM) and the displacement 
titration (0.050 µM) agreed very well. H° (direct: -54.0 kJ/mol, displacement: -50.6 kJ/mol) and 
the -TS0 (direct: +12.5 kJ/mol, displacement: +8.9 kJ/mol) differed only slightly. Furthermore, 
51 was measured in a direct titration. The high c-values of the recorded ITC titration curves made 
the extraction of the Ka value and thus the full thermodynamic profile difficult. However, H° 
can be evaluated. The obtained value of -67.0 ± 2.5 kJ/mol agrees well with the value of 
-65.6 ± 0.6 kJ/mol which was obtained by the displacement titration.  
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52 is a too weak binder to be measured in a direct titration. Here the inverse experimental design 
was chosen with 52 as a weak competing binder which was in turn replaced by 50. Again, to 
evaluate the protocol, 47 and 49, for which data from direct titrations were available, were 
titrated similarly. The applied protein concentration was 31 µM. Again, at first direct titrations of 
the weak ligands were performed to detect the concentration required to saturate the protein. This 
resulted in 90 µM (47, 49) and 180 µM (52) which exceeds 3.9- 7.6 x the protein concentration 
and 5-15x the KD. The same concentration of the weak binder was added to the syringe. The 
thermodynamic parameters of the weak binder, Ka, weak ligand and H°weak ligand, were calculated 
using the equations 5-3 and 5-4 which were adapted from Zhang et al.:159 
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49 led to very similar results for direct and displacement titrations (KD direct/ displacement: 
7.5 µM/ 9.1 µM; H° direct/ displacement: -29.9 kJ/mol /-30.6 kJ/mol; -TS0 direct/ 
displacement: +0.6 kJ/mol/ +1.8 kJ/mol). The results for 47 differed slightly stronger (KD direct/ 
displacement: 6.6 µM/ 7.2 µM; H° direct/ displacement: -35.4 kJ/mol /-39.0 kJ/mol; -TS0 
direct/ displacement: +5.8 kJ/mol/ +9.6 kJ/mol).  
The presented comparisons of the thermodynamic data from the displacement titrations with the 
data obtained by direct titrations indicate that the displacement titrations are providing reliable 
results regarding the KD value while the error in the enthalpic portion seems to be slightly higher. 
However, a qualitative comparison of the enthalpic portions appears to be justified. The 
phenomena of differing results for H° for direct and indirect titration has already been described 
elsewhere.157 As a consequence in the discussion we are only comparing the results from direct or 
indirect titration among each other, if possible. For the comparison of 49 (direct titration) and 51 
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(displacement titration) the thermodynamic data from different titration protocols were taken 
since the strongly deviating KD values did not allow for applying the same procedure.  
The binding isotherms were integrated using NITPIC160 and afterwards fitted with SEDPHAT.161 
Representative binding isotherms and fitted regression curves are shown in Figure 10-4 in the 
Appendix. All measurements were done at least in triplicate. 

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6 Kinetic and Structural Insights into the Mechanism of Binding of 
Sulfonamides to Human Carbonic Anhydrase 
6.1 Introductory Remarks 
The following chapter was prepared for submission to a scientific journal. In this chapter the 
main text and the supporting information are combined in contrast to the original draft. This 
project was a collaboration with Dres. Roberto Gaspari, Giovanni Bottegoni and Walter Rocchia 
from the group of Prof. Dr. Andrea Cavalli (Department of Drug Discovery and Development, 
Italian Institute of Technology, Genova, Italy), Dres. Daniel Schwarz and Jörg Bomke (Merck 
KGaA, Merck Serono Research, Small Molecule Platform/MIB, Darmstadt, Germany), Hans-
Dieter Gerber and Prof. Dr. Andreas Heine (Philipps University Marburg). The author of this 
thesis performed the SPR experiments, determined the complex crystal structures of 54-58 with 
hCAII and contributed to the drafting of the manuscript.  
6.2 Abstract 
The binding of sulfonamides to human carbonic anhydrase II (hCAII) is a complex and long-
debated example of protein-ligand recognition and interaction. In this study, we investigate the 
para-substituted n-alkyl and hydroxyethylene-benzenesulfonamides, providing a complete 
reconstruction of their binding pathway to hCAII by means of molecular simulations, surface 
plasmon resonance (SPR) measurements and X-ray crystallography experiments. The 
characterization of the binding pathway allows an unprecedented understanding of the structure-
kinetic relationship in hCAII/benzenesulfonamides complexes, depicting a paradigmatic scenario 
for the multi-step binding process in protein-ligand systems.  
6.3 Introduction 
Human carbonic anhydrase II (hCAII) is an enzyme that catalyzes the transformation of carbon 
dioxide into bicarbonate. It is often used as a prototypical model system for biophysical studies46 
and medicinal chemistry applications.47, 162 The catalytic site of hCAII consists of one Zn2+ ion, 
which is coordinated by three histidine residues and a water molecule (or hydroxyl ion) in a 
distorted tetrahedral geometry. Sulfonamide-carrying ligands can inhibit hCAII by directly 
binding to the catalytic Zn2+ ion of the protein and displacing the water molecule. While it is 
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generally believed that the hCAII-sulfonamide recognition process is multi-step, little is known 
about the structural features of the kinetically relevant intermediate configurations along the 
binding pathway. As in most processes of protein-ligand binding, this can be traced back to the 
transient and short-lived nature of the intermediate states, which cannot always be detected by 
experiments. 
Our knowledge of hCAII-sulfonamide complexes relies upon extensive experimental 
characterization carried out over the last few decades, which has produced key results that must 
be taken into account when considering models of enzyme-inhibitor binding. Generally, the 
binding of sulfonamides to hCAII is a slow process, which considerably depends on the nature of 
the substituents present on the benzenesulfonamide core. This points to a multi-step mechanism, 
as a single-step association would be more compatible with a diffusion-limited process, 
characterized by fast kinetics and only marginally dependent on the chemical decorations of the 
binding compounds.66 
The impact of the ligand substituents on the association kinetics was thoroughly investigated in 
the case of para-substituted n-alkyl benzenesulfonamides, where stopped-flow fluorescence 
(SFF) experiments66, 67 showed that the observed on-rate, kon, increases exponentially with the 
length of the alkyl chain. These results have been interpreted in terms of a minimal two-step 
process, although no direct evidence of an intermediate state was produced by SFF 
measurements. The dissociation constants of the alkyl-substituted sulfonamides in complex with 
the zinc-free hCAII displayed a very high correlation with the octanol-water partition coefficient, 
a fact which was used to infer the key role of hydrophobic interactions in stabilizing the putative 
intermediate state.66 From a structural standpoint, compounds containing alkyl chains can 
establish favorable interactions with the hydrophobic patch at the enzymatic cavity, often referred 
to as the “hydrophobic wall”.163 The role of these has recently been confirmed by isothermal 
titration calorimetry (ITC) experiments,58,164 molecular dynamics164 and site-directed mutagenesis 
experiments.165-167 
Further complexity to the binding mechanism is given by the charge state of the sulfonamide, 
which binds to the zinc ion in its anionic form, as reported by 15N-NMR168 and recent neutron 
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diffraction studies.169 Since benzenesulfonamides are usually weak acids, it is expected that these 
inhibitors initially bind to hCAII in their neutral form and only subsequently deprotonate, upon 
reaching the final Zn2+-coordinated configuration. On the other hand, the water molecule bound 
to the Zn2+ has a pKa value of 6.8170 and is thought to be a hydroxyl ion in the active form of the 
enzyme.46 Experimental data on the pH dependence of the association process have pointed to 
two possible mechanisms: either i) a neutral sulfonamide coordinates the Zn2+ displacing the 
hydroxyl ion, or ii) a charged sulfonamide displaces the Zn2+-bound water molecule.171 No 
consensus has yet been reached on the atomistic mechanism of sulfonamide binding to hCAII. In 
this scenario, the aim of this work is to provide a complete reconstruction of the binding process 
of para-substituted n-alkyl and hydroxyethylene-benzenesulfonamides (54-58, see Figure 6-1) to 
hCAII. The dynamical properties of the system are investigated via large-scale molecular 
dynamics (MD) simulations, allowing the identification of relevant pre-binding conformations 
adopted by compounds 54-58 upon their entrance into the enzyme cleft. A comparison between 
the predicted stability of the pre-binding conformations and the results of surface plasmon 
resonance (SPR) measurements is also reported. MD simulations clearly point to a multi-step 
binding mechanism, as previously hypothesized by Taylor, King and Burgen66, 67 and disclose the 
postulated pre-binding intermediate state. The role of the hydrophobic tail mounted on the 
sulfonamide scaffold clearly emerges, allowing a thorough characterization of the structure-
kinetics relationships (SKR) of benzenesulfonamides. We then carry out metadynamics 
simulations to provide an in-depth characterization of the protein-ligand energetic landscape, 
which allows a description of the ligand-binding pathway up to its coordination to the 
Zn2+-bound water, which is considered in our simulations as a hydroxyl ion. Subsequently, we 
estimate the environment-induced pKa shift of the compounds via a Poisson-Boltzmann 
equation-based model and then study the sulfonamide deprotonation by means of density 
functional theory calculations (DFT). These results are thoroughly discussed in light of the 
binding models recently reviewed by Krishnamurty et al.46 To describe the entire binding 
pathway, we obtain high-resolution co-crystal structures for compounds 54-58 in complex with 
hCAII. They unravel atomistic details of the stable Zn2+-bound sulfonamide/hCAII complexes 
and disclose the sulfonamide conformations as the final thermodynamic minima of the entire 
binding process.  
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6.4 Results 
6.4.1 The role of hydrophobicity in the structure-kinetic relationship 
It was previously reported, by means of SFF investigations,66 that the association rates for 54-57 
increase exponentially with the substituent length. Here, we report SPR measurements for the 
same ligand series as well as for the more hydrophilic one, compound 58. We aim to test the 
effect of the methyl-hydroxyl substitution on the binding rates, to assess whether hydrophobicity 
or chain length is the major feature responsible for the observed kon trend. 
6.4.2 Results of SPR measurements 
The ligands 54-58 were measured one after another at four independent protein surfaces of 3700 
RU, 3600 RU, 4900 RU and 4700 RU. The ligands 59 (4-CBS), 60 (sulfanilamide), 58 (94%) and 
58 (98%) were measured consecutively at four independent protein surfaces of 4900 RU, 
4800 RU, 4500 RU and 4500 RU. Mean values and the standard deviations for 54-58 are shown 
in Table 6-1. The corresponding results of the single measurements are listed in Table 6-2. The 
measured curves for each ligand are presented in Figure 10-5 - 10-8 in the Appendix. In 
preliminary tests, an impurity was discovered for compound 58. It was purified to at least 94% in 
the first sample; a second purification step provided 98% purity. Two dilution series, one with the 
substance with 94% purity and a second based on 98% purity, were measured in four independent 
SPR experiments and the kinetic parameters for the binding to hCAII were determined. As shown 
in Table 6-3, the results are very similar for both purity levels. Thus, the reduced purity of 58 
(94%) compared to the ligands 54-57 does not explain the deviating kinetic parameters. We 
validated our assay by measuring 59 and 60 as reference ligands and comparing our results with 
previously determined values by Myska60 for the binding of these compounds to the bovine CAII 
(bCAII). Both compounds possess a very similar chemical structure compared to 54-58. Two 
independent series of measurements with hCAII immobilized on both spots were performed so 
that four single measurements on four independent hCAII surfaces could be taken on two 
consecutive days. Table 6-4 lists the results of the single measurements, the mean values and the 
corresponding standard deviations. 
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Table 6-2 Results of the single measurements on four independent protein surfaces for ligands 54-58. 
 
Ligand Spot 1 (=3700 RU)       Spot 2 (=3600 RU) 
  
    
 KD (st-st) KD (kin) kon koff KD (st-st) KD (kin) kon koff 
 [nM] [nM] [ x 105 1/Ms] [1/s] [nM] [nM] [ x 105 1/Ms] [1/s] 
54 1002.0 1073.4 1.6 0.1696 1037.0 1183.9 1.5 0.1828 
55 382.2 318.8 1.9 0.0617 429.8 333.5 2.0 0.0664 
56 133.7 91.4 5.1 0.0464 157.3 93.8 5.4 0.0504 
57 63.4 57.4 8.7 0.0498 66.8 64.5 9.6 0.0617 
58A 452.8 418.3 1.6 0.0673 488.6 448.0 1.7 0.0741 
 Ligand Spot 1 (=4900 RU)       Spot 2 (=4700 RU)   
    
  
KD (st-st) KD  kin) kon koff KD (st-st) KD (kin) kon koff 
  
[nM] [nM] [ x 105 1/Ms] [1/s] [nM] [nM] [ x 105 1/Ms] [1/s] 
54 1076.0 1063.1 1.4 0.1465 1426.0 1278.4 1.2 0.1529 
55 218.0 228.8 2.2 0.0498 296.8 290.3 1.9 0.0550 
56 104.3 100.3 4.3 0.0426 106.1 107.8 4.2 0.0451 
57 53.1 51.4 6.7 0.0345 59.0 57.9 6.2 0.0357 
58A 358.2 330.3 1.7 0.0567 414.8 371.6 1.6 0.0591 
 
AFor ligand 58 a sample with a purity of 94% was used. As explained in the experimental part the results do not 
significantly differ from the sample with 98% purity. 
 
Table 6-3 Results for the measurements of 58 with two different degrees of purity.  
 
Ligand 58 (94%) 58 (98%) 
  
KD KD kon koff KD KD kon koff 
(st-st) (kin)     (st-st) (kin)     
[nM] [nM] [ x 105 1/Ms] [1/s] [nM] [nM] [ x 105 1/Ms] [1/s] 
Spot 1(= 4900 RU) 442.5 381.9 1.6 0.0599 404.2 359.2 1.7 0.0609 
Spot 2(= 4800 RU) 476.7 416.1 1.6 0.0649 444.3 387.6 1.7 0.0657 
Spot 1 (=4500 RU) 584.6 508.2 1.3 0.0665 n.d. n.d. n.d. n.d. 
Spot 2 (=4500 RU) 509.6 437.9 1.4 0.0602 414.1 394.2 1.5 0.0603 
Mean 503.4 436.0 1.5 0.0629 420.9 380.3 1.6 0.0623 
Standard Deviation 60.7 53.3 0.1 0.0034 20.9 18.6 0.1 0.0030 
 
  
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Table 6-4 Validation against reference results. 
 
Ligand 59 (4-CBS) 60 (sulfanilamide) 
  KD (st-st)B KD (kin)B kon koff KD (st-st)B KD (kin)B kon koff 
[µM] [µM] [x 104 1/Ms] [1/s] [µM] [µM] [x 104 1/Ms] [1/s] 
Spot 1(= 4900 RU) 0.99 0.89 6.5 0.0579 6.17 5.23 3.9 0.2023 
Spot 2(= 4800 RU) 0.92 0.95 6.4 0.0605 7.17 5.82 3.7 0.2147 
Spot 1 (=4500 RU) 1.01 0.90 6.2 0.0557 6.21 5.38 3.6 0.1963 
Spot 2 (=4500 RU) 0.96 0.82 6.8 0.0559 6.24 5.77 3.6 0.2080 
Mean 0.97 0.89 6.5 0.0575 6.45 5.55 3.7 0.2053 
Standard Deviation 0.04 0.05 0.3 0.0022 0.48 0.29 0.1 0.0079 
Literature (bCAII) A n.d. 0.89 4.1 0.0369 n.d. 5.88 2.3 0.133 
 
A Results for the measurements of the reference compounds 4-CBS and sulfanilamide with hCAII and comparison 
with data for bCAII from literature.60  
B The definition of the steady-state and kinetic dissociation constants (KD) are reported in Section 9.3.1.4. 
 

Although we worked with human CAII, we were able to measure similar affinity data for 59 
(hCAII: 0.89 µM, bCAII: 0.89 µM) and 60 (hCAII: 5.55 µM, bCAII: 5.88 µM) as described in 
the literature for the bovine type. Furthermore, the kinetic constants show a similar trend, 
identifying 59 (kon hCAII: 6.5x104 M-1s-1; kon bCAII: 4.1x104 M-1s-1; koff hCAII: 0.0575 s-1; 
koff bCAII: 0.0369 s-1) as the compound with the faster association and slower dissociation with 
respect to 60 (kon hCAII: 3.7x104 M-1s-1; kon bCAII: 2.3x104 M-1s-1; koff hCAII: 0.2053 s-1; 
koff bCAII: 0.1330 s-1). Additionally, this series of measurement showed that the assay was 
reproducible when similar amounts of protein were immobilized on the sensor chip. 
The running buffer in an SPR experiment often contains 0.005-0.05% Tween 20 to prevent 
unspecific binding to the tubings and other hydrophobic parts of the instruments. To exclude the 
possibility that Tween 20 interferes with the binding of ligands 54-58 to hCAII, the same series 
of measurements were performed twice with the same protein surface, once with 0.05% Tween 
20 in the running buffer and once without the detergent. The results are listed in Table 6-5.  
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Table 6-5 Effects of Tween 20 addition.  
 
With 0.05% Tween 20A 
Spot 1 (=3700 RU)   Spot 2 (=3600 RU) 
  
KD(st-st) KD (kin) kon koff KD (st-st) KD (kin) kon koff 
  
[µM] [µM] [ x 105 1/Ms] [1/s] [µM] [µM] [ x 105 1/Ms] [1/s] 
54 1002,0 1073.4 1.6 0.1696 1037,0 1183.9 1.5 0.1828 
55 382.2 318.8 1.9 0.0617 429.8 333.5 2.0 0.0664 
56 133.7 91.4 5.1 0.0464 157.3 93.8 5.4 0.0504 
57 63.4 57.4 8.7 0.0498 66.8 64.5 9.6 0.0617 
58 452.8 418.3 1.6 0.0673 488.6 448.0 1.7 0.0741 
Without Tween 20A 
Spot 1 (=3700 RU) Spot 2 (=3600RU) 
  
KD(st-st) KD (kin) kon koff KD (st-st) KD (kin) kon koff 
[µM] [µM] [ x 105 1/Ms] [1/s] [µM] [µM] [ x 105 1/Ms] [1/s] 
54  n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
55 292.3 265.9 2.1 0.0554 312.2 277,0 2.0 0.0547 
56 122,0 107.1 4.5 0.0483 126.4 113.2 4.6 0.0523 
57 66.1 60.5 7.8 0.0472 66.1 62.8 8.4 0.0528 
58 412.8 386.1 1.5 0.0596 425.2 402.2 1.7 0.0667 
 
        AThe same series of measurements was perfomed two times on the same protein surface. One time 0.05% Tween 20 
was added to the running buffer and one time omitted. Similar values were obtained in both cases. 
 
Similar values were obtained for ligands 55-58 in both cases. Ligand 54 showed sensorgrams 
which did not reach saturation when Tween 20 was not added. Thus, we did not evaluate the data 
for 54 in this case. Since 54 showed a satisfying saturation when adding 0.05% Tween 20, the 
measurements were done in the presence of the tenside.  
For the final measurements of the investigated ligand series (54-58), single measurements on four 
independent protein surfaces were performed. To partially average out the small variation of the 
kinetic constants depending on the immobilization level, we decided to determine the mean of 
these four surfaces exhibiting different protein densities. We performed experiments with 
immobilization levels at a lower rate corresponding to 1000 RU. However, the quality of the 
obtained sensorgrams was not sufficient. Our results are not significantly influenced by a mass 
Kinetic and Structural Insights into the Mechanism of Binding of Sulfonamides to Human 
Carbonic Anhydrase 
 
141 

transfer limitation even at a high immobilization level. Thus, the applied immobilization levels 
were chosen since they led to a good signal-to-noise ratio. 
The kon values determined for compounds 54-58 (Figure 6-1 and Figure 6-3b-c) by SPR 
measurements are consistent with previously reported SFF results. Although ligands 57 and 58 
are of similar length, the less hydrophobic compound (58) displays a much smaller kon. 
Conversely, a significant change in koff is experienced between 54 and 55 only, while 55-58 all 
possess very similar dissociation rate constants. We find that the trend for the equilibrium 
dissociation constants KD is driven by variation in the association kinetics, in line with the results 
obtained by King and Burgen.66  
6.4.3 Results of MD simulations 
Molecular dynamics (MD) simulations highlighted common hCAII-ligand interactions for the 
alkyl sulfonamide series (compounds 54-57). In particular, we observed that the ligands approach 
the pocket entrance by mainly exposing the polar sulfonamide to the bulk solvent, while trying to 
segregate the alkyl tail in a partly exposed pocket formed by hydrophobic residues. A 
conformational analysis revealed the exact identity of the amino acids involved in the 
hydrophobic interaction, which we took as the residues having minimum distance from the ligand 
below 3 Å in the most populated conformational cluster. This group of residues defined a 
partially solvent-exposed patch (hereafter referred to as the “hydrophobic patch”, HP), which 
grew as the size of the substituent increased (Figure 6-2 and Figure 6-3a). HP was largest for 
compound 57,where it included amino acids Ile91, Val121, Phe131, Val135, Leu198, Pro201 and 
Pro202 (according to the numbering of the PDB code 1CA2),172 and partly corresponded to the 
portion of hCAII known in the literature as the hCAII “secondary hydrophobic binding site”173 
(Figure 6-3a). After binding to the HP domain, the ligand remained transiently bound to the 
protein and, in most of the cases, was subsequently released back into the water bulk. A 
quantitative description of the release process was obtained by computing, for all ligands, the 
lifetime of the intermediate state at the HP domain (tHP). The lifetimes were computed by 
observing the time evolution of the minimum distance between the ligand and the HP patch, this 
distance being typically characterized by abrupt increases, which corresponded to ligand 
detachments from the protein surface (see Section 6.6.1.5). The lifetimes of 54-57 increased with 
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6.4.3.1 Structural characterization of the pre-binding stage 
The conformational sampling was enhanced by means of metadynamics simulations within the 
hCAII binding cavity. We focused on the compounds displaying the most sizable structural 
differences, i.e. the smallest and largest ligand of the alkyl-substituted series (54 and 57), as well 
as the hydroxyl-terminated compound 58. The free energy profile was projected over two 
collective variables, namely CV1 (distance between Zn2+ and the sulfonamide sulfur) and CV2 
(angle formed by the Zn2+ atom, the sulfonamide sulfur and the carbon atom bound to the 
sulfonamide sulfur), devised to accelerate the translation (CV1) and rotation (CV2) of the 
sulfonamides within the cavity (see also Figure 6-4a). Mainly two free energy minima were 
found, corresponding to the S and F conformations observed in MD simulations. For all 
compounds, the lowest free energy minimum corresponded to S conformations characterized by a 
CV1 value of about 6 Å and CV2 ranging from 90° to 180°. In the energetic minimum, we found 
a largely visited conformation, in which the sulfonamide interacted with the Zn2+-bound hydroxyl 
ion, showing an average distance between the sulfonamide nitrogen (Nsulf) and the Zn2+ of 
3.8 ± 0.3 Å. This geometry was the one with the smallest Zn2+-Nsulf distance obtained during our 
simulations and was characterized by two hydrogen bonds between the amide group of 
sulfonamides and both the Thr200 side chain oxygen and the Zn2+-bound hydroxyl. An additional 
hydrogen bond was observed between the sulfonamide oxygen and the Thr199 side chain. A 
pictorial representation of the S conformation is reported in Figure 6-4. For ligands 54, 57 and 58 
we observed a secondary free energy minimum, corresponding to F conformations and well 
represented by the conformational clusters reported in Figure 6-3 and in Figure 6-5. These 
geometries were stabilized by a favorable hydrophobic interaction between the ligand chain and 
the HP patch. As for compound 58, the free energy of the F conformation, relative to the global 
minimum S state, was much higher than in the case of 57. We estimated an energy separation 
between the F and the S basins for 54, 57 and 58 of roughly 9, 12 and 22 kJ/mol, respectively 
(5 kJ/mol being the error estimated on convergence, see Section 6.6.1.3). In the same order, the 
energy of saddle points which divide the F from the S region was about 10, 11 and 8 kJ/mol 
higher than the energy of the F conformation, reflecting the energetic barrier associated with the 
rotation of the compound during the F to S transition. The overall free energy landscape is 
reported in Figure 6-4. Compound 58 showed an additional low free energy region, which 
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shape and magnitude did not fully justify the placement of a full water molecule in the 
refinement. However, W8 seems to be stabilized in the hCAII-55 complex, but not to the same 
extent as in hCAII-54, hCAII-56 and hCAII-58. A density peak suggests occupancy of W8 in 
hCAII-56, however, without being connected to the remaining active site water molecules 
(Figure 6-9d). An additional water (W11) is visible in the hCAII-56 structure. It lies above W1 
and W3 and is stabilized by H-bonds to the latter water molecules. Both W8 (3.4 Å) and W11 
(4.0 Å) are stabilized by a van der Waals contact to the terminal methyl group of 56. Similar 
contacts are visible between the ethyl group of 55 to W1 (3.6 Å) and the terminal methyl group of 
57 to W1 (3.5 Å). In hCAII-57 no evidence for the presence of W8 could be detected. This is in 
good agreement with the Lee-Richard surface (Figure 6-9b-e) which extends as a consequence of 
the additional carbon atom of 57 into the region being occupied by W8 in hCAII-54, -56 and -58. 
The terminal hydroxyethylene group of 58 is visible in two orientations. The higher populated 
orientation A (58%) forms an H-bond with the glycerol molecule while the orientation B (42%) 
is similarly orientated as the tail of 57. In orientation B the terminal OH group of 58 forms H-
bonds to the neighboring water molecules W1 and W8. We assume that orientation B is the 
predominant one in the glycerol-free condition since the described H-bond between the terminal 
OH group of the tail of 58 in the orientation A to the glycerol could not be established. 
Orientation A will exclude presence of W3 as the OH group of 58 (1.7 Å) would come very 
close. Accordingly, W3 is only present when 58 is in orientation B. Ligand 54 is the only one 
which is bordered by a contiguously connected water structure on the side towards the solvent. 
This ligand shows a significantly faster dissociation than 55-58. Based on the crystallographic 
analysis the deviating water structure is the most striking difference of 54 compared to 55-58, 
thus possibly the better established water network favors the faster dissociation of 54 since the 
ligand might be easier displaced by water molecules. 
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Figure 6-9 Crystallographic Structures. a) Comparison of the water structures in complexes of the hCAII-54 and 
of the apo-protein (PDB: 3KS353). The water molecules in hCAII-54 are shown as green spheres. The carbon atoms 
of the glycerol molecule which is present in all hCAII complexes are shown in grey, the carbon atoms of 54 are 
shown in cyan. The water molecules of the apo-structure which are displaced by the glycerol molecule are shown as 
blue spheres, the water molecules of the apo-structure which are also present in the hCAII-54 structure are shown in 
red. b)-f) Binding mode of 54 (b), 55 (c), 56 (d), 57 (e) and 58 (f) in complex with hCAII. The protein surface is 
shown in gray, the carbon atoms of 54, 55, 56, 57 and 58 are colored in cyan, orange, magenta, blue and yellow, 
respectively. The carbon atoms of glycerol are colored in gray. Water molecules are shown as green spheres. The 
2Fo-Fc electron density is contoured in blue at 0.50 electrons/Å3 (0.9  for 54, 55, 57 and 58 and 1.0  for 56) for 
water molecules W1-W8. H-bond distances (2.3- 3.3 Å) are depicted as red-dotted lines. The Lee-Richard surfaces 
for 54-57 are shown in the same color as the carbon atoms of the respective ligands. They were generated for the 
hydrophobic tails of the ligands, starting with the 4-carbon atom of the phenyl ring. A contiguously connected water 
network, which borders the ligand at the solvent-exposed side, is detectable in the hCAII-54 structure only. The tail 
of 58 is visible in two orientations.  
 
 
However, as these changes occur at the already solvent-exposed face of the ligands it remains 
unclear how strongly the water structure influences the dissociation velocity. For the complex 
structures of ligands 55-58 additional molecules of the respective ligand could be found in the 
Fo-Fc difference electron densities. For 55-57 one additional ligand, for ligand 58 three additional 
ligands could be placed. Crystal packing effects together with the high concentrations of the 
ligands applied in the soaking buffer might be responsible for this observation. The additional 
binding position observed for 58 adjacent to the active site (Figure 6-7b-c) might suggest a 
putative position intermediately occupied by the ligands before they slip into the final binding 
position in the active site. This additional binding mode was only observed for 58. Further 
investigation is needed to fully unravel the significance of this mode at lower ligand 
concentrations, since no conformation of this type was observed during MD simulations of one 
single fully solvated ligand-protein complex. Due to the additional polar group 58 shows a higher 
solubility than all other compounds. This might explain why we find only for this ligand three 
additional molecules in the Fo-Fc difference electron density since saturated solutions of the 
ligands were applied. The terminal hydroxyethylene tail of this extra molecule of 58 could only 
be modeled up to the first carbon atom since the remaining atoms are not unambiguously defined 
in the difference electron density. Figure 6-7b shows the surface of the next symmetry mate in the 
crystal packing (colored in blue). It contributes to the stabilization of the binding mode of this 
additional ligand since it forms a cavity with the neighboring protein molecule (coloured in gray). 
Apart from the contact to the crystal mate also interactions to residues of the same protein 
molecule are formed thus suggesting that also the binding in solution could be established 
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(Figure 6-7b-c). The nitrogen of the additional molecule of 58 forms an H-bond to one of the 
oxygens of the carboxylic acid group of Glu69 (2.7 Å) while one of its oxygen atoms forms an 
H-bond with the carboxamide nitrogen of Asn67 (3.1 Å). Van der Waals interactions between the 
aromatic ring (4.1 Å) and the first carbon atom of the tail of 58 (4.5 Å) to the side chain of Ile91 
are detected. Since this residue is part of the hydrophobic patch, it could be envisaged that this 
pose, similarly to the ones located at the secondary patch, is also stabilized by favorable 
hydrophobic interactions. Additional binding configurations, stabilized by a subtle interplay of 
protein-ligand interactions and crystallographic packing are presented in Figure 6-10. 
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6.5 Discussion and Conclusions 
In agreement with previous SFF data, our SPR measurements show that the association rate for 
ligands 54-57 is dependent on their chemical composition. As already discussed by Taylor, King 
and Burgen,66, 67 the structural dependence of k
on 
does suggest the presence of at least one 
intermediate state. A single-step binding process would instead be compatible with a purely 
diffusion-limited binding phenomenon (about 108 M-1s-1 in the case of ligand-enzyme 
association),178 which has not been observed for the hCAII-sulfonamides complexes considered 
here. The comparison of SPR data for compound 57 and the newly analyzed compound 58 
provides additional information on the nature of the binding intermediates. Compound 57 
displays a considerably faster association than 58 and, since these two molecules differ only by 
the replacement of a methyl with a hydroxyl group in the chain, this indicates that hydrophobicity 
is key for the binding kinetics to this enzyme. MD simulations support this view and show how 
the favorable hydrophobic packing helps to precisely stabilize the geometries along a multi-step 
binding pathway. Starting from the solvated state in the bulk solution, the compounds approach 
the protein by ligating to an outer secondary hydrophobic site, adopting a particular 
conformation, named here “F conformation”. As shown in Figure 6-3, hydrophobic packing is the 
only interaction that makes F conformations largely populated. Similarly, at a later stage of the 
binding process, the ligands adopt what we named the “S conformation”, in which the apolar 
moieties of the compound’s substituents still largely interact with the hydrophobic patch of 
hCAII (Figure 6-2 and Figure 6-4), while the sulfonamide group is already engaged in hydrogen 
bonding with the protein and the Zn2+-bound hydroxyl ion. The S geometry may be regarded as 
the final conformation adopted by the ligand, before coordination with the Zn2+ ion occurs. DFT-
based calculations show that the sulfonamide deprotonation can occur when the distance between 
the sulfonamide nitrogen and Zn2+ falls between 2.50 and 2.75 Å, leading finally to the 
displacement of the hydroxyl ion and the formation of the coordinative bond between the 
deprotonated sulfonamide and the enzyme’s zinc ion. The structures of these final states between 
the sulfonamides 54-58 and hCAII were obtained by means of X-ray crystallography and are 
reported in Figure 6-9.  

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A comment is here required on the deprotonation mechanism of sulfonamides, which has 
remained an open issue in the literature.46 It might be argued that sulfonamides change their 
protonation state before reaching the S conformation. There are, however, good reasons to 
consider this an unlikely hypothesis. First, in the pre-binding F conformation, the pKa value of 
the sulfonamide changes negligibly (0.3, according to our pKa-shift estimate), which makes a 
deprotonation event in the F conformation very unlikely. Secondly, the approach to the catalytic 
Zn2+ as observed in the S conformation, does not make the sulfonamide acidic enough for a 
proton transfer. Indeed, DFT geometry optimization of S predicts that the proton transfer from 
the sulfonamide to the hydroxyl ion cannot occur spontaneously, requiring a shorter distance 
between the sulfonamide group and the Zn2+. Therefore, the present computational study points 
to a mechanism in which the sulfonamides approach hCAII in their neutral state, bind to the 
hydrophobic patch and interact with the Zn2+. Then, only if the distance between their terminal 
NH2 group and the Zn2+ is about 2.50-2.75 Å, will they get deprotonated and coordinate the Zn2+ 
ion, resulting in the final thermodynamic minimum. 
Overall, our analysis, at least for the alkyl-substituted derivatives (compounds 54-57), suggests a 
three-step process, regulated by partial kinetic constants as described in Figure 6-11 and in the 
scheme below: 
 
>!?! 1@A1B! C@ACD! E
F>?!







































<G : = 
 
where [P][L] represents the unbound protein-ligand system, [F] and [S] correspond to the 
previously discussed conformations and [PL] stands for the Zn2+-bound sulfonamide complex. 
We can get an insight into the dependence between the partial kinetic constants and the observed 
kon by first considering the conversion between [P][L] and [F] as a rapid pre-equilibration step. 
This is justified by the analysis of our MD simulations, showing that k
-1 H
k2.  
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In the pre-equilibration hypothesis the unbound system is taken to be in equilibrium with the F 
basin and yields: 1>!?!  A1B!












































<G : I= 
We now work under the hypothesis that the variation of [S] during the reaction is small enough 
for steady state kinetics to be applied: 
CB! : ACD! : ED!  
JD!JK  L












<G : M= 
The rate of formation of the bound state at the last association step is: 
ED!  J>?!JK 





















































<G : N= 
Combining equation (6-2) and (6-3) it is possible to express [S] in terms of the unbound state 
concentration [P][L]. Plugging the expression into (6-4) we get: 1A1 CEAC  E >!?!  J>?!JK  >!?!

<G : O= 
If we assume the change in concentration of [S] will be small, i.e. we apply steady-state kinetics 
for the second and third step, we reveal the following overall association constant (see (6-2)-(6-5) 
for a simple derivation) as: 
  <1PA1= Q <CEP<AC  E=











<G : G= 
In the derivation we set k
-3 = 0, similarly to what done by King and Burgen66, 67 for the 
dissociation step in the simpler two-state mechanism.  
The rate associated with the ligand diffusion, k1, as well as the deprotonation rate, k3, may be 
considered weakly dependent on the chemical decoration throughout the ligand series 54-57. 
Actually, k1 is determined by the Brownian diffusion of the ligand in solution and only weakly 
depends on the hydrodynamic radius of the molecule, which remains nearly constant across the 
series 54-57. Similarly, changes in the substituents within the ligands investigated occur rather 
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methylene group from the protein’s apolar environment to the water solution. By adopting a 
simple Arrhenius relationship, the rate k
-1 decreases by a factor exp (-	GCH2) when a methylene 
group is added to the substituent chain. The fit of the Arrhenius expression to the SFF data leads 
to a value of 	GCH2 of 1.56 ± 0.25 kJ/mol (see Figure 6-3b). The free energy penalty, per CH2 
group, associated with the transfer of an alkyl chain from a lipophilic to aqueous solvent was 
experimentally determined to be 3.35 kJ/mol.147, 179 This value can be considered consistent with 
our estimation of 	GCH2, as the benzenesulfonamides desorb from a hydrophobic surface (rather 
than from a bulk hydrophobic solution), which was in contact with approximately one half of the 
total volume occupied by the alkyl chain. 
The experimental k
off
 values, obtained by SPR experiments, are nearly independent of the 
compound structures, in agreement with previous SFF results.66, 67 The notable exception is 
ligand 54, the k
off of which is nearly three times bigger than that measured for the other 
compounds. The crystal structure of 54 in complex with hCAII shows a unique arrangement of 
crystallographic waters compared to the other derivative, which fully surround the ligand and 
connect it to the solvent exposed side. This could indicate the crucial role of a water network in 
the observed k
off
 value. On the other hand, hydrophobicity does not play a role in determining the 
off rates: the presence of the hydroxyl group in 58 does not lead to a dramatic reduction in the 
k
off with respect to the similarly sized ligand 57. In summary, the affinity of 
benzenesulfonamides for the hCAII target appears to be mostly modulated by changes in the 
association rate. This study explains the trends observed, on the basis of a structure-kinetics 
relationship retrieved by the analysis of large-scale atomistic simulations. hCAII is an excellent 
system for investigating the basic mechanisms determining the affinity of an enzyme for a 
specific inhibitor. In this case, we have shown that hydrophobicity determines the rate at which a 
class of benzenesulfonamides binds to hCAII. Moreover, this study demonstrates that 
computational modeling can be used to reconstruct the complete binding pathway of a ligand to 
its biological target, even in the highly non-trivial case where an early slow recognition process 
must be described together with a proton transfer reaction. We believe that our work offers a 
paradigmatic approach, showing how the combination of several experimental and simulative 
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methods can be generally used to produce a detailed understanding of the enzyme-inhibitor 
complexation mechanisms. 
6.6 Description of Experimental Procedures 
6.6.1 Computational section  
6.6.1.1  Protein preparation 
hCAII coordinates were retrieved from the Protein Data Bank (PDB: 1CA2).172 Amber99sb180 
force field was used for modeling the standard residues. The catalytic site was described by the 
Zinc Amber Force Field (ZAFF) force field.181 The crystallographic water bound to the zinc ion 
was assumed to be a hydroxyl ion. 
6.6.1.2  Ligand preparation 
Ligands 54-58 (Figure 6-1) were parameterized using the Generalized Amber Force Field 
(GAFF).182 Charges were refitted by means of restrained electrostatic potential (RESP).183 The 
three lowest energy structures, obtained by in-vacuo conformational search using Macromodel184 
and employing the Optimized Potential for Liquid Systems, (OPLS),185 186 were used for charge 
fitting.  
6.6.1.3  Molecular dynamics and metadynamics simulations 
MD simulations were run for 1 s (54) 1.2 s (55) 1.1 s (56) 1.1 s (57) 1 s (58) using the 
Gromacs 4.5.5 package.187 Simulations were run in the NPT ensemble, using the Parrinello-
Rahman barostat188 with time constant 
 = 2 ps and the V-rescale thermostat189 with time constant 

 = 0.1 ps. A time step dt = 2 fs was used. Geometry optimization was performed on the initial 
conformation up to a force threshold of 10 kJ mol-1 Å-1 and the resulting structure was brought 
from 0 to 300 K using a constant annealing of 400 ps. Well-tempered metadynamics190 
simulations were performed on 54, 57 and 58 using the PLUMED plugin.191 The duration of each 
run was at least 150 ns per ligand. We used two collective variables, CV1 and CV2 defined as the 
Zn-S1 distance and the Zn-S1-C1 angle, S1 and C1 representing, respectively, the sulfur of the 
sulfonamide and the carbon bound to it (see also Figure 6-4a). The initial Gaussian height was set 
to 2.5 kJ mol-1, while Gaussian widths were set to 2.5 Å and 0.5 rad for CV1 and CV2, 
respectively. The Gaussian deposition time interval was set to 2 ps. Simulations were stopped 
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after at least 5 recrossings from the lowest free energy conformation. This allowed the difference 
between the minima of the free energy profiles to remain constant within 5 kJ mol-1 over the final 
25 ns of the simulation.  
6.6.1.4  Definition of the simulation region 
We defined a simulation region as an ensemble of spheres with a 5Å radius, centered on each 
atom of the following residue group: Trp5, Trp16, Phe20, Pro21, I22, Ile91, Val121, Trp123, 
Phe131, Val135, Leu141, Ala142, Val143, Leu198, Pro201, Pro202, Leu203, Leu204 and 
Trp209. We considered the following minimum distance collective variable: 
 R  STUVWX
S YZ [VY" (6-7)
Where Y[VY represents the distance between the i-th atom of the ligand and the j-th atom of the 
residue group.  was set to 500.  
The constraining potential was introduced as:
 \<R=  L]T[R ^ R_ (6-8)
 \<R=  <R : R_=`]T[R a R_ 6-9
where s0 = 5 Å and k= 4·102 kJ mol-1·Å-1. Using these conditions, the ligand, when lying 
completely outside of the confining region, experiences a restraining force, preventing the escape 
of the ligand itself from the confinement volume. This allows sampling of a larger number of 
detachment events with respect to unconfined simulations, without biasing the dynamics during 
the event of ligand desorption. The shape of the constraining region as it appears in the hCAII 
crystal structure is displayed in Figure 6-12. Because of the relatively large Gaussian width 
employed, metadynamics simulations were allowed to sample a larger volume, i.e. the spheres 
used to define the simulation region were set to 10 Å. 
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Figure 6-14 Distribution of the tHP
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comprising His94, His96, His119, His64, Glu106, Thr199 and Thr200. In the reduced model 
used, the residues have been cut at C and one extra hydrogen was added to complete the 
coordination of the C. All waters found within 4 Å of the ligand were included in the calculation. 
(2): system (1) was modified by translating the H atom involved in the H-bond between the 
sulfonamide and the Zn2+-bound hydroxyl ion along the H-O bonding distance. The resulting 
conformation corresponded to a Zn2+-bound water molecule facing the deprotonated sulfonamide. 
Both systems were structurally optimized up to a force threshold of 4.5 10-4 atomic units. In (1) 
and (2), all the C and the oxygen atoms of the water molecules with truncated coordination were 
kept fixed during DFT geometry optimization. In (2), the geometry was optimized by first fixing 
the sulfonamide nitrogen and the transferred hydrogen and by then relaxing the whole system. 
All electron DFT calculations were performed using the CRYSTAL14 codes. Basis sets were 
taken from the crystal website library (http://www.crystal.unito.it/basis-sets.php). 
Constrained geometry optimization was performed by applying an external harmonic force 
between the sulfonamide nitrogen and the Zn2+ ion. The spring stiffness was set to 0.5 atomic 
units. Starting from the DFT-optimized S pose, the equilibrium length of the spring was gradually 
brought to 2.0 Å in ten steps. Each step corresponded to a new geometry optimization, with input 
coordinates taken from the system optimized at the previous iteration. At each step, the 
equilibrium length was reduced by 0.25 Å. The CP2K code194 was used for the constrained 
geometry optimizations. The force threshold for structural optimization was set to 4.5·10-4 atomic 
units. Goedecker-Teter-Hutter pseudopotentials195 were used for all elements. All the electrons in 
the highest energy electronic shell were considered as valence electrons. In the case of Zn, the 
semicore 3d electrons were also included. Double zeta valence basis sets with one polarization 
function196 were used.  
  
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6.6.2 Experimental section  
6.6.2.1  Expression, purification, crystallization, crystal structure determination and SPR 
measurements of hCAII 
These methods are described in Section 9.3. 
6.6.2.2  Ligand verification and purification 
6.6.2.2.1 Ligand verification 
The ligands 54, 55, 59 and 60 were purchased from Sigma Aldrich. 56 was purchased from 
Apollo Scientific Ltd., 57 and 58 from Ukrorgsyntez Ltd. (UORSY). Melting points were 
determined on a Leitz HM-Lux melting point microscope and are uncorrected. Proton NMR 
spectra were recorded on a JEOL ECA-500 MHz spectrometer (1H NMR: 500.2 MHz) or a JEOL 
ECX-400 MHz spectrometer (1H NMR: 399.8 MHz). Quantitative NMR (qNMR) 
measurements197, 198 regarding compound 58 were exclusively performed at 500.2 MHz. As 
Certified Reference Material (CRM), maleic acid ( 6.26 ppm), purchased from Sigma Aldrich, 
was used as internal reference standard. Chemical shifts are stated in parts per million (ppm) and 
were referenced to tetramethylsilane (TMS) at  0.00 ppm, except for qNMR measurements, 
where the solvent residual peak for DMSO-d6 at  2.50 ppm served as reference. qNMR purities 
for the different purity levels of compound 58 were obtained from the calculation of the observed 
integral values of the CRM and the aromatic 2`,6` protons in relation to their molar proportion to 
each other using the formula described below.197 NMR instrument parameters were in accordance 
with those required for standard qNMR measurements.198 The NMR data were processed 
employing Delta NMR Processing and Control Software, version 5.0.0. Abbreviations 
concerning signal multiplicity are as follows: bs = broad singlet, d = doublet, dm = doublet of 
multiplets, m = multiplet, psq = pseudoquartet, q = quartet, s = singlet, sext = sextet, t = triplet. 
ESI+ mass spectra were obtained from a Q-trap 2000 triple quadrupol mass spectrometer 
(Applied Biosystems). Elemental combustion analyses were determined on a vario Micro cube 
CHNS analyzer (Elementar Analysensysteme GmbH). Chromatography was performed using 
prepacked silica gel columns (Interchim PuriFlash SI-HP, 30 m). TLC was carried out using 0.2 
mm aluminium plates coated with silica gel 60 F254 (Macherey-Nagel) and the respective 
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substance spots were visualized by UV detection. Solvents for chromatography of compound 58 
were used in analytical quality without further purification. 
The analytical data is listed in Appendix 10.4. 
6.6.2.2.2 Ligand purification 
Calculation of the purity (P) of the ligand 58 according to qNMR measurements was performed 
by the following formula197: 
 b  cdedfghicjkl m njkl
ndedfghi modedfghiojkl m
 pjkl
pqdrsfi m
btuo   (6-10) 
 
The calculations of the purity of 58 of the commercial substance, after the first and after the 
second purification step are shown in Appendix 10.5. 
 
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7 Conclusions and Outlook 

The aim of drug discovery is the tailored design of ligands with desired properties for the 
respective target protein. Since the development of a new drug costs up to 1.6 billion dollars the 
decision, which of the screening hits should be pursued, is a critical step. To choose the right 
compound, knowledge about the complex recognition process between ligand and protein is 
important. The thermodynamic parameters, especially the enthalpic portion, might suggest which 
of the screening hits forms the strongest interactions without having access to the complex crystal 
structure. This concept is based on the hypothesis that enthalpic binders are better optimization 
candidates as on late stage optimization drug molecules are improved in the binding mainly for 
entropic reasons. The kinetic data give information about the association and dissociation 
behavior of a protein-ligand complex under consideration. Depending on the intended 
application, a ligand with a well-tailored residence time in the binding pocket appears promising 
for the desired therapeutic success. In this work, the binding of congeneric ligand series to their 
respective target proteins, ALR2 and hCAII, were analyzed by X-ray crystallography, ITC and 
SPR measurements in order to gain knowledge for further drug design cycles on these proteins 
but also to understand principles which can be used for related drug discovery projects. 
For ALR2 several projects could be accomplished successfully. ALR2 is an interesting target for 
the prevention of diabetic complications. However, besides epalrestat, which is marketed as a 
drug in Japan and India, the strong efforts to find an effective and safe inhibitor of this protein 
were so far not successful. This work contributes with the investigation of compound 13 as a new 
type of ALR2 inhibitor. It originates from a database search and subsequent affinity and 
selectivity determination were performed by Drs. Milan Stefek, Marta Soltesova Prnova and 
Magdalena Majekova from the Slovak Academy of Sciences in Bratislava, Slovakia. The 
compound was found to be selective for ALR2 compared to two related proteins, aldehyde 
reductase and AKR1B10, which is necessary to prevent undesired side effects. In this work the 
highly-resolved complex crystal structure of 13 could be determined (1.26 Å) which led to two 
surprising findings. First, the specificity pocket of ALR2 was found in its closed state. This result 
is astonishing since the addressing of this pocket is assumed to be a prerequisite to design a 
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selective ALR2 inhibitor. Secondly, an additional molecule of this inhibitor was found more at 
the entrance of the pocket, within a distance which allows to form an H-bond to the first molecule 
of 13. The question arose if this second molecule could always bind together with the first one. 
To answer this question ITC experiments were performed. They indicated that 13 binds with the 
same stoichiometry as other ALR2 inhibitors. In their corresponding complex crystal structures 
only one molecule could be found. Additionally, the decreased occupancy of 70% for the second 
molecule in the complex crystal structure suggests that its binding results from a rather high 
concentration of 13 which was applied in the soaking experiment. Summarized, 13 can be 
regarded due to its high affinity and selectivity for ALR2 as the first member of a new group of 
ALR2 inhibitors. The affinity of this ligand group might be further improved since the specificity 
pocket of ALR2 was not addressed. Other derivatives should be synthesized and the crystal 
structure complexed with ALR2 of the compounds with the highest affinities should be 
elucidated. 
In a cooperation with the groups of Prof. Alberto Podjarny (CNRS, Illkirch, France), Dr. Ángel 
R. de Lera (Universidade de Vigo), Drs. Maria Jesús Martin and Jesús Ángel de la Fuente 
(Biomar Microbial Technologies S. A., León), Dres. Xavier Parés and Jaume Farrés (Universitat 
Autònoma de Barcelona) two compounds were investigated which inhibit both ALR2 and the 
related protein AKR1B10. This work contributed to this project with the determination of ITC 
data. In due course of binding to ALR2, a proton entrapment of 0.6 protons per mole of formed 
complex was found, which is in good agreement with previous results. Surprisingly, for the 
binding to AKR1B10, only an entrapment of 0.1 protons per mole of formed complex was found. 
This indicated that the protonation state in AKR1B10 prior to the binding of an inhibitor is 
different for AKR1B10 than for ALR2. In a following project, a study should be performed 
which clarifies this different behavior. 
Furthermore, an ALR2 inhibitor series bearing a carboxylic acid group along with two or three 
aromatic systems was investigated using X-ray crystallography, IC50 value determination and 
ITC. This group of ALR2 inhibitors derives initially from a virtual screening campaign. In this 
work the compounds resulting from an optimization cycle should be analyzed. The ligands were 
synthesized by the group of Prof. Martin Schlitzer (Philipps-University Marburg). Unfortunately, 
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using the cocrystallization or soaking condition in citrate buffer, which were prevalent at the 
beginning of this project, the ligands did not bind to ALR2. A new soaking condition in TRIS 
buffer was established to enhance the solubility of the inhibitors resulting in complex crystal 
structures for at least some of the ligands. It could be shown that all members of this group, for 
which a complex crystal structure could be determined, adopt a very similar binding mode. 
Differences could be found in the position of the carboxylic acid group in the anion binding 
pocket. Most members form a direct H-bond to the NE1 of Trp111 while two ligands establish a 
different interaction pattern. The latter two ligands capture a water molecule which compensates 
for the lost H-bond to Trp111. The first complex crystal structure of a ligand of this series 
possessing a third aromatic moiety could be obtained. It shows that the third ring is not 
hampering the binding in a similar geometry as for the other members of this series. Additionally, 
the complex crystal structure of the first ligand of this group possessing an acrylic acid head 
group was determined. It resulted in the surprising finding that the configuration of the 
incorporated double bond changed from E to Z during the soaking procedure. This leads to the 
conclusion that the Z-configuration is better able to form the interactions in the anion binding 
pocket than the E-configuration.  
In another project the specificity pocket of ALR2 was investigated using derivatives of the 
already described inhibitor IDD393 which were synthesized by the group of Prof. Wibke 
Diederich (Philipps University of Marburg). Its portion which addresses the latter pocket was 
varied which led to derivatives which induced different conformations of the residues forming the 
specificity pocket. The comparison of two ligands, one which opens the pocket with a non-
substituted phenyl ring and one ligand which has no moiety which could open the latter pocket, 
indicated that the opening of the pocket is accompanied by a small but measurable loss in the 
enthalpic portion. Since the complex crystal structure determination provided no explanation for 
this finding it can be assumed that the residues of the specificity pocket in the open conformation 
possess a higher energetic state compared to the closed conformation. Accordingly, to open the 
pocket, some energy has to be invested, leading to a small loss in the enthalpic portion. Different 
moieties were used to address the specificity pocket. A nitro group attached in meta position to 
the phenyl ring which binds in the specificity pocket leads to a surprisingly strong enthalpic gain 
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of -35.7 kJ/mol. It was shown previously that a nitro group at this position leads to a strong 
enthalpic signal, but in this work its contribution to the enthalpic binding signal could be 
quantified for the first time. The exchange of this nitro group by a carboxylic acid group 
surprisingly leads to a changed binding mode of the ligand. The terminal phenyl ring of the 
benzoic acid moiety is not buried in the specificity pocket as found for the nitro phenyl derivative 
but is directed to the solvent-accessible entrance of the binding pocket. To establish this binding 
mode, an internal H-bond between the amide nitrogen and one of the oxygen atoms of the 
carboxylic acid group of the inhibitor, which all other members of this ligand series establish, 
cannot be formed anylonger. This altered binding mode led to a 2000-fold decreased affinity. 
Presumably, the desolvation penalty for a carboxylic acid group is higher than for a nitro group, 
which could explain this surprising finding. In a following project different terminal moieties for 
this ligand group should be investigated to elucidate which is the discriminating factor 
determining whether the specificity pocket is open or not. This knowledge might be transferred to 
similar drug design projects which involve the addressing of a transient subpocket by a moiety of 
a ligand. 
The binding of a series of benzenesulfonamide ligands to hCAII was characterized by SPR 
experiments and complex crystal structure determinations. The obtained results were compared to 
findings of MD simulations and previously published SFF measurements. Similar to the SFF 
experiments it could be shown that the association rates increase with the length of the 
hydrophobic tail which is attached in para position to the benzenesulfonamide. This is a 
surprising finding since the association rate of molecules with a long alkyl rest, at least in case 
binding would be only diffusion-controlled, should be hampered due to steric hinderence and 
consequently slowed down. Consequently, in this investigated situation, the association process 
seems to be a multi-step mechanism in which one step is favorably influenced by a hydrophobic 
interaction. The complex crystal structure determination showed that all investigated ligands 
exhibit a very similar binding mode. However, crystal structures show only the final binding 
position. With MD experiments, performed by the group of Prof. Andrea Cavalli (Italian Institute 
of Technology, Genova, Italy), the whole association process could be simulated. The obtained 
results indicated that the prebinding of the molecules to the hydrophobic patch on the surface of 
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hCAII, next to the active site, is stabilized by hydrophobic interactions of the alkyl tails of the 
ligand molecules. In a subsequent step the ligand diffuses in the final binding position. As a proof 
of concept the binding of a similar ligand molecule to hCAII which contained a 
para hydroxyethyl chain was simulated by MD experiments as well as measured by SPR. Indeed 
for this compound the association process was significantly slowed down. Thus, our results are in 
line with the assumed multi-step process with an intermediate hydrophobic stabilization. 
Knowledge about the association processes of ligands and proteins is still limited which makes 
our results a valuable contribution to this field. Especially hCAII is an excellent model system to 
investigate in the future further inhibitor series by SPR, MD and ITC experiments. ITC 
experiments should be performed for the here investigated inhibitors to correlate the 
thermodynamic data with the kinetic properties. This would make this ligand series to one of the 
first which is characterized by all the above-mentioned techniques.  
 
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8 Zusammenfassung und Ausblick 

Das Ziel der Wirkstoffentwicklung ist das Design von passenden Liganden für das jeweilige 
Zielprotein. Da die Entwicklung eines neuen Medikamentes bis zu mehr als einer Milliarde 
Dollar kosten kann, ist die Entscheidung, welche der Kandidaten, die aus einem Screening 
hervorgegangen sind, weiter verfolgt werden sollen, ein kritischer Schritt. Damit das richtige 
Molekül ausgewählt werden kann, wird Wissen über den komplexen Erkennungsprozess 
zwischen Ligand und Protein benötigt. Die thermodynamischen Parameter, besonders der 
enthalpische Beitrag, zeigen bereits, ohne dass die Komplexkristallstruktur verfügbar sein muss, 
welche der Inhibitoren die stärksten Interaktionen mit der Proteinbindetasche eingehen. Die 
kinetischen Daten geben Auskunft über das Assoziations- und Dissoziationsverhalten von 
Protein-Ligand-Komplexen. Abhängig von der beabsichtigten Indikation kann z.B. ein Ligand 
mit einer Verweildauer in der Bindetasche, die vorteilhaft für den therapeutischen Erfolg 
erscheint, ausgewählt werden. In dieser Arbeit wurde die Bindung von Liganden-Serien zu ihrem 
jeweiligen Zielprotein, ALR2 oder hCAII, mit Röntgenkristallographie, ITC- und SPR-
Messungen untersucht, mit dem Ziel die grundlegenden Prinzipen zu verstehen, die auch für 
ähnliche Wirkstoffdesign-Projekte genutzt werden können. 
Für ALR2 konnten mehrere Projekte erfolgreich abgeschlossen werden. ALR2 ist eine 
interessante Zielstruktur für die Prävention von diabetischen Spätschäden. Jedoch, mit Ausnahme 
von Epalrestat, welches in Japan und Indien auf dem Markt ist, waren die großen Anstrengung, 
um einen effizienten und sicheren Hemmstoff für dieses Protein zu finden, bisher nicht 
erfolgreich. Diese Arbeit trägt mit der Untersuchung des Inhibitors 13, einem neuen Typ von 
ALR2-Hemmstoff, zu dieser Suche bei. Das Molekül ist aus einer Datenbank-Suche und 
nachfolgender Affinitäts- und Selektivitätsbestimmungen, die von Drs. Milan Stefek, Marta 
Soltesova Prnova und Magdalena Majekova (Bratislava, Slowakei) durchgeführt wurden, 
hervorgegangen. Dieser Hemmstoff ist selektiv für ALR2 im Vergleich zu zwei verwandten 
Proteinen, Aldehyd Reduktase und AKR1B10, was notwendig, ist um unerwünschte 
Nebenwirkungen zu meiden. In dieser Arbeit konnte die Komplexkristallstruktur von 13 mit 
ALR2 erhalten werden (1,26 Å), welche zu zwei überraschenden Resultaten führte. Zunächst 
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wurde die Spezifitätstasche der ALR2 in der geschlossenen Form vorgefunden. Dies ist 
erstaunlich, da gemeinhin die Adressierung dieser Tasche als Voraussetzung für das Design eines 
selektiven ALR2-Inhibitors gilt. Außerdem wurde ein weiteres Molekül des Liganden am 
Eingang der Bindetasche, in Wasserstoffbrückenbindungsabstand zum ersten Molekül, gefunden. 
Die Frage, ob dieses zweite Molekül immer zusammen mit dem ersten bindet, sollte beantwortet 
werden. Deshalb wurden ITC-Experimente durchgeführt. Diese zeigten, dass 13 mit der gleichen 
Stöchiometrie bindet, die auch Liganden besitzen, in deren Komplexkristallstrukturen nur jeweils 
ein Molekül des Liganden aufgefunden wurde. Desweiteren weist die verringerte Besetzung von 
70% des zweiten Molekül des Liganden darauf hin, dass das zweite Molekül nur aufgrund der 
hohen Konzentrationen, die beim Soaking-Prozess genutzt werden, bindet. Zusammengefasst 
kann 13 aufgrund seiner hohen Affinität und Selektivität als das erste Mitglied einer neuen 
Gruppe von ALR2-Inhibitoren angesehen werden. Die Affinität dieser Inhibitor-Klasse könnte 
vermutlich noch weiter erhöht werden, wenn die Spezifitätstasche adressiert werden würde. 
Weitere Liganden sollten synthetisiert werden und die Komplexkristallstrukturen der Inhibitoren 
mit den höchsten Affinitäten bestimmt werden. 
In einer Kooperation mit den Gruppen von Prof. Alberto Podjarny (CNRS, Illkirch, France), Dr. 
Ángel R. de Lera (Universidade de Vigo), Drs. Maria Jesús Martin und Jesús Ángel de la Fuente 
(Biomar Microbial Technologies S. A., León), Drs. Xavier Parés und Jaume Farrés (Universitat 
Autònoma de Barcelona) wurden zwei Verbindungen (23 und 24) untersucht, die ALR2 und das 
verwandte Protein AKR1B10 inhibieren. Zu diesem Projekt wurde die Messung der 
thermodynamischen Profile beigesteuert. Im Zuge der Bindung an ALR2 wurde eine 
Protonenaufnahme von 0.6 Mol Protonen je Mol gebildeten Komplexes ermittelt. Dies stimmt 
mit bisherigen Ergebnissen an anderen Komplexen vergleichbaren Typs überein. Überraschend 
wurde für die Bindung an AKR1B10 nur eine Protonenaufnahme von 0.1 Mol Protonen je Mol 
gebildeten Komplexes gefunden. Dies zeigt, dass sich die Protonierungszustände in der 
Bindetasche von AKR1B10 vor der Bindung eines Liganden von ALR2 unterscheiden. In einem 
folgenden Projekt sollte dies näher untersucht werden, z. B. mittels pKa-Wertberechnungen für 
die Aminosäuren in der Bindetasche von AKR1B10.  
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Desweiteren wurde eine ALR2-Inhibitor-Serie mit einer Carboxylat-Gruppe und zwei oder drei 
aromatischen Systemen unter Zuhilfenahme von Röntgenkristallographie, IC50-Bestimmungen 
und ITC-Messungen untersucht. Diese Gruppe stammt ursprünglich von einer virtuellen 
Leitstruktursuche. In dieser Arbeit wurden die Verbindungen, die aus einem weiteren 
Optimierungszyklus hervorgingen, untersucht. Die Liganden wurden von der Gruppe von 
Prof. Martin Schlitzer (Philipps Universität Marburg) synthetisiert. Zu Beginn dieses Projektes 
wurde die Co-Kristallisation bzw. das Soaking in Citrat-Puffer durchgeführt. Allerdings konnte 
keiner der untersuchten Liganden unter dieser Bedingung in der Differenzelektronendichte 
gefunden werden. So musste zunächst ein neues Soaking-Protokoll in TRIS-Puffer entwickelt 
werden, um die Löslichkeit der Verbindungen zu erhöhen. Dadurch waren Kristallstrukturen im 
Komplex mit zumindest einigen der Liganden zugänglich. Es konnte gezeigt werden, dass alle 
Inhibitoren, deren Protein-Ligand-Komplex erhalten wurde, einen sehr ähnlichen Bindemodus 
aufweisen. Unterschiede konnten in der Position der Carboxylat-Gruppe in der Anionen-
Bindetasche gefunden werden. Die meisten Liganden bilden eine H-Brücke mit Trp111NE1 
während zwei Inhibitoren ein anderes Interaktionsmuster eingehen. Die letztgenannten Liganden 
interagieren mit einem Wassermolekül, wodurch die verlorene H-Brücke zu Trp111 ausgeglichen 
wird. Der erste Protein-Ligand-Komplex mit einem Liganden aus dieser Serie, der ein drittes 
aromatisches Ringsystem enthält, konnte kristallographisch aufgeklärt werden. Dieser zeigt dass 
der dritte aromatische Ring nicht die Bindung in einer ähnlichen Orientierung wie für die anderen 
Mitglieder dieser Gruppe verhindert. Außerdem konnte der erste Protein-Ligand-Komplex eines 
Inhibitors aus dieser Gruppe mit einer Acrylsäure-Kopfgruppe aufgeklärt werden. Diese führte zu 
der überraschenden Erkenntnis, dass sich die Konfiguration der in den Liganden vorliegenden 
Doppelbindung während des Soaking-Prozess von E zu Z ändert. Offensichtlich kann der Ligand 
mit der Acrylsäuregruppe in Z-Konfiguration vorteilhaftere Wechselwirkungen in der Anionen- 
Bindetasche eingehen als in E-Konfiguration. 
In einem weiteren Projekt wurde die Spezifitätstasche der ALR2 mit Hilfe von Derivaten des 
zuvor beschriebenen Inhibitor IDD393, die in der Gruppe von Prof. Wibke Diederich (Philipps- 
Universität Marburg) synthetisiert wurden, untersucht. Der Teil dieser Liganden, der die 
Spezifitätstasche adressiert, wurde variiert. So wurden Inhibitoren erhalten, durch welche 
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unterschiedliche Konformationen der Spezifitätstasche induziert wurden. Der Vergleich von zwei 
dieser Liganden, wovon einer die Spezifitätstasche mit einem nicht-substituierten Phenylring 
adressiert (49) und der andere keine Seitenkette enthält, die diese Tasche öffnen konnte (47), 
zeigte, dass die Öffnung der Tasche von einem kleinen aber doch messbaren Verlust in der 
Enthalpie einhergeht. Da die vergleichende Analyse der jeweiligen hochaufgelösten 
Proteinkristallstrukturen keine Erklärung für dieses Resultat liefert, kann vermutet werden, dass 
die Reste der Spezifitätstasche in der offenen Konformation eine höhere Energie besitzen als in 
der geschlossenen Konformation. Folglich müsste Energie investiert werden, um die Tasche zu 
öffnen, was den Verlust in der Enthalpie erklären würde. Die Liganden wurden mit 
verschiedenen Resten versehen, um die Tasche zu adressieren. Eine Nitro-Gruppe, die in 
meta Position an einen Phenylring gebunden ist, führt im Vergleich zum nicht-substituierten 
Phenylring zu einem starken enthalpischen Gewinn von -35.7 kJ/mol. Zwar wurde bereits zuvor 
gezeigt, dass ein solcher Substituent in dieser Portion zu einem starken enthalpischen Signal 
führt, jedoch konnte dieses bisher nicht quantifiziert werden. Der Austausch dieser Nitro-Gruppe 
durch eine Carboxylat-Funktion führt überraschenderweise zu einem geänderten Bindemodus des 
Liganden. Der terminale Phenylring der Benzoesäure-Gruppe des Liganden ist nicht in der 
Spezifitätstasche vergraben, wie es für das Nitrophenyl-Derivat der Fall ist, sondern dieser 
orientiert sich in Richtung des Lösungsmittel zugänglichen Eingangs der Bindetasche. Um diesen 
Bindemodus einzunehmen, muss eine interne H-Brücke zwischen dem Amid-Stickstoff und 
einem der Sauerstoffatome der Carboxylat-Funktion des Liganden, die sonst bei allen anderen 
Inhibitoren der hier untersuchten Serie vorliegt, aufgegeben werden. Dieser geänderte 
Bindemodus führt zu einer 2000-fach reduzierten Affinität im Vergleich zum Nitro-Derivat. 
Vermutlich ist die Desolvation einer Carboxylat-Gruppe deutlich unvorteilhafter als für eine 
Nitrogruppe, was dieses überraschende Resultat erklären würde. In einem folgenden Projekt 
sollten weitere Derivate aus dieser Serie untersucht werden, um besser zu verstehen, was den 
diskriminierenden Faktor für die Öffnung der Tasche darstellt. Dieses hier erhaltende Ergebnis 
kann auf ähnliche Wirkstoffdesign-Projekte, bei denen die Öffnung einer transienten Subtasche 
eine Rolle spielt, übertragen werden. 
Zusammenfassung und Ausblick 
 
179 

Die Bindung einer Serie von Benzensulfonamiden an die hCAII wurde mithilfe von SPR-
Experimenten und Proteinkristallographie untersucht. Die erhaltenen Resultate wurden mit den 
Erkenntnissen von MD-Simulationen und zuvor publizierten SFF-Messungen verglichen. 
Vergleichbar zu den Resultaten der SFF-Messungen konnte gezeigt werden, dass die 
Assoziationsrate mit der Länge der hydrophoben Alkylkette, die sich in para-Stellung zur 
Sulfonamid-Gruppe befindet, ansteigt. Dies ist zunächst ein überraschendes Resultat, denn 
zumindest in dem Fall eines rein diffusions-kontrollierten Assoziationsprozesses sollte die 
Bindung verlangsamt werden, wenn das Molekül eine sterisch anspruchsvolle Seitenkette besitzt. 
Folglich scheint der Assoziations-Prozess in der hier betrachteten Situation mehrere Schritte zu 
durchlaufen, von denen einer von einer hydrophoben Interaktion vorteilhaft beeinflusst wird. Die 
Bestimmung der Kristallstrukturen im Komplex mit dem jeweiligen Inhibitor zeigte, dass alle 
Liganden einen sehr ähnlichen Bindemodus aufweisen. Allerdings repräsentieren die 
Kristallstrukturen nur den finalen Bindemodus. Mit MD-Simulationen, die in der Gruppe von 
Prof. Andrea Cavalli (Italian Institute of Technology, Genua, Italien) durchgeführt wurden, 
konnte der gesamte Bindeprozess untersucht werden. Dies führte zu der Erkenntnis, dass die 
zwischenzeitliche Bindung der Moleküle an der hydrophoben Region, die sich in der Nähe der 
Bindetasche befindet, durch hydrophobe Interaktionen der Alkylkette der Liganden stabilisiert 
wird. Im nachfolgenden Schritt wandert das Molekül dann in die finale Bindeposition. Um diese 
Theorie zu überprüfen, wurde die Bindung eines Derivates, das eine Hydroxyethyl-Seitenkette 
besitzt, mit MD-Simulationen und SPR-Experimenten untersucht. Tatsächlich konnte mit beiden 
Verfahren gezeigt werden, dass die Bindung dieses Liganden mit der polaren OH-Gruppe an die 
hCAII stark verlangsamt erfolgt. Folglich deuten unsere Resultate darauf hin, dass die Bindung 
von Benzensulfonamiden an die hCAII aus mehreren Einzelschritten besteht und eine 
zwischenzeitliche hydrophobe Stabilisierung involviert ist. Da das Hintergrundwissen über die 
Assoziation von Proteinen und Liganden noch sehr begrenzt ist, stellt das hier erhaltene Wissen 
einen wertvollen Beitrag zu diesem Gebiet dar. hCAII kann dabei in zukünftigen Studien als 
Modellsystem genutzt werden, um weitere Inhibitor-Serien mit SPR-, ITC- und MD-
Experimenten zu untersuchen. Vor allem sollten ITC-Messungen an der hier beschriebenen 
Benzensulfonamid-Serie durchgeführt werden. Dies würde diese Protein-Liganden-Serie zu einer 
der ersten machen, die mit all den zuvor genannten Techniken untersucht wurde.  
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9 Materials and Methods 

9.1 Chemicals, Devices, Buffers and Solutions 
9.1.1 Chemicals 
Table 9-1 Chemicals in alphabetical order. 
Name Company Abbrevation 
1,4-Dithiothreitol  Roth DTT 
2-(N-morpholino)ethanesulfonic acid Roth MES 
4-(2-Hydroxyethyl)-1-piperazine ethan sulfonic acid Roth HEPES 
Acetic acid 100% Roth   
Activated carbon Roth   
Agar-Agar Roth   
Ammoniumpersulfate Roth APS 
Ammoniumsulfate Grüssing   
Ampicilline Roth   
Bromphenol blue Merck   
Calcium chloride Roth   
Chloramphenicole Roth   
Coomasie Brilliant Blue R250 Roth   
D-(+)- Xylose Sigma Aldrich   
di-Ammonium hydrogen citrate  Sigma Aldrich   
Dimethylsulfoxid  Roth DMSO 
di-Potassium hydrogen phosphate Merck   
Ethanol 99.8% Roth   
Ethylene diamine tetra acetate  Merck EDTA 
Glycerol 99% Acros Organics   
Guanidine-HCL Merck   
Hydrochloric acid 32% Fisher Chemical   
Imidazole Roth   
Isopropanol 99.5% Acros Organics   
Isopropyl--D-thiogalactopyranosid  Roth IPTG 
Lysozyme Roth   
Methanol Fisher Chemical   
N-(2-Hydroxy-1,1-bis(hydroxymethyl)ethyl)glycine Merck Tricine 
Nickel(II) sulfate Sigma Aldrich   

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Continuation of Table 9-1. 
Name Company Abbrevation 
Nicotinamide adenine dinucleotide phosphate Sigma Aldrich NADP+ 
Nicotinamide adenine dinucleotide phosphate, reduced Roth NADPH 
p-Chloromercurybenzoic acid Sigma Aldrich   
Peptone from Casein Roth   
Polyethylene glycole 6000  Sigma Aldrich PEG 6000 
Polyoxyethylene (20) sorbitan monolaurate (Tween 20) GE Healthcare   
Potassium di-hydrogen phosphate Roth   
Rotiphorese 10x SDS Roth   
Rotiphorese Gel 30 ( 30% Acrylamide/0.8% Bisacrylamide ) Roth   
Sodium chloride Roth   
Sodium dodecyl sulfate Sigma Aldrich SDS 
Sodium hydroxide Grüssing   
Tris(hydroxamethyl)aminomethane Roth TRIS 
Yeast extract Roth   
  
9.1.2 Laboratory devices  
Table 9-2 The devices which were used in this work are listed in alphabetical order. 
Device Company 
96 well microplates  Greiner Bio-One 
ÄKTA FPLC Amersham Biosciences 
ÄKTA Prime Plus FPLC GE Healthcare 
Autoclave T-Line Fedegari Autoclave Spa 
Benzamidine FF column  GE Healthcare 
Biacore S51 SPR instrument GE Healthcare 
Biofuge fresco centrifuge Hereus 
Centrifuge Avanti® J-25 Beckmann 
Centrifuge Biofuge Pico™ Hereus 
Centrifuge Multifuge™ 3 Hereus 
Glutathione sepharose high performance material  GE Healthcare 
HERAsafe™ biological safety cabinet Thermo Scientific 
HiLoad 26/600 Superdex 200 pg size exclusion column  Amersham Biosciences 
HiTrap Chelating HP column  GE Healthcare 
HiTrap DEAE FastFlow sepharose column GE Healthcare 
iEMS Reader MF Labsystems Oy 
 
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Continuation of Table 9-2. 
Device Company 
IKA® mini G centrifuge IKA 
ITC200 microcalorimeter GE Healthcare 
Microscope SZ-PT Olympus 
Nanodrop™ 2000c Thermo Scientific 
PD-10 Desalting Column GE Healthcare 
Peristaltic pump P-1  GE Healthcare 
pH-meter Five Easy™ FE20 Mettler Toledo 
Pipettes Eppendorf 
SDS-Page Mini-PROTEAN® Tetra Electrophoresis System BioRad 
Shaking incubator Innova 4200 New Brunswick Scientific 
Shaking incubator Innova 4300 New Brunswick Scientific 
Thermomixer Comfort Eppendorf 
Ultrasonic bath Elmasonic S 10 Elma 
Ultrasonic Sonifier® 250 Branson 
Vivaspin® 10,000 concentrator  Sartorius 
 
 
 
9.1.3 Solutions and Buffer 
Table 9-3 Solutions and buffers which were used in this work are listed in alphabetical order. 
Name Substances 
Citrate buffer  50 mM di-ammonium hydrogen citrate, pH 5.0 
Citrate cryo buffer 120 mM di-ammonium hydrogen citrate, 40% (w/v) PEG 6000, pH 
5.0 
Citrate stabilization buffer 120 mM di-ammonium hydrogen citrate, 25% (w/v) PEG 6000, pH 
5.0 
Coomasie blue destaining 
solution  
10% (v/v) acetic acid, 40% (v/v) methanol 
Coomasie blue staining  
solution 
10% (v/v) acetic acid, 40% (v/v) methanol,  
1 g/L Coomasie Brilliant Blue R250 
Elution buffer (ALR2) 200 mM imidazole, 16 mM TRIS and 400 mM NaCl, pH 8.0  
hCAII well solution 2.5- 3.0 M (NH4)2SO4, 100 mM TRIS,  
saturated with p-chloromercurybenzoic acid, pH 7.8 
ITC buffer (ALR2) 10 mM HEPES, Tricine or TRIS, pH 8.0 
LB media 1% (w/v) NaCl, 1% (w/v) pepton, 0.5% (w/v) yeast, autoclave 
MES cryo buffer 50 mM MES, 40% (w/v) PEG 6000, pH 5.5  
MES stabilization buffer 50 mM MES, 25% (w/v) PEG 6000, pH 5.5  
PBS buffer 139 mM NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4, 1.8 mM KH2PO4,  
pH 7.4 
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Continuation of Table 9-3. 
Name Substances 
SDS loading gel 
buffer 
1.0 M TRIS, pH 6.8 
SDS sample buffer 
4x 
250 mM TRIS, 200 mM DTT, 0.04% (w/v) bromphenol blue, 8% (w/v) SDS, 40% 
(v/v) glycerol, pH 6.8 
SDS separation gel 
buffer 
1.0 M TRIS, pH 8.8 
Sodium phosphate 
buffer  
18.4 mM di-potassium hydrogen phosphate, 25.3 mM potassium dihydrogen 
phosphate, pH 6.2 
Super LB media 0.5% (w/v) NaCl, 2.5% (w/v) pepton, 1.5% (w/v) yeast, autoclave 
TRIS 1 20 mM TRIS and 500 mM NaCl, pH 8.0 
TRIS 2 10 mM TRIS, pH 8.0 
TRIS cryo buffer 100 mM TRIS, 40% (w/v) PEG 6000, pH 8.0  
TRIS stabilization 
buffer 
100 mM TRIS, 25% (w/v) PEG 6000, pH 8.0 
Washing buffer 
(ALR2) 
20 mM TRIS, 10 mM imidazole, 500 mM NaCl, pH 8.0 
  
  
Materials and Methods 
 
185 

9.2 Experimental Procedures Regarding ALR2 
9.2.1 Expression and purification 
 
The expression and purification followed previously described protocols.134, 144, 199 A plasmid 
(pET15b, Novagen) which contained the open reading frame for the ALR2 gene together with a 
hexahistidine tag was kindly provided by Alberto Podjarny (IGBMC, Illkirch, France). The used 
ALR2 gene was sequenced. The result is shown in Figure 10-9 in the Appendix. The fusion 
protein was expressed in E. coli strain BL21 gold (DE3). An overnight culture of LB medium 
(100 mL) with 0.1 mg/mL ampicillin was inoculated and incubated for 16 hours at 310 K and 200 
rpm. 25 mL of the suspension was added to 1 L of Super-LB-medium with 0.1 mg/mL of 
ampicillin. A total volume of 4 L media has been used. The cells were grown to an OD600 of 
around 3.0 at 310 K and 200 rpm. Afterwards 1 mL of 1 M IPTG was added to 1 L of cell 
culture. The protein was expressed for 3 hours at 310 K and 200 rpm. The cells were then 
harvested by centrifugation with 6,000 rpm at 277 K for 10 minutes. The supernatant was 
discarded. The pellet of 1 L of Super LB medium was resuspended in a total volume of 25 mL of 
TRIS 1 (20 mM TRIS, 500 mM NaCl, pH 8.0). The cell walls were disrupted using ultrasound 
(six times for 1 min, duty cycle: 70%, micro tip limit: 3). During this procedure the suspension 
was kept on ice. Afterwards the suspension was centrifuged for 45 minutes at 20,000 rpm. The 
supernatants of all tubes were combined. A HiTrap Chelating HP column (GE Healthcare) was 
connected to an Äkta FPLC system (Amersham Pharmacia Biosciences). The protein solution 
was loaded on the column with a flow rate of 2.5 mL/min. TRIS 1 was injected until low 
absorption values were reached. Afterwards a short washing step (30 s, 2 mL/min) with washing 
buffer (20 mM TRIS, 10 mM imidazole, 500 mM NaCl, pH 8.0) was performed. The fusion 
protein was eluted using a linear gradient of elution buffer (200 mM imidazole, 16 mM TRIS, 
400 mM NaCl, pH 8.0). Using a Vivaspin 10,000 ultracentrifugation device (Sartorius) the buffer 
was exchanged to TRIS 2 (10 mM TRIS, pH 8.0) and concentrated to 15 mL. CaCl2 was added to 
a final concentration of 5 mM. For the cleavage of the hexahistidine tag thrombin (kindly 
provided by CSL Behring, Marburg) was added and the solution was stored for at least 20 h at 
277 K. The solution was diluted by adding TRIS 2 to a volume of 150 mL. A 5 mL HiTrap 
DEAE FastFlow sepharose column (GE Healthcare) was connected to an Äkta FPLC. The 
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. 
 
Figure 9-3 SDS gel of a typical purification of ALR2. 1:marker; 2:after lysis and centrifugation; 3:flowthrough of 
the HiTrap Chelating HP column; 4:peak after injection of washing buffer; 5:protein after HiTrap Chelating HP 
column; 6:ALR2 after cleavage; 7: ALR2 after DEAE column; 8 and 9: different batches of purfied ALR2; 
10: inhouse reference of ALR2. 

9.2.2 IC50 value determination 
The determination of IC50 values followed previously described protocols.144,199,200 After the 
purification, the protein buffer was exchanged to sodium phosphate buffer (di-potassium 
hydrogen phosphate, potassium dihydrogen phosphate, pH 6.2) using a PD10 column. The 
measurement of the IC50 value is based on the decrease of the NADPH concentration during the 
conversion of D-Xylose to Xylitol performed by ALR2. NADPH is converted to the oxidized 
form NADP+. The level of NADPH was monitored through its absorbance at 340 nm which was 
measured by a plate reader at 310 K (iEMS Reader, MF, Labsystems Oy, Finnland). NADP+ does 
not absorb at this wavelength. 96 well microplates (Greiner Bio-One) were used. Each well 
contained 250 µL of the reaction mixture consisting of 0.28 µM ALR2, 0.14 mM NADPH and 
26.5 mM D-Xylose in sodium phosphate buffer at pH 6.2. The concentration of the ALR2 stock 
was adjusted to 0.125 mg/mL. 20 different concentrations of the inhibitor were measured in 
parallel. The reaction mixture contained 5% (v/v) DMSO. Only a few investigated inhibitors 
made the addition of 10% (v/v) DMSO necessary. In each column of the plate two wells were 
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used to monitor the uninhibited reaction. NADPH and the protein were added in the last step to 
start the reaction. A multipipette was used to mix the solution in each well because a comparable 
surface shape of the drops was found to be a prerequisite for stable measurements. The rate of the 
reaction in each well with an inhibitor was divided through the rate of the uninhibited reaction. 
This ratio was plotted on the y-axis, while on the x-axis the concentration of the inhibitor was 
plotted in logarithmic scale. The range of investigated concentrations of the inhibitor was 
adjusted in a way that the resulting curve had a sigmoidal shape. The program GraFit (Version 
4.09, Erithacus Software Limited) was used to calculate the IC50 value. Each measurement was 
performed at least in triplicate. The mean values and the standard deviations were calculated.  
9.2.3 Crystallization of ALR2 
 
9.2.3.1  Crystallization of holo-crystals in citrate buffer 
After purification the protein was transferred into 50 mM diammonium hydrogen citrate pH 5.0 
using Vivaspin 10,000 ultracentrifugation device or dialysis. The concentration of the protein was 
adjusted to 30 mg/mL. The crystallization solution was prepared as shown in Table 9-4. 
 
Table 9-4 Preparation of the ALR2 crystallization solution in citrate buffer. 
 
Mixture 1  
50% (w/v) PEG 6000  340 µL 
1 M DTT  34 µL 
50 mM diammonium hydrogen citrate pH 5.0 1335 µL 
Mixture 2  
30 mg/mL ALR2 in 50 mM diammonium hydrogen citrate pH 5.0 100 µL 
200 mg/mL NADP+ in 50 mM diammonium hydrogen citrate pH 5.0 0.66 µL 
Crystallization Solution  
Mixture 1 100 µL 
Mixture 2 100 µL 
 
 
Aliquots of 200 µL of the crystallization solution were flash-frozen using liquid nitrogen. The 
final concentrations in the crystallization solution were 15 mg/mL ALR2, 5% (w/v) PEG 6000, 
5.2 mg/mL DTT and 0.7 mg/mL NADP+. The hanging drop method was used. The well solution 
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contained 120 mM diammonium hydrogen citrate (pH 5.0) with 20% (w/v) PEG 6000. 9 µL of 
the crystallization solution were equilibrated for at least 3 days at 277 K. Afterwards streak 
seeding with a horse hair was performed. The crystallization plate was transferred to 291 K 
directly after seeding. Crystals appeared after 1-3 days and reached their maximum size after two 
weeks.  
9.2.3.2  Co-crystallization in citrate buffer 
For co-crystallization experiments 9 µL of the crystallization solution were mixed with 3 µL of a 
solution containing 5 mM of the respective inhibitor in 120 mM diammonium hydrogen citrate, 
25% (w/v) PEG 6000, 5% DMSO, pH 5.0. The crystal structure ALR2-48 was obtained using 
this procedure. 
9.2.3.3  Crystallization in MES buffer 
Mixture 1 contained 100 µL of 30 mg/mL ALR2 in 50 mM MES at pH 5.5 with 0.75 µL of 
200 mg/mL NADPH and 0.1 µL 1 M DTT. Mixture 2 contained 20 mM ammonium sulfate, 
1 mM DTT, 50 mM MES and varying concentrations of PEG 6000 (10-20%) at pH 5.5. 10 µL of 
mixture 1 and 2 were mixed. As well solution 120 mM MES with 20% (w/v) PEG 6000 at pH 5.5 
was used. The droplets were equilibrated for 7 days at 295 K. Afterwards streak seeding with 
holo-crystals from the citrate condition was done. The crystals appeared after several days and 
reached their full size after three weeks.  
9.2.3.4  Soaking experiments 
New soaking procedures using MES or TRIS buffer were developed in the course of this work. In 
each case the holo-crystals were grown in citrate buffer.  
9.2.3.5 Soaking in citrate buffer 
A saturated solution of the inhibitor in citrate stabilization buffer (120 mM diammonium 
hydrogen citrate pH 5.0 with 25% (w/v) PEG 6000) was prepared. The crystals were transferred 
into the soaking drop and fished after one to three days. The complex crystal structure ALR2-51 
was obtained using this procedure. 
  
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9.2.3.6 Soaking in MES buffer 
To prevent the crystals from damage the transfer into the MES buffer was performed in a 
stepwise fashion. A saturated solution of the inhibitor in MES stabilization buffer (50 mM MES, 
pH 5.5 with 25% (w/v) PEG 6000) was prepared and mixed with citrate stabilization buffer as 
shown in Figure 9-4. The crystals were equilibrated in each drop for several hours. Afterwards 
the crystals were transferred for one to three days into the final drop which consisted of the 
saturated solution of the inhibitor in MES stabilization buffer. The complex crystal structures 
ALR2-30 and ALR2-37 were obtained using this procedure. 
 
 
 
 
Figure 9-4 Soaking experiments in MES buffer. Citrate: citrate stabilization buffer; MES: MES stabilization 
buffer; Inh.: Inhibitor. 
 
9.2.3.7 Soaking in TRIS buffer 
The same protocol as described for the soaking experiments in MES buffer was applied. Here, 
TRIS stabilization buffer (100 mM TRIS, 25% (w/v) PEG 6000, pH 8.0) was used. The complex 
crystal structures of ALR2 with 13, 31, 43, 47, 49, 50, 52 and 53 were obtained using this 
procedure. 
Materials and Methods 
 
191 

9.2.3.8 Cryoprotection of the crystals 
120 mM di-ammonium hydrogen citrate (pH 5.0), 50 mM MES buffer (pH 5.5) or 100 mM TRIS 
buffer (pH 8.0), respectively, mixed with 40% (w/v) PEG 6000, were used to cryoprotect the 
crystals. 1 mM of the corresponding inhibitor with 1% (v/v) DMSO were added. The crystals 
were briefly dipped into the cryo buffer and were afterwards flash-frozen in liquid nitrogen. 
9.2.4 Structure determination and refinement 
All datasets were collected at the synchrotron BESSY II in Berlin, Germany,201 at beamline 14.1 
or 14.2 (Table 10-3 in the Appendix). The datasets were processed and scaled with HKL2000137 
or XDS.202 Molecular Replacement was done with Phaser138 as implemented in the CCP4203 suite 
using the PDB entry 2DUX204 as a model. Using the program Phenix.refine (version 1.8.4_1496) 
of the Phenix suite141 three cycles of rigid body refinement, five cycles of simulated annealing 
and five cycles of refinement were performed. Afterwards alternating cycles of model building in 
Coot139 and five cycles of refinement in Phenix were done. The temperature factors of all atoms 
except hydrogens were anisotropically refined. The 3D coordinates of the inhibitor molecules 
were built with MOE205 and afterwards energy minimized using the Tripos force field in Sybyl206 
(Tripos International, version 2.0). The restraints file was generated using eLBOW from the 
Phenix suite.142 The final model was validated using MolProbity207 as implemented Phenix. The 
final models were deposited in the PDB.208 Statistics for data collection and refinement are 
shown in Table 10-3 in the Appendix.  
9.2.5  ITC measurements 
The measurements were performed with an ITC200 (GE Healthcare) at 298 K in HEPES buffer. In 
selected cases the overlaid protonation effect was investigated. In these cases the measurements 
were done in HEPES, Tricine and TRIS buffer. The cell was filled with a solution of ALR2 in the 
corresponding buffer with an excess of NADP+ and 3% DMSO. The syringe was filled with a 
solution containing the same concentration of NADP+ and DMSO in the corresponding buffer 
and a concentration of the inhibitor which exceeded 10-20 times the concentration of the protein 
in the cell. The concentrations of the protein and the inhibitor were adjusted to obtain curves with 
a sigmoidal shape. An initial injection of 0.3-0.5 µL which was omitted during data evaluation 
was followed by injections of 1.0-2.0 µL with spacings of 180-300 s in between.  
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For ligands with a too weak or too strong binding affinity the establishment of displacement 
titrations was necessary (see Section 5.7.2).  
For the investigation of the overlaid protonation effect the measurements were done in three 
different buffer systems (HEPES, Tricine and TRIS). This procedure was previously described in 
literature.42, 88 The measured enthalpy (H0obs) was plotted on the y-axis and the ionization 
enthalpy of the corresponding buffer system (H0ion) on the x-axis. The values for H0ion were 
taken from literature.87, 88 The slope of the regression line indicates how many protons per mole 
of formed complex are picked up (positive slope) or released (negative slope). The interception 
point with the y-axis gives the enthalpy corrected for the protonation effect (H0bind). The 
resulting plots are shown in Figure 2-6 (Chapter 2), Figure 3-5 (Chapter 3) and 
Figure 5-10 (Chapter 5).  
The peaks of the thermograms were integrated using NITPIC,160 the isotherms were fitted with 
SEDPHAT161 and the curves were plotted using GUSSI.209 Representative thermograms and 
regression curves of all investigated inhibitors are shown in Figures 10-1 - 10-4 in the Appendix. 
 
 
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9.3 Experimental Procedures Regarding hCAII 
9.3.1 Introductory remarks 
The following description of the methods used in the hCAII project was taken from the same 
manuscript which was prepared for submission to a scientific journal as chapter 6. Additionally, 
Figure 9-5 and Figure 9-6 were added. The methods for protein expression, purification, 
crystallization and soaking followed protocols previously described by Schulze Wischeler and 
coworkers.210  
9.3.1.1 Expression and purification of hCAII 
100 mL LB media containing 100 g/mL ampicillin (Roth) and 34 g/mL chloramphenicol 
(Roth) were inoculated with BL21 Codon Plus cells containing a pGEX-4T1 (GE Healthcare) 
plasmid with the sequence of the hCAII-glutathione-S-transferase fusion protein. The used hCAII 
gene was sequenced. The result is shown in Figure 10-10 in the Appendix. After shaking with 
200 rpm for 16 h at 310 K, 25 mL of this overnight culture were transferred into 1L LB media 
(with 100 g/mL ampicillin). At an OD600 of 0.6-0.8, 1 mL of a 2 M IPTG solution was added. 
After 4 h at 305 K, the cell suspension was centrifuged at 5,000 rpm. The cells were resuspended 
in PBS buffer (139 mM NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) and 
the cell walls disrupted using ultrasound. The suspension was centrifuged at 20,000 rpm. A 
column which was filled with 20 mL glutathione sepharose high performance material 
(GSH column, GE Healthcare) was equilibrated with reduced glutathione (Sigma Aldrich) 
followed by PBS buffer and afterwards loaded with the supernatant. The column was washed 
with 500 mL PBS buffer. Afterwards a solution of thrombin (CSL Behring, Marburg) was 
injected onto the column. Overnight, the fusion protein was cleaved on the column. The released 
hCAII was washed from the column with PBS buffer. To remove the thrombin, a 
HiTrap 1 mL Benzamidine FF column (GE Healthcare) was used (Figure 9-5). A final 
purification step with a HiLoad 26/600 Superdex 200 pg size exclusion column (Amersham 
Biosciences) which was pre-equilibrated with 50 mM TRIS buffer (pH 7.8) was performed 
(Figure 9-6). The purity of the protein was analyzed by SDS gel electrophoresis.  
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9.3.1.2 Crystallization and soaking 
The concentration of hCAII in 50 mM TRIS pH 7.8 was adjusted to 10 mg/mL. 2.5 L of this 
solution was mixed with 2.5 L of the well solution (2.7 M (NH4)2SO4, 100 mM TRIS, saturated 
with p-chloromercurybenzoic acid) and placed on a cover slide as a hanging drop. Crystals 
appeared overnight and reached their full size after 2 weeks. The crystals were soaked with a 
saturated solution of the inhibitor in a stabilization buffer (3.0 M (NH4)2SO4, 100 mM TRIS) for 
one day. Afterwards they were briefly dipped in the cryo buffer (2.7 M (NH4)2SO4, 100 mM 
TRIS, 25% (v/v) glycerol, 1 mM of the respective inhibitor, 1% (v/v) DMSO) for a short time 
and subsequently frozen in liquid nitrogen. 
9.3.1.3 Data collection, processing and refinement 
All data sets were collected at beamline 14.1 or 14.2 (Table 10-4 in the Appendix) at the 
synchrotron BESSY II (Berlin-Adlershof, HZB, Germany).201 The data sets were processed and 
scaled using XDS.202 Molecular replacement was done using Phaser 138 from the CCP4 suite 203 
using PDB entry 1CNI as a starting model.211 5% of the reflections were marked for the 
calculation of the Rfree value. In the Phenix suite141 the program PHENIX.refine (version 
1.8.4-1492) was used to perform three cycles of rigid body refinement and five cycles of 
Cartesian simulated annealing followed by five cycles of refinement. Then, alternating cycles of 
model building in Coot139 and refinement in Phenix were performed. Single atoms of side chains 
of amino acids were deleted if they were not clearly visible in the 2Fo-Fc electron density at 1.0 . 
Water molecules were only placed when indicated by the Fo-Fc difference electron density at 3.0 
. The tails of ligands 56-58 were not immediately visible. After assigning the core structure of 
the respective ligand to the density, they became visible atom by atom in following refinement 
cycles in the Fo-Fc electron density maps at 3.0 . An anisotropic refinement of the temperature 
factors for all atoms except hydrogens was performed. The coordinates and restraints for the 
ligands and for p-chloromercurybenzoic acid were generated using Grade.212 Finally, riding 
hydrogen atoms were added to the model using the riding model. However, since the Rfree value 
did not improve significantly we refrained from adding hydrogen atoms to the final model. 
Validation was performed using MolProbity141 as implemented in the Phenix suite and 
PROCHECK.213 The coordinates were deposited in the PDB. Statistics for data collection, 
processing and refinement are shown in Table 10-4 in the Appendix. 
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9.3.1.4 SPR measurements  
The measurements were performed on a Biacore S51 device (GE Healthcare, Uppsala). For 
immobilization, PBS buffer (139 mM NaCl, 2.7 mM KCl, 10.0 mM Na2HPO4, 1.8 mM KH2PO4) 
with 0.05% Tween 20, pH 7.4, was used as a background buffer. The standard amine coupling 
procedure was applied. A series S Sensor Chip CM5 was activated with a mixture of 0.1 M NHS 
(N-hydroxysuccinimide) and 0.4 M EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide- 
hydrochloride) at a flow rate of 10 µL/min for 10 minutes. Then, a 50 µg/mL solution of hCAII 
in 10 mM sodium acetate (pH 5.2) with 30 µM ethoxzolamide was injected for 2 minutes 
followed by an injection of 1 M ethanolamine hydrochloride (pH 8.5) for 7 minutes. This 
procedure led to immobilization levels between 3500 and 4900 RU. For measuring the 
compounds, PBS buffer with 0.05% Tween 20 and 2% DMSO, pH 7.4, was used as the running 
buffer. The compounds were injected at a flow rate of 30 µL/min for 120 s. Then, the dissociation 
was monitored for 300 s. No regeneration was needed since all the investigated compounds 
completely dissociated from the sensor chip surface in the applied time window. In total, 
10 concentrations were investigated for each compound in a twofold dilution series. For the 
different compounds, the following concentrations were measured: 54 (19.5 nM-10.0 µM), 
55 (9.8 nM-5.0 µM), 56 (3.9 nM-2.0 µM), 57 (1.2 nM-600 nM), 58 (9.8 nM–5.0 µM), 
59 (31.3 nM-16 µM) and 60 (273.4 nM-140.0 µM). A solvent correction cycle using DMSO 
concentrations between 1.4–2.8% was run in between every two sample concentration series. The 
data were evaluated with the Biacore S51 evaluation software (version: 1.2.1). The signals of the 
reference spot were subtracted from the signals of the measurement spots. Then, the sensorgrams 
were corrected for mismatches in the DMSO concentrations. Two blank injections, carried out 
contemporary to the injections of the respective ligand, were subtracted from the sensorgrams. 
For each single measurement, the most robust method for fitting was chosen with a global 
maximum response (Rmax) and a constant value of 0 for the shift of the refractive index (RI) at the 
beginning and end of each injection. The kinetic parameters kon and koff were obtained using a 
simple 1:1 interaction model including a term for a mass transfer limitation as implemented in the 
evaluation software. The test for a mass transfer limitation as implemented in the evaluation 
software showed that the curve that was fitted into the sensorgrams was not mass-transfer-
limited. Thus, the obtained kinetic constants of our final results were reliable. KD (kinetic) was 
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obtained by koff/kon. KD (steady state) was obtained by plotting the binding level at the end of 
each injection against the concentration of the compound and fitting it to a single-site binding 
isotherm.  
 
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10.3 Analytical Data for Ligand 52 
10.3.1 Ligand 52: 
Mp: 232°C .1H-NMR (d6-DMSO, 30 °C, 500 MHz): H(ppm) =4.56 (d, 3J = 6.3 Hz,2H, 
H10),4.91 (s, 2H, H7),6.92 (dt, 3JH,F, 3JH,H= 8.6 Hz, 4J = 2.6 Hz, 1H, H2),7.07(dd, 3JH,F= 11.0 Hz, 
4J = 2.6 Hz, 1H, H6),7.44 (pst, 3J = 7.6 Hz, 1H, H13),7.58 (d, 3J = 8.0 Hz, 1H, H12),7.81 (d, 3J = 
7.7 Hz, 1H, H14),7.91 (s, 1H, H16),7.93 (dd, 3J = 8.7 Hz, 4JH,F= 7.3 Hz, 1H, H3),9.12 (t, 3J = 6.2 
Hz, 1H, NH),13.10 (bs, 1H, COOH).13C-NMR (d6-DMSO, 30 °C, 100 MHz): C(ppm) =42.5 
(C10),65.9 (7),101.7 (d, 2JC,F= 26.0 Hz, C6),108.2 (d, 2JC,F= 22.1 Hz, C2),119.0 (d, 4JC,F= 2.9 Hz, 
C4), 127.7, 128.1, 128.5 (C13, C14, C16),130.8 (C15),131.8 (C12),133.0 (d, 3JC,F= 10.6 Hz, C3), 
140.0 (C11),157.2 (d, 3JC,F= 11.6 Hz, C5),163.7 (C9),164.3 (d, 1JC,F= 248.5 Hz, C1),167.3 
(C17),170.0 (C8).MS (ESI-):m/z (%) = 172 (100, [M-2H]2-), 346 (27, [M-H]-).HRMS(ESI+) 
calcd for C17H15FNO6[M+H]+348.088341; found:348.088200. Anal. calcd for: C17H14FNO6:C, 
58.79; H, 4.06; N, 4.03; found:C,58.79; H, 4.23; N, 4.29. 

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10.4 Analytical Data for Ligands 54-60 
10.4.1 Ligands 54-58: 
Benzenesulfonamide (54) lit.214-216:mp: 151-153 °C(lit.216 155-158 °C);1H NMR (500 MHz, 
DMSO-d6)  7.85-7.82 (m, 2H), 7.61-7.54 (m, 3H), 7.32 (bs, 2H); MS (ES+) m/z 175 
[M + NH4]+; analysis (calcd., found for C6H7NO2S): C (45.85, 45.30), H (4.49, 4.43), N (8.91, 
9.02). 
4-Methylbenzene-1-sulfonamide (55) lit.214-216: mp: 137-139 °C(lit.216136 °C); 1H NMR (400 
MHz, DMSO-d6)  7.71 (dm, 2H, J = 8.2 Hz), 7.36 (d, 2H, J = 8.5 Hz), 7.25 (bs, 2H), 2.37 (s, 
3H); MS (ES+) m/z 189 [M + NH4]+; analysis (calcd., found for C7H9NO2S): C (49.11, 48.97), H, 
(5.30, 5.27), N, (8.18, 8.13). 
4-Ethylbenzene-1-sulfonamide (56) lit.217:mp: 110-111 °C(lit.217 109-111 °C); 1H NMR 
(500 MHz, DMSO-d6)  7.73 (dm, 2H, J = 8.3 Hz), 7.39 (dm, 2H, J = 8.3 Hz), 7.23 (bs, 2H), 
2.67 (q, 2H, J = 7.7 Hz ); 1.19 (t, 3H, J = 7.7 Hz) MS (ES+) m/z 203 [M + NH4]+; analysis 
(calcd., found for C8H11NO2S): C (51.87, 51.86), H (5.99, 5.94), N (7.56, 7.72). 
4-Propylbenzene-1-sulfonamide (57) lit.218:mp: 101-105 °C(lit.218 98-101 °C) 1H NMR (400 
MHz, DMSO-d6)  7.73 (dm, 2H, J = 8.2 Hz), 7.37 (dm, 2H, J = 8.0 Hz), 7.25 (bs, 2H), 2.62 (t, 
2H, J = 7.6 Hz ); 1.61 (sext, 2H, J = 7.6 Hz), 0.89 (t, 2H, J = 7.3 Hz) MS (ES+) m/z 217 (100, 
[M + NH4]+); analysis (calcd., found for C9H13NO2S): C (54.25, 53.81), H (6.58, 6.55), N (7.03, 
7.21). 
4-(2-Hydroxyethyl)-benzene-1-sulfonamide (58) lit.219:The commercial compound was 
chromatographed twice on a prepacked silica gel column utilizing chloroform:ethyl acetate, 10:1 
(v/v) as eluent. mp: 85-88 °C(lit.21954-55 °C);TLC (CHCl3:EtOAc, 10:1 v/v): Rf = 0.13; 1H NMR 
(500 MHz, DMSO-d6)  7.72 (dm, 2H, J = 8.3 Hz), 7.40 (dm, 2H, J = 8.3 Hz), 7.24 (bs, 2H), 
4.68 (bt, 1H) 3.63 (m, 2H) 2.79 (t, 2H, J = 6.7 Hz); MS (ES+) m/z 219 [M + NH4]+; analysis 
(calcd., found for C9H13NO2S): C (47.75, 47.69), H, (5.51,5.67), N, (6.96, 6.88). 
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10.4.2 Ligands 59 and 60: 
4-Carbonyloxybenzene-1-sulfonamide (4-sulfamoylbenzoic acid) (59) lit.220, 221: mp: 
276-277 °C (lit.222282-283 °C); 1H NMR (500 MHz, DMSO-d6)  13.33 (bs, 1H), 8.11 (dm, 2H, 
J = 8.6 Hz), 7.94 (dm, 2H, J = 8.6 Hz), 7.51 (bs, 2H); MS (ES-) m/z 200 (100, [M - H]-); analysis 
(calcd., found for C7H7NO4S): C (41.79, 42.14), H (3.51, 3.66), N (6.96, 7.13). 
4-Aminobenzene-1-sulfonamide (sulfanilamide) (60) lit.221: mp: 165-167°C(lit.222 163-165 °C); 
1H NMR (500 MHz, DMSO-d6)  7.45 (dm, 2H, J = 8.9 Hz), 6.58 (dm, 2H, J = 8.9 Hz), 5.76 (bs, 
2H),MS (ES+) m/z 190 (100, [M + NH4]+); analysis (calcd., found for C6H8N2O2S): C (41.85, 
41.86), H (4.68, 4.69), N (16.26, 16.29). 
 

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10.5 Calculation of the Purity of Ligand 58 According to qNMR 
Measurements 
 
P = purity of sample (%) 
Ianalyte = integral of analyte signal 
NCRM = number of CRM protons 
Manalyte = molecular mass of analyte 
mCRM = mass of CRM 
ICRM = integral of CRM signal 
Nanalyte = number of analyte protons 
MCRM = molecular mass of CRM 
msample = mass of sample/analyte 
PCRM = purity of CRM (%) 
 
qNMR data of commercial 58: 
(Ianalyte) of 58:  1.61 
(NCRM) of CRM 2 
(Manalyte) of 58: 201.24 g/mol 
(mCRM) of CRM: 4.22 mg 
(ICRM) of CRM.  2.00 
(Nanalyte) of 58:  2 
(MCRM) of CRM:  116.07 g/mol 
(msample) of 58: 6.93 mg  
(PCRM) of CRM:  100%  
 
purity (P) of commercial 58 in %: 
 
P = Ianalyte * NCRM * Manalyte * mCRM * pCRM / ICRM * Nanalyte * MCRM * msample 
 
P = 1.61* 2 * 201.24 g/mol * 4.22 mg * 100% / 2.00 * 2 * 116.07 g/mol * 6.93 mg  
= 84.99% 
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qNMR data of chromatographed 58 (1. purification step): 
(Ianalyte) of 58:  1.84 
(NCRM) of CRM 2 
(Manalyte) of 58: 201.24 g/mol 
(mCRM) of CRM: 4.16 mg 
(ICRM) of CRM:  2.00 
(Nanalyte) of 58:  2 
(MCRM) CRM:  116.07 g/mol 
(msample) of 58: 7.04 mg  
(PCRM) of CRM:  100%  
 
purity (P) of chromatographed 58 in % (1. purification step): 
 
P = 1.84 * 2 * 201.24 g/mol * 4.16 mg * 100% / 2.00 * 2 * 116.07 g/mol * 7.04 mg  
= 94.25% 
 
qNMR data of chromatographed 58 (2. purification step): 
 (Ianalyte) of 58:  2.07 
(NCRM) of CRM 2 
(Manalyte) of 58: 201.24 g/mol 
(mCRM) of CRM: 4.07 mg 
(ICRM) of CRM.  2.00 
(Nanalyte) 58   2 
(MCRM) of CRM:  116.07 g/mol 
(msample) of 58: 7.48 mg  
(PCRM) of CRM:  100%  
 
purity (P) of chromatographed 58 in % (2. purification step): 
 
P = 2.07 * 2 * 201.24 g/mol * 4.07 mg * 100% / 2.00 * 2 * 116.07 g/mol * 7.48 mg  
= 97.64% 


 
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10.6 Crystallographic Table of ALR2 Complex Crystal Structures 
Table 10-3 Crystallographic table of ALR2 complex crystal structures. 
 
  ALR2-13 ALR2-28-P21 ALR2-30 ALR2-31 ALR2-37 
PDB entry 4QX4 4YU1 4PR4 4PRR 4NKC 
BESSY beamline   14.2  14.1  14.2  14.2  14.2 
Data collection and processing           
Wavelength [Å] 0.91841 0.91841 0.91841 0.91841 0.91841 
Space group P21 P21 P21 P21 P21 
Unit cell parameters           
a,b,c [Å] 49.4, 66.9, 47.4 
49.5, 66.4, 
47.4 
49.4, 66.5, 
47.3 
49.3, 66.9, 
47.2 
49.2, 66.4, 
47.2 
 [°] 91.9 92.3 92.3 92.5 92.5 
Matthews coefficient [Å3/Da]/ Solvent content [%] 2.3/ 45.6 2.2/ 42.9 2.2/ 42.8 2.2/ 42.8 2.1/ 42.3 
Diffraction data A           
Resolution range [Å] 
17.84-1.26  47.39-1.02 49.33-1.06 18.78-1.01 18.46-1.12 
(1.28-1.26) (1.08-1.02) (1.08-1.06) (1.03-1.01) (1.14-1.12) 
Unique reflections 79172(3759) 150587(23315) 129820(6126) 148147(7006) 116660(5682) 
R(I)sym [%] 5.1 (30.0) 4.9 (46.3) 4.1 (42.7) 5.6 (42.1) 5.2 (40.4) 
Completeness [%] 95.0 (90.4) 96.7 (92.9) 93.7 (88.5) 92.6 (87.2) 99.2 (99.2) 
Redundancy 2.7 (2.7) 3.4 (3.2) 2.6 (2.5) 2.1 (1.8) 2.9 (2.7) 
I/(I) 21.6 (3.9) 14.0 (2.5) 24.5 (2.5) 16.9 (2.0) 18.9 (2.4) 
Refinement           
Resolution range [Å] 17.84-1.26 47.39-1.02 49.33-1.06 18.78-1.01 18.46-1.12 
Reflections used in refinement 
(work/free) 
79143 150569 129790 148117 116632 
(75204/3939) (143039/7530) (123246/6544) (140709/7408) (110758/5874) 
Final R values for all reflections (work/free) [%] 13.3/15.3 13.3/15.0 13.7/15.3 14.4/15.5 12.2/14.2 
Protein residues 316 316 315 315 314 
Atoms inhibitor (1st/2nd), cofactor 18/18/48 19/-/48 20/-/48 19/-/48 20/-/48 
Water molecules 334 413 359 334 360 
RMSDs from ideality B           
Bond lengths[Å]/ bond angles [°] 0.006/1.2 0.008/1.4 0.006/1.3 0.006/1.3 0.007/1.4 
Ramachandran plot C           
Residues in most favored regions [%] 91.0 89.9 91.7 91.7 91.7 
Residues in additional allowed regions [%] 9.0 10.1 8.3 8.3 8.3 
Residues in generously allowed regions [%] 0 0 0 0 0 
Mean B-factor [Å2] D           
Protein 11.2 9.8 10.6 10.4 12.3 
Inhibitor (1st/2nd), Cofactor 9.3/18.0/6.9 8.6/-/6.2 12.2/-/6.4 10.1/-/6.7 13.3/-/6.9 
Water molecules 24.2 23.2 24.1 23.3 25.6 
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Continuation of Table 10-3. 
 
  ALR2-43 ALR2-47 ALR2-48 ALR2-49 ALR2-50 
PDB entry 4PRT 4PUU 4PUW 4Q7B 4QR6 
BESSY beamline  14.1 14.2 14.2 14.2 14.2 
Data collection and processing   
    
Wavelength [Å] 0.91841 0.91841 0.91841 0.91841 0.91841 
Space group P21 P21 P21 P21 P21 
Unit cell parameters   
    
a,b,c [Å] 49.3, 67.0, 47.3 
49.3, 66.4, 
47.2 
49.4, 66.7,  
47.4 
49.3, 66.7,  
47.3 
49.5, 66.7,  
47.4 
 [°] 92.5 91.8 92.0 92.1 92.6 
Matthews coefficient [Å3/Da]/ Solvent content [%] 2.2/ 43.1 2.1/ 42.4 2.2/ 43.1 2.2/ 42.8 2.2/ 43.1 
Diffraction data A   
    
Resolution range [Å] 
38.6-0.96 17.32-1.14 49.38-1.12 18.73-1.19 49.47-1.05  
(1.02-0.96) (1.16-1.14) (1.14-1.12)  (1.21-1.19) (1.07-1.05) 
Unique reflections 185561(29443) 109695(5447) 117148(5781) 97712(4840) 142734(7043) 
R(I)sym [%] 3.4 (40.9) 5.5 (36.9) 5.9 (42.6) 5.5 (44.6) 4.3 (46.6) 
Completeness [%] 99.3 (97.6) 99.1 (99.0) 99.7 (100.0) 99.8 (98.9) 100.0 (100.0) 
Redundancy 3.5 (3.1) 2.9 (2.6) 2.5 (2.3) 3.2 (3.0) 3.9 (3.6) 
I/(I) 19.4 (2.8) 19.1 (2.7) 16.0 (2.4) 20.0 (2.5) 30.1 (2.8) 
Refinement   
    
Resolution range [Å] 38.6-0.96 17.32-1.14 49.38-1.12 18.73-1.19 49.47-1.05 
Reflections used in refinement  
(work/free) 
185561 109668 117119 97684 142704 
(176283/9278) (104171/5497) (111252/5867) (92805/4879) (135543/7161) 
Final R values for all reflections (work/free) [%] 12.6/13.7 13.7/15.6 13.7/15.7 13.8/16.0 14.1/15.7 
Protein residues 316 316 316 315 316 
Atoms Inhibitor 24 15 18 22 25 
Water molecules 412 380 402 370 355 
RMSDs from ideality B   
    
Bond lengths[Å]/ bond angles [°] 0.006/1.3 0.005/1.2 0.006/1.3 0.006/1.2 0.005/1.3 
Ramachandran plot C   
    
Residues in most favored regions [%] 91.7 91.4 91.0 91.3 91.7 
Residues in additional allowed regions [%] 8.3 8.6 9.0 8.7 8.3 
Residues in generously allowed regions [%] 0 0 0 0 0 
Mean B-factor [Å2] D   
    
Protein 9.3 11.0 9.8 11.1 10.7 
Inhibitor , Cofactor 7.0 (-), 5.9 10.7 (1.0), 6.1 9.4 (1.0), 6.2 11.3 (1.0), 6.4 8.5 (0.8), 6.4 
Ala 299- Tyr309 - 21.4 (1.9) 12.7 (1.3)  22.5 (2.0) 14.5 (1.4) 
Water molecules 24.3 24.2 22.3 24.9 22.3 
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Continuation of Table 10-3. 
 
  ALR2-51 ALR2-52 ALR2-53 
PDB entry 4QBX 4YS1 4RPQ 
BESSY beamline  14.2 14.2  14.2 
Data collection and processing  
 
  
Wavelength [Å] 0.91841 0.91841 0.91841 
Space group P21 P21 P21 
Unit cell parameters  
 
  
a,b,c [Å] 49.4, 66.9,  47.4 
49.3, 66.6, 
47.3 
49.6, 66.8,  
47.2 
 [°] 92.3 92.1 93.1 
Matthews coefficient [Å3/Da]/ Solvent content [%] 2.2/ 43.2 2.2/ 42.7 2.2/ 43.1 
Diffraction dataA  
 
  
Resolution range [Å] 
17.43-0.98  49.28-1.07 35.08-1.20  
(1.00-0.98) (1.13-1.07) (1.22-1.20) 
Unique reflections 175882(8807) 131957(20414) 92652(4516) 
R(I)sym [%] 6.0 (41.4) 6.5 (46.6) 3.9 (41.8) 
Completeness [%] 100.0 (99.9) 97.6 (93.6) 96.8 (94.2) 
Redundancy 3.7 (3.5) 3.8 (3.6) 2.4 (2.3) 
I/(I) 22.1 (2.6) 14.0 (2.7) 24.1 (2.5) 
Refinement  
 
  
Resolution range [Å] 17.43-0.98 49.28-1.07 35.08-1.20 
Reflections used in refinement  
(work/free) 
175851 131957 92626 
(167049/8802) (125359/6598) (87981/4645) 
Final R values for all reflections (work/free) [%] 13.5/15.1 13.2/14.8 14.2/16.5 
Protein residues 316 316 314 
Atoms Inhibitor 25 27 30 
Water molecules 396 411 293 
RMSDs from ideality B  
 
  
Bond lengths[Å]/ bond angles [°] 0.006/1.3 0.005/1.3 0.005/1.2 
Ramachandran plot C  
 
  
Residues in most favored regions [%] 91.4 90.6 92.0 
Residues in additional allowed regions [%] 8.6 9.4 8.0 
Residues in generously allowed regions [%] 0 0 0 
Mean B-factor [Å2] D  
 
  
Protein 8.8 9.0 12.2 
Inhibitor , Cofactor 10.5 (1.2) 15.3 (1.7) 15.0 (1.2) 
Ala 299- Tyr309 7.3 (0.8), 5.1 8.8 (1.0), 5.2 10.7 (0.9), 7.9 
Water molecules 22.5 23.1 24.3 
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10.7 Crystallographic Table of hCAII Complex Crystal Structures 
Table 10-4 Crystallographic table of hCAII complex crystal structures 
 
  hCAII-54 hCAII-55 hCAII-56 hCAII-57 hCAII-58 
PDB entry 4YX4 4YXI 4YXO 4YXU 4YYT 
BESSY beamline  14.1 14.1 14.2 14.1  14.1 
Data collection and processing  
   
  
Wavelength [Å] 0.91841 0.91841 0.91841 0.91841 0.91841 
Space group P21 P21 P21 P21 P21 
Unit cell parameters  
   
  
a,b,c [Å] 42.4, 41.5,  72.3 
42.5, 41.5,  
72.5 
42.4, 41.6,  
72.3 
42.3, 41.7,  
72.2 
42.5, 41.7,  
72.3 
 [°] 104.4 104.5 104.3 104.3 104.3 
Matthews coefficient [Å3/Da]/ Solvent content [%] 2.1/ 40.6 2.1/ 40.9 2.1/ 40.8 2.1/ 40.8 2.1/ 41.0 
Diffraction data A  
    
Resolution range [Å] 
35.70-1.01 41.11-0.96  35.05-1.06  41.44-1.08 41.14-1.07 
(1.07-1.01) (1.02-0.96) (1.12-1.06)  (1.15-1.08) (1.13-1.07) 
Unique reflections 126327(19756) 148298(23592) 108590(17145) 103099(16077) 107591(17203) 
R(I)sym [%] 4.9 (41.9) 4.4 (38.4) 7.7 (49.0) 5.5 (38.6) 5.8 (49.1) 
Completeness [%] 98.7 (96.0) 99.2 (98.1) 98.0 (96.3) 98.0 (95.0) 99.3 (98.9) 
Redundancy 3.2 (2.8) 3.5 (3.2) 3.6 (3.6) 3.3 (3.2) 3.2 (3.0) 
I/(I) 11.0 (2.0) 13.3 (2.4) 9.1 (2.1) 12.1 (2.6) 11.6 (2.1) 
Refinement  
   
  
Resolution range [Å] 35.70-1.01 41.11-0.96 35.05-1.06 41.44-1.08 41.44-1.08 
Reflections used in refinement 
(work/free) 
126327 148294 108590 103099 107591 
(120010/6317) (140879/7415) (103160/5430) ( 97944/5155) (102211/5380) 
Final R values for all reflections (work/free) [%] 15.1/17.0 14.0/15.3 14.9/16.4 14.4/16.3 14.4/16.6 
Protein residues 257 257 257 258 257 
Atoms Inhibitor 10/-/-/- 11/11/-/- 12/12/-/- 13/13/-/- 13/13/13/11 
Water molecules 249 258 235 244 245 
RMSDs from ideality B  
   
  
Bond lengths[Å]/ bond angles [°] 0.005/1.1 0.005/1.1 0.005/1.1 0.005/1.1 0.005/1.1 
Ramachandran plot C  
   
  
Residues in most favored regions [%] 88.4 88.9 89.4 88.9 88.9 
Residues in additional allowed regions [%] 11.1 10.6 10.2 10.6 10.6 
Residues in generously allowed regions [%] 0.5 0.5 0.5 0.5 0.5 
Mean B-factor [Å2] D  
   
  
Protein 12.6 10.7 12.5 10.4 10.4 
Inhibitor (1st, 2nd, 3rd, 4th) 10.7/-/-/- 8.4/16.1/-/- 11.1/19.1/-/- 9.5/14.6/-/- 8.3/13.6/19.0/17.4 
Water molecules 27.0 25.0 26.6 24.0 24.5 
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Table 10-3 and Table 10-4: 
ANumbers in brackets represent highest resolution shells. 
BRMSD were calculated with MolProbity207 as implemented in the Phenix suite.141  
CPROCHECK213 was used to generate the Ramachandran plots.  
DMOLEMAN223 was used to calculate the mean B-factors. Numbers in brackets represent the ratios of the mean B-  
factor of the residues 299-309 or the ligand, respectively, compared to the mean B-factor of all protein residues. 
 
 
 
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10.8 Sequencing Results of ALR2 and hCAII 

 
Figure 10-9 Sequencing result of ALR2 and comparison with the UniProt entry P15121. The sequence conflict 
in position 4 (LI) is already documented in the UniProt entry. 
 
 
 
Figure 10-10 Sequencing result of hCAII and comparison with the UniProt entry P00918. 
  
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